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Background: Regular fish consumption is consistently associated with a range of 
health benefits, particularly cardiovascular related. In excitable tissue such as skeletal 
and cardiac muscle, fish or fish oil (FO) intake increases membrane phospholipid 
concentration of long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA), 
especially docosahexaenoic acid (DHA). Of physiological consequence, skeletal muscle 
and cardiac function has been demonstrated to be modified, even during episodes of 
hypoxia/ischaemia. There is evidence that shows variation in the patterns by which 
DHA phospholipid incorporation occurs according to tissue type. However, little is 
known about whether incorporation of DHA is associated with specific physiological 
properties unique to the tissue. In addition, it is not known if physiological effects can 
be attributed to the supplementation of FO doses achievable within a typical Western-
style human diet (high SFA and n-6 PUFA). Some physiological effects have been 
reported in skeletal muscle using human dietary achievable FO doses. The physiological 
effects demonstrated within the myocardium and pacemaker regions of the heart are 
postulated to underpin the cardiovascular health benefits of regular fish intake observed 
at a population level. However, previous studies have relied upon FO doses well above 
what could be achieved in the habitual human diet. This research therefore aimed, 
firstly, to characterise patterns of phospholipid DHA incorporation throughout muscle 
types with unique physiological properties, including ventricular myocardium, 
following supplementation of FO doses achievable within a typical Western-style 
human diet. Secondly, it aimed to relate ventricular myocardial phospholipid DHA 
concentrations to cardiac physiology at rest; and during ischaemia and reperfusion; that 
may explain the cardiovascular health benefits associated with regular fish consumption 
in humans.  
Methods: The research commenced with a study which evaluated the optimal 
anaesthetic to use while characterising in vivo cardiac function in the rat using a Millar 
conductance catheter. The remainder of studies investigated the effect of supplementing 
FO to a control diet (10% fat wt/wt) devoid of LC n-3 PUFA and containing high 
amounts of SFA (5%), MUFA (2.5%) and n-6 PUFA (2.5%), typical of a Western-style 
diet in rats for 4 – 6 weeks. Dietary achievable FO doses (LowFO: 0.32% and ModFO: 




PUFA content remained high. Following dietary supplementation, cardiac function was 
assessed in vivo under pentobarbital anaesthetic (60mg/kg i.p), instrumented with lead-I 
ECG and a 6mm miniaturised 2-French pressure-volume conductance catheter. The 
heart rate, heart rate variability and ventricular haemodynamic function was evaluated: 
under resting conditions; during prolonged regional ischaemia; and the post-ischaemic 
recovery. Cardiac arrhythmias were evaluated from continuous ECG and aortic pressure 
recordings during: 15 min regional ischaemia; and 15 min reperfusion. Regional 
ischaemia was achieved by surgical occlusion of the left anterior descending coronary 
artery with reperfusion induced by release of the occlusive snare. Tissue was collected 
at completion of cardiac haemodynamic studies for morphological measurements and 
the analysis of phospholipid fatty acid composition via gas chromatography. 
Results: Relative fatty acid phospholipid concentrations of LC n-3 PUFA, particularly 
DHA was higher in myocardial (Control: 5.0 ±0.2%; LowFO: 13.1 ±0.9%; ModFO: 
18.3 ±0.4%, p <0.001) and skeletal muscles following supplementation with both doses 
of FO. Across five different hind-limb muscles within the rat, selected for their unique 
fibre type proportions, DHA preferentially incorporated in relation to the proportion of 
fast oxidative glycolytic (FOG) fibre type (Control soleus DHA: 8.3 ±0.1%, proportion 
of soleus FOG fibre type: 13%; Control gastrocnemius(red) DHA: 12.6 ±0.2%, 
proportion of FOG fibre type: 62%; ρ = 0.94, r2 = 0.89). Phospholipid concentrations of 
DHA were further increased with FO feeding in a dose-dependent manner across all 
muscle types (ModFO soleus DHA: 18.9 ±0.7%; ModFO gastrocnemius(red) DHA: 
23.0 ±0.5%). Supplementation of FO was associated with slower resting heart rate in a 
dose-related manner (Control: 453 ±6, LowFO: 433 ±4, ModFO: 402 ±5 beats.min-1, p 
<0.01) with no compromise to cardiac output and without change in time or frequency 
domains of heart rate variability. During 15 min regional ischaemia, the ModFO dose 
reduced the incidence and severity of arrhythmias, including reduced cases of fatal 
ventricular fibrillation (Fatal VF: Control: 61%, LowFO: 40%, ModFO: 25%, p <0.05). 
During 15 min reperfusion, the incidence and severity of arrhythmias was reduced by 
both FO doses, with few statistical differences between FO doses. Prolonged ischaemia-
induced reductions in rate pressure product (indirect index of myocardial oxygen 
consumption) recovered faster in the ModFO group and post-ischaemic left ventricular 
pressure-volume loop integrity (shifted downwards and right with reduced ejection 




fraction: Control: -18% LowFO: -11% ModFO: -10%, p <0.05). Ischaemic zone at risk 
was not statistically different between groups, indicating an equivalent ischaemic insult. 
Discussion and conclusions: This research establishes that supplementing FO doses 
achievable within a typical Western-style human diet produces robust and preferential 
fibre type dependent incorporation of DHA into excitable membranes of skeletal 
muscles and the heart. Of physiological consequence, resting heart rate was slowed, 
hearts remained in normal sinus rhythm for longer during an arrhythmogenic stimulus 
and heart function was controlled during ischaemia to ensure maintenance of mean 
arterial pressure. These effects occurred in the absence of any well-defined changes in 
heart rate variability, indicative that the autonomic nervous system was not involved. 
Rather, it appears that FO facilitates adaptations in the intrinsic control of the heart to 
provide cardiac nutritional pre-conditioning, similar to ischaemic pre-conditioning and 
exercise training. The physiological changes described in the heart were observed, for 
the first time, after supplementing FO doses achievable within a typical Western-style 
human diet (Human equivalence: LowFO ≈ EPA+DHA 570mg/d or ≈ 2 salmon [100g] 
serve/week; ModFO ≈ EPA+DHA 2.3g/d or ≈ 6 capsules per/day). The LowFO dose 
appears to be close to the threshold required for improving ischaemic heart function. 
Whereas, during reperfusion both FO doses were almost equally effective, particularly 
in relation to arrhythmia based outcomes, suggesting that the threshold for effectiveness 
may be even lower. This research provides evidence to rationalise how increasing 
dietary FO intake in a typical Western-style diet high in SFA and n-6 PUFA offers the 
potential to slow resting heart rate, prevent sudden (arrhythmic) cardiac death and 
attenuate the decline of post-ischaemic myocardial function leading to heart failure. 
Consequently, increasing fish or FO intake in the Western diet offers a safe and 
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According to the World Health Organisation approximately 38 million deaths 
worldwide each year are caused by non-communicable or ‘chronic disease’ and this 
number is disproportionately increased in populations with low to middle 
socioeconomic status. Lifestyle factors such as dietary patterns have been identified to 
place substantial influence on mortality and morbidity rates of chronic disease. Dietary 
fish oil (FO) is a rich source of poly-unsaturated fatty acids (PUFA), in particular, it 
contains high levels of long chain omega-3 PUFA (LC n-3 PUFA) which is a subclass 
of PUFA, with the other being omega-6 (n-6 PUFA). Recently, blood levels of LC n-3 
PUFA, specifically eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) have 
been demonstrated to be in the very low or low range in populations investigated across 
the globe (Stark et al., 2016). This is alarming given that decades of evidence from 
numerous epidemiological, clinical, cohort, observational and animal studies 
demonstrate dietary intake of fish or FO to be closely associated with a significant 
number of health benefits and decreased risk of chronic disease. 
Health benefits of FO include: improving brain development and functioning; mental 
health outcomes; attenuating cognitive decline; and beneficial effects on metabolic 
syndromes, dyslipidaemias and inflammatory problems (Gogus & Smith, 2010; Ruxton 
et al., 2004; Sidhu, 2003). The most well known and researched effect, is the 
association FO has with reduced cardiovascular disease morbidity and mortality 
outcomes (Gogus & Smith, 2010; Yashodhara et al., 2009). However, limited 
understanding of the underlying physiological mechanisms and FO doses required to 
improve cardiovascular health is leading to confusing and mixed conclusions being 
made about their benefits (Alexander et al., 2017; Nestel et al., 2015). The majority of 
previous research has relied upon ex vivo animal models and unrealistic doses of FO, 
which would not be achievable in the human diet to demonstrate physiological effects 
(Matthan et al., 2005; McLennan, 2014). As such, this thesis aimed to characterise 
cardiac function following supplementation of FO doses achievable in the typical 
Western-style human diet whilst using a physiologically appropriate in vivo animal 
model. This will help to establish the action by which increased fish or FO intake 




1.1.2 What are fatty acids? 
Dietary fats, along with carbohydrates and protein make up the three main 
macronutrients of the mammalian diet. Most dietary fats are found in the form of 
triglycerides which is a glycerol head group attached to three individual aliphatic fatty 
acid chains. Other less common forms of dietary fat include phospholipids, phytosterols 
and lipoproteins which are associated with cholesterol. Triglycerides are important 
dietary sources of fuel for mammals because they yield substantial quantities of energy 
(ATP) when they are metabolised into free fatty acids. Metabolism of triglycerides 
occurs in the duodenum following the secretion of pancreatic lipases and bile which 
hydrolyse the ester bond between the glycerol head group of the triglyceride and the 
individual fatty acid chains. This process splits triglycerides into diglycerides, 
monoglycerides and free fatty acids. They are subsequently mixed with fat soluble 
contents of the diet such as vitamins, cholesterol and bile salts to form micelles. 
Micelles are absorbed into enterocyte cells and their contents are resynthesized into 
triglycerides before being repackaged with cholesterol and proteins to form lipoprotein 
lipids. Lipoproteins are excreted into the lymphatic system and are then able to circulate 
in the blood stream. Lipoprotein lipase enzymes located on endothelial surfaces of 
capillaries throughout the body partially digest lipoproteins to release free fatty acids 
and glycerol into the plasma (Kratky et al., 2005). Plasma free fatty acids can diffuse 
rapidly across phospholipid bilayers, but there are a wide range of membrane associated 
proteins which also act to facilitate the uptake of free fatty acids into the membrane, for 
a detailed review see (Su & Abumrad, 2009). Free fatty acids are then incorporated into 
the membrane phospholipid bilayer in variable proportions throughout different tissues 
and play an important role in the functioning of cellular processes (Spector & Yorek, 
1985). 
Fatty acids are made up of a hydrocarbon chain with a hydrophobic methyl group at one 
end and a hydrophilic carboxyl group at the other. Fatty acids chains contain different 
numbers of carbon atoms and can therefore be categorised into short chain (< 6 carbon 
atoms), medium chain (< 12 carbons atoms) and long chain (>18 carbon atoms). 
Furthermore, each fatty acid can contain saturated or varied amounts of unsaturated 
bonds, and each chain attached to the glycerol head group may be the same or different. 




saturated with hydrogen bonds or one/more carbon atom is bonded to another carbon 
via a double bond) of the carbon atoms found in the fatty acid aliphatic chain. There are 
three major classes of fatty acids: saturated fatty acids (SFA) which contain no double 
bond, monounsaturated fatty acids (MUFA) which contain one double bond and poly-
unsaturated fatty acids (PUFA) which contain more than one double bond (Figure 1.1). 
The most common SFA found in the mammalian diet are Palmitic acid (16:0) and 
Stearic acid (18:0) and are mainly derived from animal-based products including meat 
and dairy. The typical Western-style diet contains high amounts of SFA (USDA, 2016). 
The most relevant MUFA to the mammalian diet is Oleic acid (18:1n-9) which is also 
found in animal fats but commonly sourced from plant-based foods such as processed 
oils including olive, canola and sunola oil. There are several types of important PUFA 
which will be discussed in the next section. 
Several methods can be used for the nomenclature of fatty acid chains, most commonly 
in nutritional literature, they are referred to using their trivial name e.g. Linoleic acid. 
However, this method is often not concise enough to describe the chemical structure of 
the fatty acid chain. Therefore ‘lipid number’ nomenclature which identifies the number 
of carbon atoms and number/location of double bonds is also used. This method takes 
the form of C:Dn-x, where C is the number of carbon atoms, D refers to the number of 
double bonds and n-x gives information about the location of the first double bond. The 
methyl end of the aliphatic chain is referred to as the ‘omega’ carbon which is 
synonymous with ‘n’ and ‘ω’. Therefore n-x identifies precisely which carbon atom the 
first double bond is found. For example, the omega-6 fatty acid Linoleic acid is named 
18:2n-6, informing the reader that Linoleic acid is made up of eighteen individual 
carbon atoms of which two have double bonds and the first double bond is found at the 
sixth carbon from the omega end of the aliphatic chain (Figure 1.2). Throughout this 
thesis, fatty acids will be referred to using their trivial name followed by the lipid 





Figure 1.1: Overview of fatty acid classification/nomenclature and biosynthesis of n-3 & n-6 PUFA 
Example SFA (No double bonds), MUFA (1 double bond), n-6 PUFA (The first double bond appears at the 6th carbon atom from the omega carbon) 





There are several important PUFA present in the mammalian diet which can be further 
classified into n-6 or n-3 PUFA depending on the location of the first double bond from 
the omega carbon (Figure 1.1). Mammals have the ability to produce a range of de novo 
fatty acids from palmitic acid via elongation, desaturation and hydroxylation. However, 
mammals lack the enzymes necessary to introduce double bonds beyond carbon 9, 
meaning both n-6 and n-3 PUFA cannot be synthesised de novo. These fatty acids must 
be obtained in the diet or formed from metabolism of other PUFA present in the diet. 
PUFA that can only be obtained from the diet are referred to as ‘essential’ fatty acids. 
The n-6 and n-3 biosynthetic pathways which are available in mammals predominantly 
take place in the endoplasmic reticulum except for the final conversion which occurs in 
the peroxisome (Figure 1.2). Linoleic acid (LA: 18:2n-6) is an essential n-6 PUFA in 
the mammalian diet and acts as the precursor for n-6 PUFA de novo enzymatic 
elongation and desaturation to form a range of longer chain n-6 fatty acids including 
Arachidonic acid (AA: 20:4n-6), which is particularly important for platelet and 
endothelial wall physiology.  
The typical Western-style diet is rich in LA due to its presence in many common 
cooking oils such as corn oil, sunflower oil, soybean oil and safflower oil. Short-chain 
Alpha-linolenic acid (ALA: 18:3n-3) which is found in seeds and nuts such as 
flaxseeds, soybeans and walnuts is an essential n-3 PUFA in the mammalian diet. 18C 
ALA acts as a pre-cursor for n-3 PUFA de novo enzymatic synthesis of 
eicosapentaenoic (EPA: 20:5n-3) acid and docosahexaenoic acid (DHA: 22:6n-3). For 
this reason, it has been argued that EPA and DHA should not be considered essential 
fatty acids (Sinclair et al., 2002). However, there is considerable debate regarding the 
efficiency rate in the conversion of ALA to DHA in mammals, with studies showing 
oral doses of ALA to produce blood levels of DHA ranging from non-detectable to 
9.8% (Domenichiello et al., 2014; Gibson et al., 2013; Hussein et al., 2005; Metherel et 
al., 2016). This is a result of delta (∆) six desaturase enzymes which are used in two 
steps in the pathway for the conversion of ALA to EPA and DHA (Figure 1.2). Firstly, 
ALA competes with the n-6 PUFA LA to produce EPA, secondly the EPA metabolite 
docosapentaenoic acid (DPA: 22:5n-3), competes with both LA and ALA for the ∆ six 
desaturase before the formation of DHA (Gibson et al., 2013; Leonard et al., 2004). A 





some increased formation of EPA, but in the presence of high LA concentrations, 
saturation of the ∆ six desaturase enzyme reduces the conversion of DPA to DHA 
(Figure 1.2) (Wood et al., 2015). Further evidence for this suggestion is found in a 
study that demonstrated synthesis rates of DHA to be higher when using precursors 
beyond ALA (Metherel et al., 2018). Therefore, dietary intakes of foods high in pre-
formed DHA & EPA, such as marine based foods, are essential to increase the 
concentration of LC n-3 PUFA in the mammalian phospholipid membrane. 
   
 
Figure 1.2: Overview of n-3 & n-6 PUFA biosynthesis in the mammalian body. 
The pathway of enzymatic desaturation and elongation is shown for both n-3 & n-6 
PUFA. Steps labelled with an * occur in the endoplasmic reticulum, the final step 
labelled with # occurs in the peroxisome. It can be observed how increased dietary 
intakes of ALA can saturate the ∆6 desaturase enzyme and reduce the conversion of 
DPA – DHA. The figure was adapted from (Gibson et al., 2013). 
Abbreviations: LA = Linoleic acid; ALA = Alpha-linolenic acid; AA = Arachidonic acid; 





1.1.3 Membrane phospholipid fatty acid incorporation  
Phospholipids and cholesterol are the main components, which make up the membrane 
lipid bilayer found in mammals. The phospholipid composition of the membrane lipid 
bilayer, however, is not a static environment. Alterations of the fatty acid composition 
of membrane phospholipids can occur through a range of factors including exercise 
(Andersson et al., 2000; Andersson et al., 1998; Helge et al., 2001), oxidative stress 
(Hulbert et al., 2007), ageing (Paradies et al., 1992) and pathological states 
(Gudbjarnason, 1980). Perhaps of most importance to this thesis is the potent influence 
that dietary interventions can exert on the membrane phospholipid composition 
(Abeywardena et al., 2016; Charnock et al., 1986; Henry et al., 2015; Slee et al., 2010). 
The proposed consequences of altering membrane phospholipid composition include 
direct effects on: membrane fluidity and the environment surrounding membrane 
receptors, proteins and channels; phospholipase release of fatty acids and indirect 
effects of free fatty acids including: enzymatic and non-enzymatic eicosanoid 
production; altered intracellular signalling processes; fatty acid oxidation and free 
radical production and free radical induced upregulation of antioxidants (Mozaffarian & 
Wu, 2011).   
Tissue membrane phospholipid composition in the rat is made up predominantly of 
Stearic acid (18:0), LA and AA, together these fatty acids represent approximately 45 – 
60% of the relative phospholipid composition. The next greatest contributors are Oleic 
acid (18:1n-9) which makes up approximately 10% and DHA which adds 
approximately 10%; the remaining fatty acids contribute < 5%. The composition of 
liver, cardiac, skeletal muscle and neural phospholipid has been demonstrated to 
maintain relatively constant SFA and MUFA concentrations when changes to the diet 
are made (Ayre & Hulbert, 1996a; Hulbert et al., 2005). However, when small changes 
to n-3 and n-6 PUFA content are made in the diet, phospholipids are very responsive, 
and the PUFA relative phospholipid composition can change dramatically (Hulbert et 
al., 2005). Interestingly, AA is preferentially incorporated into phospholipids over EPA 
when diets which are low in LC n-3 PUFA are supplied to rats (Slee et al., 2010). It is 
thought this occurs as a result of any available EPA being metabolised to DHA to 
maintain abundant phospholipid DHA concentrations (Tran et al., 2001). However, 





preferentially incorporated into phospholipids at the expense of n-6 PUFA such as AA 
and LA (Owen et al., 2004; Slee et al., 2010). The level of incorporation of individual 
fatty acids into phospholipids strongly reflects the type of fatty acids included in the diet 
and varies in tissue with different functions including cardiac, kidney, liver, lungs, 
plasma, neural, skeletal muscle and erythrocytes (Charnock et al., 1989; Spector & 
Yorek, 1985).  
1.1.4 The role of fish oil in excitable tissue  
Excitable tissues are made up of cells which use the movement of ions between cellular 
compartments and the extracellular environments to create a resting membrane potential 
that is capable of depolarisation. In myocardial and skeletal muscle cells, depolarisation 
culminates into a contraction via excitation-contraction coupling. Excitation-contraction 
coupling is the process which allows an electrical stimulus to be converted into 
mechanical energy at the actin and myosin filaments in skeletal and myocardial cells. 
This process is dependent upon the movement of a range of ions between cellular 
compartments. However, cellular membranes are impermeable to the movement of ions; 
therefore this passage of ions relies upon a vast array of receptors, ligands, gates and 
channels embedded within the membrane (Spector & Yorek, 1985). Interactions 
between the hydrophilic fatty acid tails and membrane bound proteins, receptors and 
channels are closely linked to cellular function (Stubbs & Smith, 1984). As such, 
alterations in membrane phospholipid composition can lead to altered cellular 
functioning.  
The incorporation of DHA into skeletal and myocardial membrane phospholipids is an 
important example of linking cellular function to membrane composition. It has been 
well documented that excitable tissues including myocardial and skeletal muscle in 
humans (Andersson et al., 2002; Harris et al., 2004; Innis, 2007) and animals (Ayre & 
Hulbert, 1996a; McLennan & Abeywardena, 2005; Peoples & McLennan, 2010; Stark 
et al., 2007b) exhibit similar phospholipid fatty acid composition, much higher in DHA 
compared to tissues such as kidney, liver and plasma (Charnock et al., 1989; Nikolaidis 
et al., 2006). Of particular interest to this thesis, it has now been established that very 





influence phospholipid concentrations of LC n-3 PUFA, particularly DHA in excitable 
membranes of the myocardium and skeletal muscles (Henry et al., 2015).  
1.1.5 Skeletal muscle structure and function 
Skeletal muscle can be classified into two overarching categories based on the 
abundance of fibres making up the myofibril. The first class is known as slow-twitch 
oxidative fibres otherwise referred to as Type I muscle fibres. The second are known as 
fast twitch fibres. Fast twitch fibres can be further categorised to include two 
subcategories: 1) fast oxidative glycolytic and 2) fast glycolytic fibres otherwise known 
as Type IIa and Type IIb respectively. Type I, IIa & IIb categorisation of skeletal 
muscles is based off contractile properties of the muscle, whereas oxidative or 
glycolytic categorisation is based on enzymatic processes. Both methods aim to 
describe the unique rate of contraction, metabolism and fatigue profiles displayed 
between fibre types. For the simplicity of reading, discussion of muscle fibres will be 
referred to using the slow oxidative (SO), fast glycolytic (FG) and fast oxidative 
glycolytic (FOG) terminology throughout this thesis.  
The specific muscle function characteristics observed throughout different muscle fibres 
can be attributed to various isoforms of the myosin heavy chain (MHC) proteins located 
in the thick filaments of the sarcomere (Wells et al., 1996). The MHC proteins found 
within muscle fibres mediate metabolic and contractile responses of skeletal muscle 
(Hashimoto et al., 2016). Skeletal muscles made up with predominately SO fibres are 
characterised by a slow rate of contraction, primarily use oxidative metabolism and 
display resistance to fatigue. Slow oxidative muscle fibres are primarily made up of 
MHCslow isoform. This MHC isoform is associated with low basal rates of ATP 
consumption and has a high ATP reserve capacity; this leads to the fatigue resistant 
characteristics associated in muscles with high proportions of MHCslow isoform (Han et 
al., 2001). In contrast, FG fibres are characterised by a fast rate of contraction, primarily 
rely upon glycolytic metabolic pathways and display a rapid fatigue profile. Muscles 
containing high proportions of FOG fibres display characteristics of both SO and FG 
muscle fibres. For example, the FG and FOG have a high proportion of the MHC2 





isoform rapidly fatigue because they rely upon high rates of ATP consumption and do 
not have large ATP reserves (Han et al., 2001). 
1.1.6 The influence of fish oil on skeletal muscle function  
Human studies have demonstrated several unique physiological roles for FO which may 
contribute to improved muscular performance (Mickleborough, 2013). These changes in 
function include increased muscle blood flow (Walser et al., 2006), attenuated post-
exercise inflammation after eccentric exercise (Tartibian et al., 2011) and attenuated 
loss of twitch potentiation following downhill running (Mickleborough et al., 2015). 
Animal research investigating the health effects of adequate FO intake on skeletal 
muscle function has produced contradicting results. It was suggested that both n-6 
PUFA and n-3 PUFA are essential to maintaining muscle function in rats, as 
deficiencies in either class of fatty acid were demonstrated to result in poor contractile 
performance compared to rats receiving diets high in n-6 and n-3 PUFA (Ayre & 
Hulbert, 1996b). Whereas, more recent studies have demonstrated that incorporation of 
LC n-3 PUFA into skeletal muscle phospholipids contributes to improved fatigue 
resistance (Henry et al., 2015; Peoples & McLennan, 2010, 2014) and enhanced oxygen 
efficiency (Peoples & McLennan, 2010).  
Perhaps most important to this research is evidence which demonstrates dietary 
achievable FO doses to maintain skeletal muscle contractile performance during 
normoxic conditions (Henry et al., 2015). Diving mammals such as the seal are required 
to maintain contractile function during periods of hypoxia when they dive for >12 
minutes. It has now been demonstrated that the seal concentrates large amounts of DHA 
in swimming skeletal muscle phospholipids and it has been hypothesised that this helps 
conserve oxygen (Trumble & Kanatous, 2012). Additionally, it has been demonstrated 
that therapeutic doses of FO in the auto-perfused in vivo rat hind-limb delays hypoxic 
skeletal muscle fatigue, suggesting a physiological role of DHA in skeletal muscle 
during low-oxygen stress (Peoples & McLennan, 2017). The outcomes of both animal 
and human studies combined suggest DHA play an important role in skeletal muscle 
function and health. However, the recent identification of a specific physiological role 
of DHA in skeletal muscle function, particularly during hypoxia/ischaemia has never 





1.1.7 Myocardial membrane structure and function 
Striated myocardium is an involuntary excitable tissue that is found in the walls of the 
heart. Myocardial cells (myocytes) form a thick muscular layer between the epicardium 
and endocardium of the heart and coordinate contractions to ensure blood is 
rhythmically pumped away from the heart into the circulation. Like skeletal muscle, 
calcium ions (Ca2+) are the principal intracellular signalling ions which play critical 
roles in both the action potential and contractile phase of the myocyte through 
excitation-contraction coupling. The handling, storage and re-uptake of Ca2+ in the 
myocardium are tightly regulated throughout the entire cardiac cycle and has been 
described in depth elsewhere (Berridge, 2006; Bers, 2008; Fearnley et al., 2011). 
Ventricular myocytes contain a slightly different MHC isoform to what is observed for 
skeletal muscle. Ventricular myocytes predominately contain the MHCβ isoform, which 
is associated with low basal rates of ATP consumption and high ATP reserves (Sieck & 
Regnier, 2001). Interestingly, MHCβ isoform found in myocytes is somewhat similar to 
the the MHCslow isoform found predominantly in SO skeletal muscle fibres. This 
similarity may be reflective of both types of muscle requiring a fatigue resistant 
physiological role. Both SO skeletal and cardiac muscles are required to sustain 
repeated contractile force production and relaxation over prolonged periods of time. 
Given that SO skeletal muscle and cardiac muscle share a somewhat similar MHC 
isoform and fatigue resistant profile, it is likely that the fatty acid incorporation patterns 
between the two types of muscle are also similar.  
1.1.8 The influence of fish oil on the cardiovascular system 
Dietary fish intake has been consistently associated with a cardio-protective effect in 
decades of human epidemiological and observational studies (Bang & Dyerberg, 1972; 
Burr et al., 1989; Hirai et al., 1980; Kagawa et al., 1982; Kromhout et al., 1985). 
Initially, research suggested that reduced CVD outcomes associated with FO intake was 
attributable to an anti-atherogenic and anti-thrombotic mechanism (Fischer & Weber, 
1984; Siess et al., 1980). More recently, research has identified other vascular effects 
including favourable changes to blood pressure and endothelial functioning, all of 
which likely contribute to the cardiovascular protective effect observed (Adkins & 





majority of experiments which have demonstrated anti-atherogenic, anti-hypertensive, 
anti-thrombotic actions from FO have relied on very high doses to produce a typically 
modest effect, and this effect is usually only demonstrable in previously diseased 
populations (Geleijnse et al., 2002; Sekikawa et al., 2008). Despite the focus of initial 
research on vascular related outcomes, there is now growing evidence which 
demonstrates that regular fish consumption has a direct cardio-protective effect on the 
myocardium rather than vascular outcomes (Flock et al., 2013; McLennan, 2014). It is 
hypothesised that the direct cardio-protective action of FO upon the myocardium is 
closely linked to the incorporation of LC n-3 PUFA into myocardial membrane 
phospholipids (Abeywardena et al., 2016; McLennan, 2014). The effects of FO 
supplementation attributable to the heart directly include modification of heart rate 
(Dallongeville et al., 2003; Geelen et al., 2005; Grimsgaard et al., 1998; Mozaffarian. et 
al., 2005), heart rate variability (Christensen et al., 2001; Xin et al., 2013) and improved 
cardiac contractile function in healthy (McLennan et al., 1992a) and ischaemic hearts 
(Pepe & McLennan, 2002). However, the most extensively studied and important effect 
of FO is its anti-arrhythmic action (Matthan et al., 2005; McLennan, 2014).  
The current thesis builds on several decades of original animal research that points to 
the essential role that DHA, derived from FO, plays in optimal heart function in both 
health and disease (Abdukeyum et al., 2008; Abeywardena et al., 2016; Charnock et al., 
1992; Hartog et al., 1987; McLennan, 2014; McLennan & Abeywardena, 2005; 
McLennan et al., 1992a; McLennan et al., 2007; Peoples et al., 2008; Pepe & 
McLennan, 1996, 2002). Such studies have investigated the physiological effects of LC 
n-3 PUFA on cardiac function in animals using doses of FO ranging from 1.25% to 
12% wt/wt. Despite the consistent demonstration of FO providing a cardio-protective 
action in epidemiological and animal studies, there is still debate as to the potential 
cardiovascular health benefits of FO in humans. This is because of the consistent mixed 
conclusions published regarding FO by large-scale random control trials (RCT) using 
supplements in order to replicate dietary fish intake and the meta-analyses of these trials 
(Alexander et al., 2017; Bosch et al., 2012; Galan et al., 2010; Kromhout  et al., 2010; 
O’Keefe et al., 2017; Rauch et al., 2010; Roncaglioni et al., 2013; Svensson et al., 
2006; Tavazzi et al., 2008; Valagussa et al., 1999; Yokoyama et al., 2007). An example 





recommendations on clinical evidence for LC n-3 PUFA in the prevention and 
treatment of cardiovascular disease. The review concludes that while there are clear 
benefits of eating fish, there is no support from RCT or their meta-analyses to 
recommend the use of refined FO supplements (Nestel et al., 2015). Given that the 
observational and animal evidence remains consistent, yet there are regularly 
differences reported between RCT, perhaps the design and interpretation of RCT 
outcomes requires a better understanding of the doses of FO required and the underlying 
physiological mechanisms of action of FO. The challenge in explaining physiologically 
plausible mechanisms of action of FO requires animal and cellular work to be 
completed. 
1.1.9 Linking animal fish oil studies to human health 
Historically, animal work has relied upon high doses of FO which would not be easily 
achieved in the human diet. Consequently, the relevance of findings from such studies 
are ambiguous when extrapolated to human health. However, diets supplemented with 
1.25% wt/wt FO consistently exhibit the same or very similar physiological effects as 
diets supplemented 12%. For example, the anti-arrhythmic, heart rate slowing and 
enhanced oxygen efficiency actions attributable to FO have been demonstrated at doses 
of 1.25, 3, 6 and 12% FO (Abeywardena et al., 2016; McLennan, 1993; McLennan et 
al., 1992a; McLennan et al., 1992b; Pepe & McLennan, 2002; Pepe & McLennan, 
2007). Despite this observation, no studies to date have characterised the effect of FO 
on cardiac function using dietary achievable equivalent doses. Currently, 250mg/day 
EPA+DHA has been identified in epidemiology and randomized trials for 
cardiovascular protection (Kris-Etherton et al., 2009; Mozaffarian et al., 2005a) and 
500mg/day of EPA+DHA is recommended for cardiovascular health in males 
(Colquhoun et al., 2008). Furthermore, it has been demonstrated that dietary intakes of 
FO ranging from as low as 180mg/day up to 1g/day in men and women are associated 
with reduced risk of primary cardiac arrest and sudden cardiac death, (Patterson et al., 
2015; Siscovick et al., 1995). Therefore, the minimum dose of FO this series of projects 
will supplement animals will be equivalent to ∼570mg/day EPA+DHA in humans 





health, they will be supplemented to a background diet high in SFA and high in n-6 
PUFA, typical of the current Western-style dietary fat proportions (USDA, 2016).  
Characterising the effectiveness of FO in the heart also requires the most 
physiologically stable experimental model. The importance of using a physiologically 
stable model is highlighted in skeletal muscle studies investigating muscle function. It 
has been demonstrated that the auto-perfused in vivo hind-limb model provides 
improved oxygen delivery, long term viability, physiologically relevant blood flow and 
vascular tone when compared to in situ hind-limb perfusion methods (Peoples et al., 
2013). This explains the different outcomes observed in original animal investigations 
of skeletal muscle metabolism using an in situ rat hind-limb model (Ayre & Hulbert, 
1996b) compared to research using the auto-perfused in vivo hind-limb model (Henry et 
al., 2015; Peoples & McLennan, 2010, 2014, 2017). Both skeletal (Bonen et al., 1994) 
and cardiac (Kuzmiak-Glancy et al., 2015) muscle performance are intimately linked to 
blood flow and oxygen delivery. This makes the choice of experimental model critical 
when trying to evaluate physiologically relevant muscle function. In fact, recently it has 
been suggested that FO does not enhance myocardial efficiency (Goo et al., 2014), yet 
the experiment was conducted using perfusate in an in situ model. There is extensive 
evidence demonstrating the importance of whole blood perfusion when using this type 
of model (Pepe & McLennan, 1993; Topping & Trimble, 1985). In effect, the 
physiologically relevant aspect of oxygen conductance is altered and renders the heart to 
conditions never experienced in vivo when perfusate is used ex vivo instead of whole 
blood. Although ex vivo studies using perfusate have provided many insights, a whole 
blood perfusion method offers specific advantages for the physiological questions 
relating to FO and cardio-protection being explored in this thesis. As such, this research 
will use a physiologically stable in vivo model of cardiac function to assess the effects 
of FO on healthy and ischaemic cardiac function. Not only does an in vivo model 
optimise oxygen diffusion and conductance to the heart but it also gives a more accurate 
representation of normal physiological function because metabolic waste clearance, 
vascular responses, humoral changes and neural inputs to the heart are maintained.  
Cardiovascular disease persists as a principal contributing factor to worldwide mortality 
rates and the impact of cardiovascular disease is expected to increase substantially as 





improvements in the treatment and prevention of cardiovascular disease over recent 
decades, it has been demonstrated that traditional risk factors are evolving and there are 
increasing cases of cardiovascular disease in the absence of Standard Modifiable 
cardiovascular Risk Factors ‘SMuRFs’ (Vernon et al., 2017). Therefore, elucidating the 
physiological actions of FO doses achievable within a typical Western-style human diet 
containing high amounts of SFA and n-6 PUFA, whilst using a physiological relevant in 
vivo model, is important for informing further human research. A better understanding 
of the benefits fish or FO intake provides the heart will contribute to informed 





AIMS AND HYPOTHESES 
This thesis took a translational approach, using human research to inform in vivo animal 
studies, which in turn aims to inform further human research. The overarching aim 
relevant to all studies completed was to characterise cardiac function following 
supplementation of human dietary achievable FO doses, within a nutritionally relevant 
Western-style diet (high SFA and n-6 PUFA) and a physiologically appropriate in vivo 
animal model. 
 
More specifically, this thesis aimed to determine the effects of suppleming dietary 
acheivable FO doses on: 
Aim 1: (Chapter 2) 
incorporation patterns of LC n-3 PUFA throughout excitable tissue with unique 
physiological roles from within the same animal.  
Aim 2: (Chapter 4) 
resting cardiac function, including heart rate, heart rate variability and 
haemodynamic performance of the heart. 
Aim 3: (Chapter 5) 
arrhythmia generation during ischaemia and reperfusion injury. 
Aim 4: (Chapter 6) 
cardiac haemodynamic function during ischaemia and in the proceeding post-
ischaemic recovery. 











Membrane fatty acid incorporation, 
tissue mass and body weight following 
supplementation of human dietary 











2.1 INTRODUCTION   
Investigations of FO supplementation in animals have historically used high intake 
ranges to achieve membrane phospholipid incorporation and elucidate physiological 
mechanisms of action of LC n-3 PUFA (Charnock et al., 1989; Charnock et al., 1986; 
Matthan et al., 2005; McLennan, 2014; McLennan et al., 1992a; Slee et al., 2010). 
However, phospholipid incorporation does not need the high intakes previously 
supposed. It has now been demonstrated that myocardial and skeletal muscle 
composition is particularly sensitive to DHA incorporation and changes occur in the rat, 
when using low doses of DHA-rich FO (Henry et al., 2015; McLennan et al., 2007; Slee 
et al., 2010).  
2.1.1 Skeletal muscle phospholipid fatty acid composition 
Comparative physiology studies have demonstrated that incorporation of PUFA into 
skeletal muscle phospholipids across mammals is closely linked to the contractile 
characteristics of the muscle. For example, phospholipids from the rapidly contracting 
skeletal muscle in the European brown hare which can reach peak running velocities of 
80kmh-1 have been reported to contain a very high concentration of PUFA (Valencak et 
al., 2003). Furthermore, n-6 PUFA has been demonstrated to be associated with 
increased maximum running speed in a range of land based mammals (Ruf et al., 2006) 
and in salmon (McKenzie et al., 1998). Likewise, pectoral muscles in the hummingbird 
or shaker muscles in the rattlesnake which both have very high contractile frequencies 
have been shown to incorporate DHA preferentially compared to slow frequency 
contracting leg and ventral muscles within each animal respectively (Infante et al., 
2001). Interestingly, despite having similar contractile profiles, the pectoral muscle of 
the hummingbird contained almost two-fold more DHA than the shaker muscle of the 
rattle snake. The authors attributed this difference to double packing of mitochondrial 
inner phospholipids (where the oxidative phosphorylation machinery is located) in the 
hummingbird pectoral muscles to optimise the rapid and sustained contraction (Infante 
et al., 2001).  
It has also been hypothesised that enhanced muscle performance associated with 





(Daveloose et al., 1993; Stillwell & Wassall, 2003). However, the aforementioned 
studies are linked by the type of skeletal muscle fibre required to achieve these types of 
contraction. Muscle comprised of predominately FG and FOG fibres are characterised 
by a powerful and fast rate of contraction. To produce powerful and rapid contractions 
an extensive network of sarcoplasmic reticulum (SR) is needed for the distribution and 
reuptake of Ca2+ by the SR Ca2+-ATPase (SERCA) (Berchtold et al., 2000). Therefore, 
preferential DHA incorporation into muscles with greater SERCA content suggests that 
the role of PUFA in skeletal muscle is not only related to increased membrane fluidity 
and improved oxidative phosphorylation, but also intimately linked to Ca2+ handling.  
Exercise training also exerts an influence on membrane phospholipid fatty acid profiles 
observed in skeletal muscle. Human studies have demonstrated that low-intensity 
exercise increases oleic acid concentrations and reduces the concentration of total n-6 
PUFA, particularly AA in skeletal muscle membrane phospholipids (Andersson et al., 
1998). Similarly, oleic acid and DHA have been demonstrated to increase in the 
phospholipids of knee extensor muscles (Helge et al., 2001) and the vastus lateralis 
muscle following endurance training in healthy males when compared to untrained 
males consuming the same diet (Andersson et al., 2000). Therefore, it appears as though 
intrinsic contractile properties of the muscle combined with exercise training could 
partly explain the differences observed in relative phospholipid composition between 
muscle fibre types.  
Importantly for this thesis, manipulation of dietary fatty acid profiles strongly 
influences skeletal muscle phospholipid fatty acid composition. Altering the diet has 
been demonstrated to produce rapid changes in fatty acid phospholipid profiles of 
skeletal and cardiac muscle in animals (Ayre & Hulbert, 1996a; Pan & Storlien, 1993) 
and in humans (Andersson et al., 2002; McGlory et al., 2014). In fact, it has been 
demonstrated that altering the diet produces a much stronger effect on the fatty acid 
profile of skeletal muscle then exercise training does in the rat (Turner et al., 2004). 
Furthermore, there is evidence to show that when FO is supplemented to the diet of rats, 
LC n-3 PUFA, in particular, DHA is preferentially incorporated into cardiac and 
skeletal muscle phospholipids (Henry et al., 2015; Peoples & McLennan, 2014; Stark et 





observed regardless of whether more EPA or DHA is present in the original oil 
preparation supplied (Ayre & Hulbert, 1996a). 
2.1.2 Myocardial phospholipid fatty acid composition    
Myocardial membrane phospholipid LC n-3 PUFA concentrations reflect the type of 
fatty acids supplied in the diet in a similar manner to what is observed in skeletal 
muscles. Increased incorporation of LC n-3 PUFA into myocardial phospholipids 
occurs at the cost of reduced total n-6 PUFA as also observed in skeletal muscle 
(Charnock et al., 1986; Metcalf et al., 2007; Slee et al., 2010). It has also been 
demonstrated that myocardial phospholipids preferentially accumulate DHA, well 
above circulating fatty acid levels (Christensen & Høy, 1992; Owen et al., 2004; Slee et 
al., 2010), regardless of whether a DHA (Slee et al., 2010) or EPA (Pepe & McLennan, 
1996) predominant oil is used in the diet, similar to skeletal muscle. Dose-response 
investigations have shown a linear relationship between FO supplementation and LC n-
3 PUFA phospholipid concentrations in myocardial cells (Matthan et al., 2005; Owen et 
al., 2004). However, these findings have been reconsidered after Slee, E.L. et al., 2010 
demonstrated dosages above 1.25% wt/wt lay in the asymptotic range of a hyperbolic 
curve when doses below 1.25% are considered, particularly for DHA (Figure 2.1). This 
study also demonstrated that the lowest concentration of FO in the rat to alter 
phospholipid incorporation is 0.16%, and the authors predicted that the threshold for 
DHA incorporation is even lower at 0.0027%. This observation, together with the 
demonstration that similar cardiac physiological effects occur when using doses of 
1.25% or 12%, suggests that doses above 1.25% are beyond a critical saturation point to 
produce phospholipid and physiological changes. Time-course investigation of fatty 
acid incorporation demonstrates that DHA is rapidly up-taken by the myocardium 
before reaching a plateau point, whereas EPA increases linearly (Owen et al., 2004). 
However, the optimal supplementation time for dietary achievable doses to achieve 
maximal myocardial phospholipid DHA incorporation in the rat is four weeks (Slee et 
al., 2010). 
Throughout this thesis, ‘low doses' of FO will be referred to as ‘dietary achievable FO 
doses’. This terminology will be used because ‘low intake’ is commonly used to 





whereas ‘low doses’ describes the treatment (supplementing FO using doses lower than 
previous studies (Owen et al., 2004)). Human ‘dietary achievable’ equivalent doses of 
FO in the rat, range from 0.16 – 1.25% wt/wt with 0.16% representing an easily 
achievable dose from direct fish consumption (≈1 salmon [100g] serve/week) and 
1.25% representing a dose achieved via capsule supplements (≈6 capsules per/day) 
(Slee et al., 2010). Doses higher than 1.25% and below 3% (≈15 capsules per/day) 
would not be easily achievable in the human diet except with concentrated products; 
they will be referred to as ‘therapeutic’. Doses above 3% will be referred to as ‘supra-
therapeutical’ because they would be hard to achieve in the human diet even with 
concentrated capsule supplements, making findings from previous studies using such 







Figure 2.1: Dose relationships of dietary fish oil feeding & rat myocardial DHA & EPA 
incorporation. Colours bands represent doses described in Table 2.1. Figure adapted 
from Slee, E.L et al., 2010. 
 
Table 2.1: Equivalence of rat fish oil doses to the human diet. 
Rat Diet 











5 9.1 33 28 
1.25 2.3 8 6.8 
0.31 0.57 2 1.7 
*Based on human energy intake of 8700 kJ per day, †Based on salmon n-3 content of 
1.9g/100g, ‡Based on typical FO capsule content of 330mg EPA+DHA. (Slee et al., 
2010) 
Fill represents historically common doses which will be referred to as supra-
therapeutical in this thesis. 
Fill represents the ModFO dose of this study which would require ≈6 FO capsules 
per/day in humans. 
Fill represents LowFO dose of this study which would require ≈2 salmon [100g] 
serve/week in humans. 
 




   
 





2.1.3 The effect of fish oil on excitable membrane composition 
Skeletal muscle membrane phospholipids incorporate DHA in a very similar fashion to 
myocardial phospholipids with dietary intervention. However, very few studies have 
investigated the specific incorporation patterns of DHA throughout skeletal muscle fibre 
types, and the conclusions have been mixed. Originally, studies demonstrated that DHA 
concentrations are highest in SO muscles such as the soleus (Blackard et al., 1997; 
Kriketos et al., 1995), but more recently it has been demonstrated that DHA levels are 
higher in mixed FOG and FG fibres of the gastrocnemius (Henry et al., 2015). To the 
knowledge of the author, no studies to date have investigated the specific phospholipid 
incorporation patterns of DHA throughout an entire array of skeletal muscle fibre types 
within the one animal. Therefore, systematic investigations to be completed in this 
thesis, within the rat, will allow observations to be made for the first time. Phospholipid 
DHA incorporation patterns will be determined, with knowledge of the type of muscle 
fibre predominantly making up each individual skeletal muscle. Using the rat hind-limb 
is the ideal model to investigate a cross section of muscles due to the well-known and 
consistent fibre type composition profile available (Armstrong & Phelps, 1984). 
Additionally, the use of the rat allows for sampling of heart and skeletal muscle tissue 
from within the same animal. Most importantly, the use of an animal model allows for 
precision dosing of LC n-3 PUFA and removes the influence of exercise training which 
is difficult to control in human trials, allowing definitive separation of dietary groups 
and confident conclusions to be made as a direct result of altering the diet only. 
Furthermore, all animals in the dietary investigations of this thesis will be fed a Control 
diet which contains 5% SFA, 2.5% SSO and the remaining 2.5% will be OO which will 
be exchanged for FO to provide a LowFO (0.31%) and ModFO (1.25%) diet. This 
replicates a typical Western style diet more closely with a high SFA and high ratio of n-
6 to n-3 PUFA content (USDA, 2016) than previous low dose studies (Henry et al., 
2015; Slee et al., 2010). Therefore, the primary objective of the this study was to 
characterise the influence of providing human dietary achievable FO doses, for four 
weeks, on phospholipid DHA incorporation across a range of skeletal muscles and 






2.1.4 The effect of fish oil on skeletal muscle mass 
Incorporation of LC n-3 PUFA into skeletal muscle phospholipids is associated with 
anti-catabolic and/or anabolic properties leading to maintenance of and increased lean 
muscle mass. Skeletal muscle hypertrophy occurs when the ratio of muscle protein 
synthesis exceeds that of muscle protein breakdown (Phillips et al., 1997). 
Supplementing therapeutic doses of FO has been demonstrated to improve muscle 
protein synthesis rates independent of training in elderly, middle-aged and young 
individuals (Smith et al., 2011; Smith et al., 2015). Muscle protein synthesis rates in 
mammals are closely linked to the rapamycin complex and key regulatory kinases, 
including mTOR, p70S6K1 and focal adhesion kinase (Dickinson et al., 2011). 
Supplementation of FO in humans has been demonstrated to increase phosphorylation 
of mTOR and p70S6K1 (Smith et al., 2011), increase the total protein content of focal 
adhesion kinase (McGlory et al., 2014) and altered mitochondrial function along with 
extracellular matrix organisation (Yoshino et al., 2016). Animal studies have 
demonstrated that supra-therapeutical doses of FO stimulates endogenous glucose 
production and increases phosphorylation of anabolic signaling kinases in ageing rats 
(Kamolrat et al., 2013), enhances insulin-sensitive protein metabolism in steers 
(Gingras et al., 2007), reduce myosin heavy chain loss during hindlimb immobilisation 
in the rat (You et al., 2010) and enhance gene expression of growth regulatory factors 
involved in myogenesis (Castillero et al., 2009). Given the evidence, it is likely that LC 
n-3 PUFA is acting through a combination of the mechanisms discussed to increase 
muscle protein synthesis rates resulting in increased skeletal muscle mass. As such, the 
second objective of this study was to determine the influence of human dietary 
achievable FO doses on skeletal muscle mass. 
2.1.5 The effect of fish oil on body weight 
In contrast to the lean tissue anabolic effects of LC n-3 PUFA discussed, it has also 
been suggested that increasing FO intakes may help reduce body weight in humans via 
an anti-obesity effect (Buckley & Howe, 2009, 2010; Couet et al., 1997; Kabir et al., 
2007). The changes in body weight observed with FO supplementation in humans have 
been attributed to changes in fat oxidation pathways, gene expression, altered energy 





(Thorsdottir et al., 2007) and reduced fat deposition (Baillie et al., 1999). Animal 
studies have provided some evidence to support this by demontrating that FO 
supplementation can attenuate body fat gain in obesogenic dietary models (Belzung et 
al., 1993), particularly visceral fat accumulation (Ruzickova et al., 2004) and reduce 
body weight in mice which were obese before supplementation began (Huang et al., 
2004). However, the animal research that supports effects in obesity to date has used FO 
doses which are extremely high even in reference to supra-therapeutical doses (5 to 60% 
wt/wt, equivalent in man to FO: 28g/d and more) and could not be achieved in the 
human diet. Therefore, the third objective of this study was to determine the influence 
of human dietary achievable FO doses, provided in the presence of a typical Western-





 2.2 AIMS AND HYPOTHESES 
The primary aim of this study was to establish fatty acid composition of a range of 
skeletal muscles and myocardial phospholipids in the rat following supplementation of 
FO doses achievable within a typical Western-style human diet. The secondary aim was 
to describe the effect of FO on skeletal muscle mass and identify any changes to whole 
body weight.   
Specifically, these experiments had the following aims and hypotheses: 
Aim 1: Determine the influence of supplementing human dietary achievable FO doses 
to a typical Western-style diet on phospholipid DHA concentrations in excitable tissues 
including cardiac and skeletal muscle from within the same animal. 
Hypothesis 1: Myocardial and skeletal muscle phospholipids will 
incorporate DHA at the expense of total n-6 PUFA concentrations, in 
particular AA. 
Hypothesis 2: Incorporation of DHA into skeletal muscle phospholipids will 
be muscle fibre type specific. 
 
Aim 2: Quantify if the supplementation of human dietary achievable FO doses to a 
typical Western-style diet high in SFA and n-6 PUFA influences muscle mass. 
Hypothesis 3: Incorporation of LC n-3 PUFA into skeletal muscle 
phospholipids will result in increased muscle mass. 
 
Aim 3: Describe the influence of supplementing human dietary achievable FO doses to 
a typical Western style diet high in SFA and n-6 PUFA on body weight.  
Hypothesis 4: The addition of human dietary achievable FO doses to a 






2.3 METHODS  
2.3.1 Animals & ethical considerations 
A primary cohort (cohort 1) of twenty three (23) male rats (Sprague Dawley) was used 
for the general methods of this thesis (Chapter 3) and a second cohort (cohort 2) of sixty 
two (62) male rats (Sprague Dawley) were used for the investigations of the effects of 
LC n-3 PUFA on biochemical and physiological outcomes (Chapters 2, 4, 5 & 7). All 
animals were obtained from the Animal Resource Centre (Perth, Western Australia) and 
housed at the University of Wollongong’s animal housing facility. All experiments 
contained within this thesis were approved by the University of Wollongong animal 
ethics committee and were conducted according to the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes (NHMRC, 2004).  
2.3.2 Standardisation  
The animals were housed with a 12-hour light-dark cycle, and the temperature 
maintained between 20°C-22°C. Animals were able to access food and water ad libitum 
prior to the feeding protocol beginning. All animals were weighed upon arrival at the 
animal housing facility and before any experiments taking place. 
2.3.3 Diet composition 
Animals were randomly assigned to one of three isoenergetic prefabricated diets after 
consuming regular lab chow for a minimum of one week. The pre-fabricated diets have 
been previously developed for use in similar feeding studies (Slee et al., 2010). All diets 
contained 10% fat, 50% carbohydrate and 20% protein by weight plus minerals and 
vitamins based on the American Institute of Nutrition AIN-93M diet (Reeves, 1997), 
differing only in the fatty acid composition making up the total fat. All components 
used in the diets were carefully weighed and combined in the laboratory by the primary 
investigator and then frozen at -20ºC to ensure quality control. A small amount of food 
dye was added to the mixture to allow identification of the different dietary groups. The 
diets contained a balanced mix of macro and micro nutrients consisting of (as a 
percentage of dry weight) 56.5% corn-starch, 10% sucrose. 9% casein, 5% fibre, 10% 





were used to make up the total 10% of fat in the diet. All diets contained 5.5% beef 
tallow, 2.5% n-6 PUFA rich sunflower seed oil and the remaining 2.5% was made up of 
olive oil. This specific mix of oils was used to replicate the high amounts of SFA and n-
6 PUFA found in a typical western diet (Simopoulos, 2008; USDA, 2016). Extra light 
olive oil was used as the refining process to produce extra light olive oil removes the 
majority of the antioxidant polyphenols commonly present in less refined oils. FO 
(0.31% - LowFO, 1.25% - ModFO) was substituted for olive oil  using DHA-rich tuna 
FO (Nu-Mega Ingredients Pty Ltd, Australia) to create experimental groups. The DHA-
rich tuna FO provided LC n-3 PUFA concentrations of 26% DHA and 7% EPA, with 
the remaining major fatty acids being made up of 20% 16:0 Palmitic acid and 15% 18:1 
Oleic acid (Table 2.3). The experimental doses of FO used in this thesis were selected 
as they were calculated to be equivalent to doses that are achievable in the human diet 
and they have previously been demonstrated to increase incorporation of LC n-3 PUFA 
into myocardial and skeletal muscle phospholipids (Henry et al., 2015; Slee et al., 
2010). Conversion of doses from rat to human equivalent is completed based on an 
average human energy intake of 8700kJ per/day, average salmon n-3 PUFA content of 
1.9g/100g and the typical capsule content of 330mg EPA+DHA (Slee et al., 2010). The 
equivalent rat energy intake is approximately 325kJ/day, based on a 300g rat eating 
















Table 2.2: Nutrient composition of rat diets. 
Ingredient Amount Source 
Cornstarch 565g Frutex (Aus) 
Sucrose 100g Commercially available 
Casein 90g Rogers & Company (Aus) 
Fibre 50g MP BioMedicals (Aus)  
Vitamin 10g MP BioMedicals (Aus) 
Mineral 35g MP BioMedicals (Aus) 
Oil* 100g Variable sources 
Gelatine 50g Commercially available 
Total 1000g  
Water 400mL  







Table 2.3: Proportion of oils and fatty acids of all three diets. 
Fat Source (% of diet) Control LowFO ModFO 
Beef Tallow 5.5% 5.5% 5.5% 
Sunflower Oil 2.5% 2.5% 2.5% 
Olive Oil 2.0% 1.69% 0.75% 
DHA-rich Tuna FO 0% 0.31% 1.25% 
Fatty Acid Profile (% fat in diet)   
14:0 2.04 2.13 2.41 
16:0 17.21 17.51 18.40 
18:0 12.07 12.14 12.37 
18:1n-9 41 39.12 33.45 
18:2n-6 (LA) 19.29 19.07 18.43 
18:3n-3 (ALA) 0.55 0.55 0.56 
20:4n-6 (AA) 0.02 0.08 0.24 
20:5n-3 (EPA) 0 0.22 0.87 
22:5n-3 (DPA) 0 0.03 0.14 
22:6n-3 (DHA) 0 0.89 3.61 
Σ SFA 32.22 32.73 34.28 
Σ MUFA 43.73 42.06 37.01 
Σ PUFA 19.9 20.89 23.87 
Σ n-6 PUFA 19.35 19.19 18.7 
Σ n-3 PUFA 0.55 1.69 5.17 
Σ EPA + DHA 0 1.11 4.48 
n-6:n-3 35.35 11.32 3.62 
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 18:0 = stearic acid; 18:1n-9 = oleic 
acid; 18:2n-6 = linoleic acid (LA); 18:3n-3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic 
acid (AA); 20:5n-3 = eicosapentaenoic acid (EPA); 22:5n-3 = docosapentaenoic acid (DPA); 
22:6n-3 = docosahexaenoic acid (DHA); SFA = saturated fatty acid; MUFA = 






2.3.4 Dietary feeding protocol 
Animals were randomly placed on the pre-fabricated diet between 8-10 weeks of age 
and allowed ad libitum access to the diet and water for a minimum of four (4) weeks 
and a maximum of six (6) weeks. Animals and their food were checked every two days 
to ensure the diet was being consumed and there were no signs of animal distress. All 
animals were weighed before beginning the diet and then weighed once again before 
experimental procedures.   
2.3.4a Body weight and food intake measurements 
A subgroup (N=32) of animals were investigated throughout the feeding protocol to 
determine if there were any differences in feeding patterns or weight gain with the 
different oils. Food intake was measured twice weekly to the nearest gram and then 
normalised to grams consumed/100 g body weight/day. Body weight change was 
measured weekly to the nearest gram, and tissue was collected at the end of the feeding 
protocol. A correction factor was calculated for the daily evaporation of water weight in 
the different diets while stored in the same environmental conditions as the animals to 
make an accurate measurement of the amount of food consumed by the animals.  
2.3.5 Tissue collection 
Note: The methods and results for tissue collection and biochemical analyses are 
reported in this chapter. However, the animals used for tissue collection were 
anaesthetised and physiological protocols (Chapter 4, 5 and 7) were undertaken 
beforehand. Upon completion of the protocols animals were euthanased via rapidly 
removing the heart from the animal and exsanguination and tissue collection began. 
2.3.5a Cardiac tissue collection 
The major vessels were cut from the heart, and the heart was submerged into an ice cold 
perfusate to arrest beating. Excised hearts were then flushed with an ice cold 0.9% NaCl 
solution to remove any remaining blood. The great vessels were then dissected off the 
heart, and the heart was weighed to obtain a heart mass. The atria were dissected off to 
obtain a ventricle mass, and the right ventricle was dissected off to obtain a left ventricle 





in liquid nitrogen, then stored at -80oC until fatty acid or tissue morphological and 
biochemical analyses.   
2.3.5b Skeletal muscle tissue collection 
Following exsanguination and removal of the heart, muscles were dissected from the 
left lower limb. An incision was made from the ileum toward the foot, and the skin was 
removed via blunt force. A selection of muscles from the upper thigh and lower limb 
were then carefully dissected. Physical force was used to separate larger muscle groups 
into red, white and red/white sections (Armstrong & Phelps, 1984). Surgical scissors 
and curved forceps were used to separate the fascia between smaller muscle groups 
being dissected; scissors were used to remove any remaining connective tissue/tendon. 
Following muscle dissection, the tibia was removed via cutting the ligaments at the 
knee and ankle using a scalpel and then measured to the nearest millimetre.  
2.3.5c Skeletal muscle mass measurement 
Following dissection, a pre-defined selection of muscles representing a cross section of 
SO, FG and FOG fibre types from the left thigh and lower limb were weighed to the 
nearest milligram. The muscles of the upper limb included the: quadricep(red), 
quadricep(white), quadricep(mixed), pectineus and adductor longus. Muscles from the lower 
limb included the: soleus, gastrocnemius(red), gastrocnemius(white), gastrocnemius(mixed) 
plantaris, extensor digitorum longus (EDL) (Table 2.4).  Muscles which were 
predominantly made up of SO fibres included: soleus and Adductor longus. Muscles 
which were predominantly made up of FG fibres included: quadricep(white), 
gastrocnemius(white), EDL and pectineus. Muscles which were predominantly made up of 
FOG fibres included: quadricep(red), gastrocnemius(red) and plantaris (Armstrong & 
Phelps, 1984). Following measurements, each muscle was immediately frozen in liquid 
nitrogen using liquid nitrogen cooled tongs. Muscles were then stored at -80oC until 










Table 2.4: Known fibre-type composition of the selected rat hind-limb muscles 
used to analyse LC n-3 PUFA phospholipid concentrations. 
  Fibre type (% population) 
Skeletal muscle Mass (g) FOG FG SO 
Upper-limb     
quadricep(red) 0.75 ± 0.02 53 ± 9 40 ± 8 7 ± 1 
quadricep(white) 0.78 ± 0.06 25 ± 6 74 ± 6 1 ± 1 
pectineus 0.28 ± 0.01 35 ± 4 55 ± 4 10 ± 2 
adductor longus 0.10 ± 0.01 18 ± 4 1 ± 1 81 ± 4 
Lower-limb     
soleus 0.19 ± 0.02 13 ± 4 0 87 ± 4 
gastrocnemius(red) 0.15 ± 0.03 62 ± 3 8 ± 4 30 ± 2 
gastrocnemius(white) 0.13 ± 0.01 16 ± 3 84 ± 3 0 
plantaris 0.45 ± 0.03 50  3 41 ± 3 9 ± 1 
extensor digitorum 
longus (EDL) 
0.23 ± 0.08 42 ± 7 56 ± 8 2 ± 1 
Typical muscle mass and fibre type population (%) according to FOG, FG & SO 
classifications of the rat hind-limb skeletal muscles measured in this study. Ordered by 
muscle mass (heaviest to lightest). Table adapted from Armstrong et al. 1984.  





2.3.6 Membrane phospholipid fatty acid analysis     
The fatty acid composition of heart and skeletal muscle tissue collected at the end of 
experimental procedures was analysed using gas chromatography to determine 
phospholipid LC n-3 PUFA incorporation of DHA and EPA. The following outlines in 
detail the acidified total lipid extraction (Folch et al., 1957), solid phase separation into 
phospholipid fractions (Kim & Salem, 1990) and transesterification (Lepage & Roy, 
1986) techniques used in this study. All solvents used throughout the process contained 
0.01% butylated hydroxytoluene as an antioxidant.   
2.3.6a Total lipid extraction 
Heart and skeletal muscle tissue samples were thawed on ice before preparation 
occurred. Tissues were cut into sample sizes of 100-150mg and washed with a 
phosphate buffered saline solution to remove any external contaminants (blood etc.) and 
placed into labelled 2mL Eppendorf tubes. An equal volume of stainless steel beads to 
tissue mass were then added to the tube along with 1mL of chloroform: methanol (2:1). 
The tubes were capped and then placed in a cardiac tissue homogenization blender 
(Bullet Blender®, Next Advance Inc, New York, USA) and homogenised following the 
manufacturer's instruction’s for 4 minutes at speed 8. The homogenates were then 
transferred to labelled Pyrex PTFE screw cap tubes and another 2mL of chloroform: 
methanol was used to wash out Eppendorf tubes. The samples were then rotated for 3-4 
hours at 4ºC to separate lipid from protein. Following rotation, 2mL of 1M H2SO4 was 
added to the tubes, and they were vortexed for 10seconds before being centrifuged at 
1000rom (210 x g) and 4ºC for 10min (Hettich Zentrifugen Rotina 46 R). The top (acid) 
layer was removed to a waste beaker, and a Pasteur pipette was used to go through the 
middle protein plug and transfer the bottom solvent layer into new tubes. A further 2mL 
of 1M H2SO4 was added, and the procedures described above were repeated. The 
bottom layer was then again collected, and a small amount of sodium hydrosulphite was 
added, and the tube was shaken to remove any remaining aqueous phase. The solution 
was then filtered through a Pasteur pipette with a small amount of silane treated glass 






2.3.6b Phospholipid separation 
The samples were dried down under nitrogen while sitting in a heating block set at 
37ºC. The phospholipid filters (Sep-Pak Silica Classic Filters, Waters Corporation, 
NSW, AUS) were numbered and placed into holding racks with 10mL glass syringes 
inserted into the filters as the reservoir for solvents. The filters were washed with 5mL 
hexane before running the samples through the filter. Once samples were dry, 5mL of 
hexane was added to bind the lipids in the tube and given a vortex (10sec) before being 
passed through the filters. A further 3mL hexane was used to wash out test tubes, and 
this was run through the filter also. Triglycerides were then eluted with 3 x 5mL ethyl 
acetate and discarded. Phospholipids were eluted with 3 x 5mL methanol.  
2.3.6c Transesterification       
Extracted phospholipids were dried under nitrogen in a heating block and then 
redissolved in 2mL methanol: toluene (4:1 v/v). A Gilson positive displacement pipette 
was used to add 200µL of the volatile acetyl chloride to the culture tubes very slowly 
while vortexing to methylate the samples. Teflon tape was then wrapped clockwise 
around the thread of the tubes, and they were capped tightly. The tubes were placed into 
a heating block which had been pre-heated to 100ºC for sixty minutes. This enhances 
the methylation process of the fatty acids. Following methylation, the tubes were 
transferred to a metal rack sitting in icy water and allowed to cool for ten minutes. Very 
slowly, 5mL of a 6% solution of potassium carbonate (K2CO3) was added to neutralise 
the volatile acetyl chloride. The tubes were transferred to a pre-cooled centrifuge (4ºC) 
and spun at 3000rpm (1895 x g) for ten minutes resulting in an upper toluene phase of 
fatty acid methyl esters. This upper toluene phase was carefully drawn off and 






2.3.6d Analysis using gas chromatography 
Samples were analysed using a Shimadzu GC-17A gas chromatograph with flame 
ionisation detection. The gas chromatograph used a 30m x 0.25mm internal diameter 
capillary column under the following conditions:  
 
Running Conditions: 
Injector Temperature: 260 °C 
Detector Temperature: 260°C  
Carrier Gas: Ultra-high purity hydrogen 




Initial: 185 °C 
Ramp: 5°C / minute for 15 minutes 
Maintain: 260 °C for 5 minutes 
Total Run time: 20 minutes 
 
Individual fatty acid peaks on the chromatograph were identified by comparison to 
authentic fatty acid methyl ester standards (F.A.M.E MIX C4-C24, Sigma-Aldrich, 
Castle Hill, Aus). Peak quantitation was calculated by area for corrected normalisation. 
The relative proportions of EPA+DHA and other fatty acids in the tissue samples were 
divided by the total area of fatty acids to give the relative amount of each fatty acid (% 
total fatty acids). 
2.3.7 Chemicals 
All chemical used in this study were sourced from Sigma-Aldrich (Castle Hill, Aus). 
Solvents used in this study including chloroform, hexane, methanol, ethyl acetate and 
toluene were analytical grade. Butylated hydroxyl toluene was made up to 0.01% w/v in 





in concentrate and diluted to make a stock 1M solution. Sodium hydrosulphite and 
Potassium carbonate (K2CO3) were purchased as powders and stored according to 
manufacturer’s instructions before use. Fatty acid standards (F.A.M.E MIX C4-C24, 
Sigma-Aldrich, Castle Hill, Aus) were purchased neat and were stored at -20ºC until 
use; they were then dissolved in toluene for analysis. 
2.3.8 Statistics 
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise 
stated. The effects of diet treatment on experimental outcomes were tested via ANOVA. 
Individual group means were compared using Bonferroni’s post-hoc analysis. All 
statistical analyses were performed in a blinded manner and completed using SPSS 21 






Fatty acids are reported as relative percent composition of phospholipid membranes; 
minor fatty acids were analysed but omitted from the reported results. Fatty acid 
analysis was started from Stearic acid (16:0) in cardiac phospholipids and Myristic acid 
(14:0) in skeletal muscle phospholipids and continued until docosahexaenoic acid 
(DHA - 22:6n-3). 
2.4.1 The effect of fish oil supplementation on cardiac phospholipid fatty acids  
Total LC n-3 PUFA content was significantly higher in the LowFO and ModFO group 
compared to the Control group. Elevated LC n-3 PUFA concentrations were 
predominantly associated with a significantly greater DHA incorporation in both FO 
supplemented groups. The composition of DHA in myocardial phospholipids was 
5.02% in the Control group, 13.10% in the LowFO group and 18.35% in the ModFO 
group (Table 2.5). EPA was not detected in the Control group but was present in both 
FO groups (LowFO: 0.11%, ModFO: 0.39%) in very small amounts. Elevated LC n-3 
PUFA concentrations were associated with lower total n-6 PUFA content. More 
specifically, the LowFO and ModFO groups displayed significantly less AA and LA in 
their phospholipid composition compared to the Control group (Table 2.5). As a result 
of these differences the n-6:n-3 ratio for both the FO supplemented groups was lower 
than the Control group. Additionally, Oleic acid (18:1n-9) and total MUFA was 












Table 2.5: The effect of fish oil on phospholipid fatty acid composition in the 
left ventricle. 
 Control LowFO ModFO Trend p 
16:0 12.0 (±0.5) 13.1 (±0.4) 13.1 (±0.3)  
16:1 0.79 (±0.1) 0.79 (±0.1) 0.55 (±0.06)*† 0.031 
18:0  22.2 (±0.7) 21.4 (±0.3) 23.0 (±0.5)  
18:1n-9  9.3 (±0.5) 8.5 (±0.3) 6.0 (±0.3)* 0.002 
18:1n-7 3.4 (±0.1) 3.3 (±0.2) 3.2 (±0.1)  
18:2n-6 (LA) 26.1 (±1.4) 20.8 (±0.6)* 18.5 (±0.6)* < 0.001 
18:3n-3 (ALA) 0.39 (±0.02) 0.43 (±0.01) 0.39 (±0.02)  
20:4n-6 (AA) 19.7 (±0.6) 16.7 (±0.4)* 14.2 (±0.7)*† < 0.001 
20:5n-3 (EPA) ND 0.11 (±0.01) 0.39 (±0.02)† < 0.001 
22:5n-3 (DPA) 0.98 (±0.08) 1.3 (±0.1)* 1.3 (±0.02)* 0.002 
22:6n-3 (DHA) 5.0 (±0.2) 13.1 (±0.9)* 18.3 (±0.4)*† < 0.001 
Σ SFA 34.2 (±0.4) 34.5 (±0.3) 36.1 (±0.8)  
Σ MUFA 13.5 (±0.7) 12.7 (±0.5) 9.8 (±0.3)* 0.007 
Σ PUFA 52.2 (±0.9) 52.7 (±0.3) 53.9 (±0.8)  
Σ n-6 PUFA 45.7 (±1.0) 37.7 (±0.7)* 33.3 (±1.1)*† < 0.001 
Σ n-3 PUFA 6.4 (±0.3) 14.9 (±0.8)* 20.5 (±0.4)*† < 0.001 
Σ EPA + DHA 5.0 (±0.2) 13.1 (±0.9)* 18.7 (±0.4)*† < 0.001 
n-6:n-3 7.1 (±0.4) 2.5 (±0.2)* 1.6 (±0.07) * < 0.001 
Values are mean ± SEM (n = 4 – 5 per group). ND = Not Detected. *p <0.05 vs Control 
diet. †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc test).   
Abbreviations: 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = stearic acid; 18:1n-9 = 
oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n-3 = α-linolenic acid 
(ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid (EPA); 22:5n-3 = 
docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA = saturated fatty 









2.4.2 The effect of fish oil supplementation on skeletal muscle phospholipid fatty 
acids 
soleus phospholipid DHA composition was significantly greater in the LowFO 
(13.79%) and ModFO (18.98%) groups compared to the Control (8.35%) group (Table 
2.6). EPA was not detected in the soleus of the Control or LowFO group but was 
present in the ModFO group in a very small amount. The Control group displayed the 
highest AA phospholipid concentration (16.61%) and reduced in a dose-dependent 
manner in the LowFO (13.46%) and ModFO (10.89%) groups. Other differences unique 
to the soleus which occurred in the phospholipid composition included a significantly 
lower concentration of LA and Stearic acid in the ModFO group compared to the 
Control group (Table 2.6). 
quadriceps(red) phospholipid DHA composition was significantly greater in the LowFO 
(15.94%) and ModFO (21.72%) groups compared to the Control (11.24%) group 
(Table 2.7). EPA was not detected in the quadriceps(red) of the Control but was present 
in the LowFO and ModFO groups. The Control group displayed the highest AA 
phospholipid concentration (16.19%) and reduced in a dose-dependent manner in the 
LowFO (12.23%) and ModFO (9.37%) groups. Other differences unique to the 
quadriceps(red) which occurred in the phospholipid composition included a significantly 
lower concentration of Vaccenic acid (18:1n-7), LA and ALA in the ModFO group 








Table 2.6: The effect of fish oil on phospholipid fatty acid composition of the 
soleus. 
 Control LowFO ModFO Trend p 
14:0 4.3 (±0.3) 5.6 (±0.3) 5.9 (±0.4)  
16:0 12.9 (±0.2) 13.6 (±0.6) 13.9 (±0.5)  
16:1 0.94 (±0.1) 0.90 (±0.1) 0.7 (±0.1)  
18:0  19.9 (±0.1) 18.9 (±0.3) 18.4 (±0.2)* 0.03 
18:1n-9  9.7 (±0.2) 9.9 (±0.9) 7.9 (0.2) 0.07 
18:1n-7 2.7 (±0.1) 2.2 (±0.07) 2.3 (±0.0)  
18:2n-6 (LA) 21.7 (±0.5) 18.9 (±0.3) 17.8 (±0.7)* 0.014 
18:3n-3 (ALA) 0.70 (±0.02) 0.61 (±0.01)* 0.64 (±0.02) 0.013 
20:4n-6 (AA) 16.6 (±0.2) 13.4 (±0.4)* 10.8 (±0.6)*† < 0.001 
20:5n-3 (EPA) ND ND 0.55 (±0.09)*† < 0.001 
22:5n-3 (DPA) 1.7 (±0.1) 1.6 (±0.1) 1.7 (±0.1)  
22:6n-3 (DHA) 8.3 (±0.1) 13.7 (±0.2)* 18.9 (±0.7)*† < 0.001 
Σ SFA 37.3 (±0.2) 38.3 (±0.4) 38.2 (±0.3)  
Σ MUFA 13.4 (±0.3) 13.1 (±1.2) 11.0 (±0.3)  
Σ PUFA 49.1 (±0.4) 48.5 (±1.4) 50.7 (±0.6)  
Σ n-6 PUFA 38.3 (±0.4) 32.4 (±1.3)* 28.7 (±1.1)* < 0.05 
Σ n-3 PUFA 10.7 (±0.1) 16.1 (±0.4)* 21.9 (±0.7)*† < 0.001 
Σ EPA + DHA 8.3 (±0.1) 13.7 (±0.2)* 19.5 (±0.7)*† < 0.001 
n-6:n-3 3.5 (±0.07) 2.0 (±0.07)* 1.3 (±0.09)*† < 0.001 
Values are mean ± SEM (n = 5 per group). ND = Not Detected. *p <0.05 vs Control 
diet, †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc test). 
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = 
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n-
3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid 
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA 









Table 2.7: The effect of fish oil on phospholipid fatty acid composition in the 
quadriceps(red). 
 Control LowFO ModFO Trend p 
14:0 4.6 (±0.8) 4.9 (±0.3) 5.3 (±0.4)  
16:0 15.5 (±0.3) 16.8 (±0.5) 15.8 (±0.5)  
16:1 0.82 (±0.09) 1.0 (±0.2) 0.79 (±0.05)  
18:0  18.1 (±0.4) 17.6 (±0.9) 16.9 (±0.2)  
18:1n-9  7.4 (±0.2) 8.0 (±0.2) 7.1 (0.3)  
18:1n-7 3.0 (±0.1) 2.7 (±0.08) 2.4 (±0.09)* 0.008 
18:2n-6 (LA) 20.5 (±0.7) 17.9 (±0.1) 17.8 (±0.8)* 0.029 
18:3n-3 (ALA) 0.62 (±0.04) 0.68 (±0.03) 0.5 (±0.02)* 0.022 
20:4n-6 (AA) 16.1 (±0.2) 12.2 (±0.3)* 9.3 (±0.5)*† < 0.001 
20:5n-3 (EPA) ND a 0.31 (±0.02) 0.5 (±0.06)* < 0.05 
22:5n-3 (DPA) 1.7 (±0.1) 1.7 (±0.1) 1.4 (±0.1)  
22:6n-3 (DHA) 11.2 (±0.3) 15.9 (±0.2)* 21.7 (±0.6)*† < 0.001 
Σ SFA 38.3 (±0.3) 39.4 (±0.6) 38.1 (±0.5)  
Σ MUFA 11.3 (±0.1) 11.8 (±0.4) 10.4 (±0.4)  
Σ PUFA 50.3 (±0.2) 48.6 (±0.5) 51.4 (±0.8)† 0.021 
Σ n-6 PUFA 36.7 (±0.5) 30.1 (±0.3)* 27.2 (±0.8)*† < 0.001 
Σ n-3 PUFA 13.6 (±0.4) 18.4 (±0.3)* 24.2 (±0.5)*† < 0.001 
Σ EPA + DHA 11.2 (±0.3) 16.0 (±0.3)* 22.2 (±0.6)*† < 0.001 
n-6:n-3 2.6 (±0.1) 1.6 (±0.03)* 1.1 (±0.05)*† < 0.001 
Values are mean ± SEM (n = 4 – 5 per group). ND = Not Detected. a Only detected in 3 
samples. *p <0.05 vs Control diet, †p <0.05 vs LowFO diet (One-way ANOVA with 
Bonferroni post-hoc test). 
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = 
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n-
3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid 
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA 







quadriceps(white) phospholipid DHA composition was significantly greater in the LowFO 
(14.05%) and ModFO (20.50%) groups compared to the Control (8.56%) group (Table 
2.8). EPA was not detected in the quadriceps(white) of the Control group but was present 
in the LowFO and ModFO groups. The Control group displayed the highest AA 
phospholipid concentration (17.45%) and reduced in a dose-dependent manner in the 
LowFO (15.29%) and ModFO (12.83%) groups. Other differences unique to the 
quadriceps(white) included a significantly lower concentration of Oleic acid (18:1n-9) in 
the LowFO and ModFO group compared to the Control group and a significantly lower 
concentration of LA and Palmitoleic acid in the LowFO group compared to the Control 
group (Table 2.8). 
extensor digitorum longus (EDL) phospholipid DHA composition was significantly 
greater in the LowFO (15.82%) and ModFO (20.71%) groups compared to the Control 
(10.82%) group (Table 2.9). EPA was detected in small amounts in the EDL of all 
groups; however it was significantly greater in both FO supplemented groups. The 
Control group displayed the highest AA phospholipid concentration (15.85%) and 
reduced in a dose-dependent manner in the LowFO (13.49%) and ModFO (9.96%) 
groups. Other differences unique to the EDL included a significantly higher total PUFA 









Table 2.8: The effect of fish oil on phospholipid fatty acid composition in the 
quadriceps(white). 
 Control LowFO  ModFO Trend p 
14:0 5.9 (±0.3) 6.3 (±0.1) 5.1 (±0.1)†  
16:0 21.7 (±0.4) 22.3 (±0.2) 21.9 (±0.1)  
16:1 0.92 (±0.1) 0.82 (±0.03) 0.93 (±0.01)  
18:0  14.5 (±0.3) 14.2 (±0.5) 13.7 (±0.1)  
18:1n-9  8.7 (±0.1) 7.1 (±0.09)* 7.6 (±0.1)* <0.01 
18:1n-7 2.9 (±0.1) 2.7 (±0.1) 2.5 (±0.1)  
18:2n-6 (LA) 15.3 (±0.3) 12.7 (±0.6)* 11.6 (±0.07)* < 0.01 
18:3n-3 (ALA) 0.96 (±0.05) 0.8 (±0.03) 0.79 (±0.03)  
20:4n-6 (AA) 17.4 (±0.6) 15.2 (±0.1)* 12.8 (±0.3)*† < 0.001 
20:5n-3 (EPA) ND 0.07 (±0.01)* 0.37 (±0.09)*† < 0.001 
22:5n-3 (DPA) 2.5 (±0.3) 2.3 (±0.1) 1.7 (±0.3)* 0.045 
22:6n-3 (DHA) 8.5 (±0.2) 14.0 (±0.4)* 20.5 (±0.3)*† < 0.001 
Σ SFA 42.5 (±0.9) 43.8 (±0.6) 40.9 (±0.1)  
Σ MUFA 12.6 (±0.2) 10.7 (±0.2)* 11.1 (±0.09)* 0.021 
Σ PUFA 44.8 (±0.9) 45.4 (±0.7) 47.9 (±0.2)* 0.035 
Σ n-6 PUFA 32.7 (±0.6) 28.0 (±0.5)* 24.4 (±0.2)*† < 0.001 
Σ n-3 PUFA 12.0 (±0.4) 17.3 (±0.4)* 23.4 (±0.2)*† < 0.001 
Σ EPA + DHA 8.5 (±0.2) 14.1 (±0.4)* 20.8 (±0.2)*† < 0.001 
n-6:n-3 2.7 (±0.06) 1.6 (±0.04)* 1.0 (±0.02)*† < 0.001 
Values are mean ± SEM (n = 5 per group). ND = Not Detected. *p <0.05 vs Control 
diet, †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc test). 
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = 
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n-
3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid 
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA 









Table 2.9: The effect of fish oil on phospholipid fatty acid composition in the 
extensor digitorum longus (EDL). 
 Control LowFO ModFO Trend p 
14:0 3.2 (±0.1) 2.8 (±0.2) 2.8 (±0.1)  
16:0 19.8 (±0.3) 20.7 (±0.5) 20.2 (±0.1)  
16:1 0.85 (±0.09) 0.77 (±0.07) 0.82 (±0.06)  
18:0  18.1 (±0.5) 17.2 (±0.2) 16.7 (±0.2)  
18:1n-9  8.2 (±0.2) 7.0 (±0.08) 7.9 (±0.2)  
18:1n-7 2.8 (±0.1) 2.5 (±0.1) 2.4 (±0.05)  
18:2n-6 (LA) 17.7 (±0.5) 16.7 (±0.7) 15.4 (±0.3)  
18:3n-3 (ALA) 0.73 (±0.05) 0.74 (±0.04) 0.71 (±0.02)  
20:4n-6 (AA) 15.8 (±0.2) 13.4 (±0.4)* 9.9 (±0.2)*† < 0.001 
20:5n-3 (EPA) a 0.03 (±0.02) 0.15 (±0.04)* 0.48 (±0.04)*† < 0.001 
22:5n-3 (DPA) 1.6 (±0.09) 1.7 (±0.05) 1.6 (±0.04)  
22:6n-3 (DHA) 10.8 (±0.2) 15.8 (±1.1)* 20.7 (±0.4)*† < 0.001 
Σ SFA 41.2 (±0.3) 40.8 (±0.4) 39.8 (±0.2)  
Σ MUFA 11.9 (±0.2) 10.3 (±0.2) 11.2 (±0.2)  
Σ PUFA 46.7 (±0.5) 48.7 (±0.5) 48.9 (±0.4)* 0.047 
Σ n-6 PUFA 33.5 (±0.3) 30.2 (±0.8)* 25.3 (±0.2)*† < 0.001 
Σ n-3 PUFA 13.2 (±0.1) 18.4 (±1.0)* 23.5 (±0.5)*† < 0.001 
Σ EPA + DHA 10.8 (±0.2) 15.9 (±1.1)* 21.1 (±0.4)*† < 0.001 
n-6:n-3 2.5 (±0.02) 1.6 (±0.1)* 1.1 (±0.03)*† < 0.001 
Values are mean ± SEM (n = 4 – 5 per group). a Only detected in 2 samples. *p <0.05 vs 
Control diet, †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc 
test). 
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = 
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n-
3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid 
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA 







gastrocnemius(red) phospholipid DHA composition was significantly greater in the 
LowFO (19.32%) and ModFO (23.07%) groups compared to the Control (12.61%) 
group (Table 2.10). EPA was detected in small amounts in the gastrocnemius(red) of all 
groups; however it was significantly greater in both FO supplemented groups. The 
Control group displayed the highest AA phospholipid concentration (15.83%) and 
reduced in a dose-dependent manner in the LowFO (12.29%) and ModFO (9.44%) 
groups. Other differences unique to the gastrocnemius(red) included a significantly lower 
concentration of Vaccenic acid, ALA and total MUFA in the LowFO and ModFO 
groups compared to the Control group. The ModFO group also showed a significantly 








Table 2.10: The effect of fish oil on phospholipid fatty acid composition in the 
gastrocnemius(red). 
 Control LowFO ModFO Trend p 
14:0 3.9 (±0.1) 4.9 (±0.4) 4.1 (±0.2)  
16:0 16.5 (±0.4) 16.0 (±0.2) 17.3 (±0.5)  
16:1 0.23 (±0.08) 0.20 (±0.01) 0.23 (±0.07)  
18:0  17.0 (±0.4) 16.4 (±0.3) 17.4 (±0.2)  
18:1n-9  8.3 (±0.2) 7.6 (±0.04) 7.6 (±0.2)  
18:1n-7 2.8 (±0.1) 2.3 (±0.08)* 2.2 (±0.06)* < 0.01 
18:2n-6 (LA) 19.7 (±0.8) 18.1 (±0.7) 16.0 (±0.4) * 0.01 
18:3n-3 (ALA) 0.70 (±0.03) 0.59 (±0.07)* 0.49 (±0.07)*† < 0.001 
20:4n-6 (AA) 15.8 (±0.4) 12.2 (±0.1)* 9.4 (±0.3)*† < 0.001 
20:5n-3 (EPA) 0.11 (±0.01) 0.28 (±0.01)* 0.54 (±0.06)*† < 0.001 
22:5n-3 (DPA) 1.9 (±0.1) 1.6 (±0.1) 1.3 (±0.1) * 0.021 
22:6n-3 (DHA) 12.6 (±0.2) 19.3 (±0.2)* 23.0 (±0.5)*† < 0.001 
Σ SFA 37.6 (±0.2) 37.4 (±0.3) 38.9 (±0.7)  
Σ MUFA 11.4 (±0.2) 10.2 (±0.1)* 10.1 (±0.3) * < 0.01 
Σ PUFA 50.9 (±0.3) 52.3 (±0.4) 50.9 (±0.7)  
Σ n-6 PUFA 35.6 (±0.5) 30.4 (±0.6)* 25.5 (±0.7)*† < 0.001 
Σ n-3 PUFA 15.3 (±0.2) 21.8 (±0.1)* 25.4 (±0.5)*† < 0.001 
Σ EPA + DHA 12.7 (±0.2) 19.6 (±0.2)* 23.6 (±0.5)*† < 0.001 
n-6:n-3 2.3 (±0.06) 1.3 (±0.04)* 1.0 (±0.04)*† < 0.001 
Values are mean ± SEM (n = 5 per group). *p <0.05 vs Control diet, †p <0.05 vs 
LowFO diet (One-way ANOVA with Bonferroni post-hoc test). 
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = 
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n-
3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid 
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA 






2.4.2a Differences in phospholipid composition between muscles following fish 
oil supplementation 
Total phospholipid LC n-3 PUFA, particularly DHA following dietary FO 
supplementation was significantly greater in cardiac muscle and across all skeletal 
muscles sampled in the hind-limb for the LowFO and ModFO groups compared to the 
Control group. The lowest concentration of phospholipid DHA were observed in the 
Control group left ventricle (5.02%) phospholipids and the greatest DHA concentrations 
were observed in the gastrocnemius(red) (23.07%) skeletal muscle phospholipids of the 
ModFO group (Figure 2.2). When DHA was plotted against the percentage of muscle 
fibre type typical for each muscle there was a strong association between % fast 
oxidative glycolytic and % phospholipid DHA (Spearman correlation ρ = 0.91, r2 = 
0.87). However, no relationship was apparent between % fast glycolytic or % slow 
oxidative fibres (Figure 2.3). The association was even stronger when the left ventricle 
(not containing FOG) was included in the analysis (ρ = 0.94, r2 = 0.89). Interestingly, 
different muscle’s with unique fibre type profiles such as the Control gastrocnemius(red) 
(%FOG: 62) and LowFO soleus (%FOG: 13) showed ‘overlap’ of DHA concentrations 
(Control gastrocnemius DHA: 12.61%, LowFO soleus DHA: 13.79%) when comparing 
between dietary treatments.  
Total phospholipid n-6 PUFA following dietary supplementation was significantly 
lower in cardiac muscle and across all skeletal muscles sampled in the hind-limb for the 
LowFO and ModFO groups compared to the Control group. The lowest concentration 
of phospholipid AA were observed in the ModFO gastrocnemius(red) (9.44%) skeletal 
muscle phospholipids and the greatest phospholipid AA concentrations were observed 
in the left ventricle (19.74%) phospholipids of the Control group. Additionally, LA was 
significantly lower in all muscles of the ModFO group except the EDL when compared 
to the Control group. These changes in muscle phospholipid composition were reflected 
by a significantly lower n6:n3 ratio across all muscle in the LowFO and ModFO groups 

























































































Figure 2.2: The effect of supplementing dietary achievable fish oil doses on 
phospholipid concentrations of DHA and AA across different muscles.  
Values are mean ± SEM (n = 4 – 5 per group). *p <0.05 vs Control diet, †p <0.05 vs 
LowFO diet (One-way ANOVA with Bonferroni post-hoc test). 








Figure 2.3: Spearman correlations of DHA incorporation across cardiac and skeletal muscles with different proportions of muscle fibre 
types. 
 
Overlap Zone: A potential area where similar metabolic properties may be displayed in muscles with different fibre type composition but similar 
DHA concentration following supplementation. For example, the LowFO muscle with 0% FOG fibres shares similar DHA levels to the Control muscle 





2.4.3 The effect of fish oil supplementation on tissue mass 
The mass of the muscles collected in this study was comparable to previously published 
data in the rat (Armstrong & Phelps, 1984). Total heart mass and tibia length were in 
the healthy range (Yin et al., 1982). Total heart mass was not significantly different 
between groups and this did not change when normalised to tibia length (Table 2.11). 
Individual hind-limb skeletal muscles were anatomically referenced to the upper hind-
limb or lower hind-limb to calculate a total mass. There were no significant differences 
demonstrated between any of the groups for total upper hind-limb or lower hind-limb 
muscle mass. Comparison of individual muscle mass was also completed. There were 
no significant differences between dietary groups for the mass of any of the individual 
muscles measured (Table 2.11). Muscles were categorised into fibre type groups (SO, 
FG, FOG) based on the proportion of muscle fibres present within the muscle 
(Armstrong & Phelps, 1984). When analysing muscles categorised as SO, FG or FOG 
the gastrocnemius(mixed) and quadriceps(mixed) were not included as it is unclear what the 
fibre type proportions would have been in these muscles. There were no significant 
differences between any of the groups when muscle were analysed in this way (Table 







Table 2.11: The effect of fish oil on tissue mass in the rat. 
 Control LowFO ModFO 
  
Tibial length (cm) 4.6 (±0.04) 4.68 (±0.09) 4.63 (±0.04) 
  
Cardiac muscle mass (g)  
^ Total heart  1.51 (±0.05) 1.55 (±0.05) 1.62 (±0.04) 
# Ventricular   1.27  (±0.03) 1.28 (±0.03) 1.32 (±0.03) 
Left ventricle  0.98 (±0.02) 0.99 (±0.03) 1.04 (±0.03) 
Total heart/Tibial length 
(g/cm) 0.32 (±0.01) 0.34 (±0.01) 0.35 (±0.01) 
    
Skeletal muscle mass (g)    
Lower hind-limb     
soleus 0.19  (±0.03)  0.18 (±0.02)  0.24 (±0.03) 
gastrocnemius(red) 0.23 (±0.03) 0.24 (±0.01) 0.29 (±0.04) 
gastrocnemius(white) 0.22 (± 0.02) 0.20 (±0.01) 0.17 (±0.02) 
gastrocnemius(mixed) 2.03 (±0.09) 2.02 (±0.06) 1.77 (±0.07) 
plantaris 0.49 (±0.02) 0.52 (±0.04) 0.47 (±0.03) 
extensor digitorum longus 0.19 (±0.01)  0.17 (±0.02) 0.20 (±0.01) 
Total – Lower hind-limb 3.39 (±0.12) 3.31 (±0.07) 3.33 (±0.27) 
    
Upper hind-limb    
quadriceps(red) 0.26  (±0.02)  0.25 (±0.01)  0.31 (±0.03) 
quadriceps(white) 0.30  (±0.02)  0.29 (±0.01)  0.29 (±0.03) 
quadriceps(mixed) 2.23 (±0.11) 2.28 (±0.20) 2.38 (±0.14) 
adductor longus 0.14  (±0.03)  0.11 (±0.01)  0.10 (±0.02) 
pectineus 0.14  (±0.04)  0.12 (±0.02)  0.13 (±0.02) 
Total – Upper hind-limb 2.97 (±0.15) 3.08 (±0.19) 3.20 (±0.17) 
    
Fibre type    
Slow oxidative 0.34  (±0.03)  0.29 (±0.02)  0.42 (±0.27) 
Fast glycolytic 0.88 (±0.06) 0.80 (±0.03) 0.81 (±0.04) 
Fast oxidative glycolytic 1.03  (±0.05)  0.99 (±0.05)  1.07 (±0.08) 
Values are mean ± SEM (n = 12 – 16 per group). ^ Total heart mass included the atria 
but not the great vessels. # Ventricular mass included the left and right ventricle. No 





2.4.4 The effect of fish oil supplementation on body weight and food consumption 
Body weight and food consumption were monitored in a subgroup from the Control, 
LowFO and ModFO diets throughout the feeding protocol. There were no significant 
differences between the baseline body weights of all groups prior to dietary 
supplementation (Table 2.12). Body weight significantly increased at each week of 
measurement for all groups (Figure 2.4A). However, there were no significant 
differences between any of the groups for total weight gain. The ModFO group 
displayed a significantly greater weight gain to week three and four compared to the 
Control group (Figure 2.4B). At week four the LowFO group had significantly greater 
weight gain compared to the Control group. At the end of the feeding protocol, there 
were no significant differences between the groups in post supplementation body weight 
or body weight normalised to tibia length (Table 2.10).   
 
 
Table 2.12: The effect of fish oil on body weight measurements. 
 Control LowFO ModFO 
Body weight (pre) (g) 426 (±9) 434 (±11) 425 (±9) 
Body weight (post) (g) 512 (±16) 540 (±18) 542 (±14) 
Body weight (post)/Tibial length 109 (±3.5) 116 (±4.2) 116 (±2.9) 
Key: Pre = Prior to fatty acid supplementation, Post = Following 4 weeks of dietary 













































Figure 2.4: The effect of fish oil on A: Change in body weight from baseline B: 
Body weight at weekly intervals.  
Values are mean ± SEM (n = 20 – 22 per group). *p <0.05 vs Control diet, †p <0.05 vs 





Food intake is represented as grams consumed/100grams body weight/day. Food intake 
was reduced at each week of the feeding period by all groups (Figure 2.5). There was 
no statistically significant interaction found between dietary treatment and food intake 

























Figure 2.5: The effect of fish oil on food intake at weekly intervals. 
Values are mean ± SEM (n = 20 – 22 per group). All values are in grams / 100grams 







Excitable tissues incorporated LC n-3 PUFA, particularly DHA following 
supplementation of FO doses achievable within a typical Western-style human diet 
(high SFA and n-6 PUFA). Compared to the Control group, concentrations of DHA in 
myocardial phospholipids were more than twice as high in the LowFO diet and 
approximately three-fold higher in the ModFO group; some skeletal muscle 
phospholipids displayed even greater changes. Higher phospholipid concentration of 
DHA predominantly occurred at the expense of n-6 PUFA, particularly AA, although it 
was not in direct exchange for only one type of fatty acid or even for n-6 PUFA 
entirely. For the first time, this study demonstrated that DHA is incorporated 
preferentially into predominantly fast oxidative glycolytic (FOG) fibre type skeletal 
muscle membranes compared to slow oxidative (SO) and fast glycolytic (FG) fibre type 
membranes. Nonetheless, FO supplementation did not influence individual skeletal 
muscle mass or total hind-limb skeletal muscle mass. However, and in contrast to the 
fourth hypothesis, relative change of body weight at the completion of supplementation 
was greater in the FO diets. The robust and preferential incorporation of DHA into 
excitable membrane phospholipids when made available via the diet emphasises the 
important role it plays in the healthy physiological functioning of excitable tissue. 
2.5.1 Excitable tissue phospholipid LC n-3 PUFA concentrations 
Following supplementation of dietary achievable FO doses to animals, substantial 
changes were observed in the membrane phospholipid fatty acid composition of all 
excitable tissues measured. The current study is the first to report changes in cardiac and 
skeletal muscles encompassing a full range of contractile properties. The doses used in 
this study were chosen as they are equivalent to what can be achieved in the human diet 
either by fish consumption or via supplementation (Table 2.1). A 100g serve of salmon 
has been demonstrated to contain 2000mg of LC n-3 PUFA, in the form of EPA 
≈550mg and DHA ≈1450mg (USDA, 2009). Considering an average salmon portion is 
≈250g, this would require only a single salmon meal per week to achieve equivalent 
levels of incorporation as the LowFO dose. The ModFO dose would represent 
approximately 7-8 fish meals per week which would be towards the upper boundary of 





(Slee et al., 2010). Therefore, the doses used in this study indicate that a modest 
increase in fish intake in humans would alter phospholipid DHA incorporation and 
could contribute to some of the physiological benefits displayed in populations with 
high habitual intakes of fish.  
Higher total phospholipid LC n-3 PUFA concentrations were driven via DHA that 
appeared to be preferentially incorporated into excitable phospholipids rather than EPA. 
Incorporation of DHA into excitable membrane phospholipids was largely due to the 
DHA-rich tuna oil used in the FO diets which contains 30% DHA and only 7% EPA. 
Interestingly, myocardial phospholipid DHA composition has been demonstrated to 
increase (15.4 > 27.2, ↑ 11.8%) more than phospholipid EPA (0.3 > 3.1, ↑ 2.8%) 
composition even when a high EPA oil is used (Pepe & McLennan, 1996). 
Notwithstanding, DHA-rich tuna oil was specifically used to better replicate the oils 
available in typical oily table fish. Table fish such as tuna, salmon, sardine, mackerel 
and anchovy contain naturally higher concentrations of DHA than EPA (Strobel et al., 
2012). Whereas, the supplements used in the majority of RCT predominantly have 
much higher doses of EPA than DHA (Bays, 2006). Therefore, the use of DHA-rich 
tuna oil in future RCT would allow stronger conclusions to be drawn between the 
outcomes described and directly relating them to an increase in fish intake in the human 
diet.  
The current study demonstrated that when n-6 PUFA and SFA were held constant, in-
line with levels consumed in the typical Western diet, the supplementation of dietary 
achievable FO doses resulted in higher phospholipid DHA concentrations in excitable 
tissues of the animals. It has been well established that incorporation of fatty acids into 
excitable membrane phospholipids of the rat are reflective of the fatty acids being 
supplied in the diet, particularly at therapeutic and supra-therapeutical doses, not easily 
achievable in the human diet (Charnock et al., 1986; Peoples & McLennan, 2010; Pepe 
& McLennan, 2002). However, in recent centuries the typical n-6 to n-3 ratio in humans 
has increased to ≈10:1 from an estimated 1:1 prior to the agricultural revolution 
(DeFilippis & Sperling, 2006). It has been suggested that it is essential to reduce the n-
6:n-3 ratio, by altering intakes of both n-3 and n-6 PUFA, to reduce competition for 
phospholipid space and enable phospholipid incorporation of LC n-3 PUFA (Hulbert et 





ratio is based on trials which have altered the amount of LC n-3 PUFA supplied while 
maintaining n-6 PUFA levels (Ayre & Hulbert, 1996a; Hulbert et al., 2005). Studies 
which have altered both sub-classes of PUFA, demonstrate that incorporation of DHA 
into myocardial phospholipids occurs relative to the absolute LC n-3 PUFA supplied in 
the diet, regardless of background concentrations of n-6 PUFA (Slee et al., 2010; Stark 
et al., 2007a; Stark et al., 2007b). Comparison of myocardial phospholipid 
incorporation patterns between studies using dietary achievable FO doses demonstrates 
that DHA is preferentially incorporated into myocardial phospholipids, regardless of the 
background fat profile (Table 2.13). Results from this study support the latter 
observations and extend them to demonstrate that high concentrations of SFA together 
with high concentrations n-6 PUFA does not prevent the incorporation of DHA into 
excitable phospholipids of the rat. In fact, the incorporation of DHA into myocardial 
and skeletal phospholipids resulted in a concomitant reduction of AA in all tissues 
measured, with some equal and smaller decreases in LA in some tissues, causing a 
reduction in total n-6 PUFA content. These changes resulted in a reduction of the n3:n6 
ratio of the phospholipid without changing the total n-6 PUFA being supplied in the 
diet.  
Table 2.13: Comparison of myocardial phospholipid DHA concentrations from 
studies using diets with different background oil blends. 
 Background oil 
blend 
Membrane phospholipid DHA composition 
Study Control 0.31%FO ∆ 1.25%FO ∆ 
Henry et al. 
(2015) 
OO 6.2 16.8 +10.6 20.4 +14.2 
Slee et al. 
(2010) 
OO 7.7 14.9 +7.2 19.3 +11.6 




6.7 14.3 +7.6 19.4 +12.7 
Current study SFA/SSO (High 
SFA & n-6 
PUFA) 
5.0 13.1 +8.1 18.4 +13.4 
Abbreviations: SFA = saturated fatty acid; OO = olive oil; SSO = sunflower seed oil; ∆:= 
change from control. 
 
Interestingly, phospholipid DHA composition was not absent in Control animals despite 
LC n-3 PUFA being removed from the diet. Animals in the Control diet likely obtained 





particularly DHA and AA are crucial in the healthy development of the foetus neural 
and vascular systems (Crawford, 1993; Crawford et al., 1997). Because of this, these 
fatty acids are incorporated very efficiently from maternal into foetal phospholipids via 
the placenta throughout the third trimester of pregnancy in a process known as 
biomagnification (Ruyle et al., 1990). Additionally, it is well established that the 
newborn continues to receive DHA and AA postnatally through maternal breast milk 
(Makrides et al., 1996). This means the newborn tissue is supplied with abundant DHA 
and is one of the reasons why deficiency studies need to use two generations of animals 
to produce a truly DHA-deficient model (Moriguchi et al., 2001).  
Another possible source of DHA in the Control animals is via conversion from ALA 
that was present in small amounts from OO using ∆ six desaturase enzymes (Gibson et 
al., 2013). The conversion of EPA to DHA using this pathway also explains why EPA 
was either not detected or only detected in very small amounts, yet DHA was present in 
Control animal phospholipids. Incorporation of DHA may have also occurred during the 
lab chow feeding before the beginning of the animals being placed on the experimental 
diets. Lab chow contains a mixture of protein sources, one of which is fishmeal 
containing LC n-3 PUFA (Pepe & McLennan, 1996). Trace amounts of ALA and LC n-
3 PUFA may also have been present in the Control diet due to their presence in the 
casein and starch being used in the diet mixture and contamination of equipment used to 
mix the different diets (Greiner et al., 2003). Importantly, this demonstrates the strong 
response of excitable tissue including cardiac and skeletal muscle to preferentially 
incorporate and maintain even very small amounts of DHA made available.  
2.5.2 Excitable tissue membrane phospholipid fatty acid differences 
Very few studies have investigated the specific incorporation patterns of DHA 
throughout muscle fibre types, and the conclusions have been mixed. Some studies have 
demonstrated that DHA levels are highest in SO muscles such as the soleus (Blackard et 
al., 1997; Kriketos et al., 1995) but more recently it has been demonstrated that DHA 
levels are higher in mixed FOG and FG fibres of the gastrocnemius (Henry et al., 2015). 
In this study, muscles with an abundance of SO fibres such as the soleus and 
quadriceps(white) had the lowest concentration of DHA, whereas muscles with high 





highest DHA concentrations. Therefore, this study supports the findings demonstrated 
by Henry et al. 2015, and extends them to demonstrate that DHA incorporation into 
skeletal muscles is strongly correlated with the population of FOG muscle fibres in the 
rat hind-limb. The contrasting findings demonstrated by Kriketos et al. 1995 and 
Blackard et al. 1997 can be accounted for by differences in dietary feeding protocols. 
The current study used a diet which contained 10% fat wt/wt, whereas the diet used by 
Kriketos et al. 1995 contained 59% fat wt/wt, which does not represent a diet relevant to 
human nutrition and likely influenced muscle phospholipid fatty acid incorporation 
patterns. Animals in the study conducted by Blackard et al. 1997 were fed lab chow ad 
libitum before measurements were made. Lab chow contains a mixture of protein 
sources, one of which is fishmeal containing DHA (Pepe & McLennan, 1996). 
Incorporation of DHA may have occurred as a result of lab chow feeding artificially 
increasing phospholipid DHA concentrations of the soleus. Importantly, Control 
animals in this study were fed a pre-fabricated diet which did not contain any DHA and 
all muscles compared were sampled from within the same animal, allowing a precise 
representation of incorporation patterns. Therefore, this study investigated tissue DHA 
incorporation in a systematic way, confirming differences and establishing a pattern 
associated with muscle fibre type. For the first time, muscle fibre type dependent 
incorporation of DHA was demonstrated in the rat, with FOG muscles able to 
preferentially incorporate DHA and maintain it in the phospholipid at higher 
concentrations than FG and SO muscles, even in the absence of FO supplementation.   
Previous research has demonstrated that incorporation of DHA into skeletal muscle 
membrane phospholipids results in improved fatigue resistance (Peoples & McLennan, 
2010), maintained force development over a range of contraction patterns (Henry et al., 
2015) and enhanced oxygen efficiency (Peoples & McLennan, 2010). Human studies 
have also demonstrated several unique physiological roles for FO during exercise which 
may contribute to improved muscular performance (Mickleborough, 2013) and 
improved whole body oxygen efficiency (Peoples et al., 2008). Therefore, although not 
investigated directly in this study, the correlation between greater DHA concentrations 
and high proportions of FOG muscle fibres is likely linked to the physiological 





Muscle fibres of the quadriceps(red) and gastrocnemius(red) are predominantly used for 
powerful and rapid contractions such as jumping and sprinting. This type of contraction 
is suited to FOG muscle fibres as it requires a high turnover of rapidly produced ATP 
via non-oxidative pathways. These types of muscles display a high proportion of the 
MHC2 isoform that rapidly fatigues due to high rates of ATP consumption and small 
ATP reserves (Han et al., 2001). Comparative physiology studies have demonstrated 
that mammals which rely upon FOG muscle fibres for increased running speeds are 
closely associated with high concentrations of PUFA in skeletal muscle membrane 
phospholipids irrespective of the animals diet (Ruf et al., 2006; Valencak et al., 2003). 
Whereas, cardiac and soleus membranes which, respectively, display high amounts of 
the MHCβ and MHCslow isoform, had the least amount of DHA. These MHC isoforms 
are associated with low basal rates of ATP consumption and high ATP reserve capacity 
to serve their similar physiological function of slow and regular contractions without 
fatigue (Han et al., 2001). Therefore, differences in ATP turnover and storage displayed 
within these isoforms of MHC may be one reason for the associated differences in DHA 
incorporation displayed between FOG and SO muscles in this study.  
It is well-established that mitochondrial membrane phospholipids are intricately 
involved in the electron transfer and oxidative phosphorylation pathways of ATP 
production (Fleischer et al., 1962). Due to the reliance upon ATP, the ventricle and 
soleus contain very high concentrations of mitochondria relative to FOG muscles fibres 
of the quadriceps(red) and gastrocnemius(red), which predominantly use non-oxidative 
metabolism to generate ATP. Mitochondrial phospholipids naturally contain less PUFA 
than the whole tissue; this difference in phospholipid composition is proposed to be a 
result of selective pressure towards oxidative damage resistant membranes to counteract 
the increased concentrations of reactive oxygen species in the vicinity (Tsalouhidou et 
al., 2006). Membrane fractions were not separated in this study when measuring fatty 
acid composition. This is important because the mitochondrial membrane would contain 
lower relative concentrations of PUFA, which would contribute to reduced whole tissue 
phospholipid LC n-3 PUFA. Therefore, the lower phospholipid DHA concentrations 
measured in ventricular and soleus tissue could also be associated with the overall high 





Cardiac and skeletal muscles are intimately reliant upon the efficient movement and 
handling of Ca2+ in the sarcoplasmic reticulum (SR). In particular FOG muscle fibres 
have been demonstrated to have extensive networks of SR (Welch & Altshuler, 2009), 
and these muscles were associated with much higher levels of DHA. Phospholipids in 
the rabbit (Gould et al., 1987) and trout SR have been demonstrated to incorporate 
DHA at high levels, even when the diet is deficient of PUFA (Ushio et al., 1997). 
Higher phospholipid DHA concentrations in SR phospholipids helps explain why SR-
rich predominantly FOG muscle fibres of the quadriceps(red) and gastrocnemius(red) were 
observed to have the highest phospholipid concentrations of DHA in this study. The SR 
is responsible for excitation-contraction coupling in both cardiac and skeletal muscle. 
This is an energy dependent pathway which relies on the sarcoplasmic reticulum Ca2+ 
ATPase (SERCA) active pump. 
It is well established that membrane protein interactions and function can be affected by 
changing the phospholipid fatty acid composition (Bretscher, 1973). The role of 
SERCA in the membrane is to transfer Ca2+ from the cytosol to the lumen of the SR via 
active ATP hydrolysis during muscle relaxation (Endo, 1977). Therefore, muscles made 
up of majority FOG fibres which produce rapid and powerful contractions such as the 
quadriceps(red), and gastrocnemius(red) rely upon SERCA to cycle Ca2+ efficiently to 
allow repeated contractions. Comparative biology studies have shown that pectoral 
muscles in the hummingbird or shaker muscles in the rattlesnake which both contract 
very rapidly and require efficient SERCA activity incorporate LC n-3 PUFA, 
particularly DHA preferentially into the SR compared to other muscles within the 
animal (Infante et al., 2001). Additionally, skeletal muscle in rat’s supplemented FO has 
been demonstrated to be more resistant to fatigue and able to maintain contractile force 
production (Henry et al., 2015; Peoples & McLennan, 2010, 2014). Therefore, it 
appears likely that when made available in the diet, DHA is preferentially incorporated 
into FOG membranes because of the high proportion of SR membrane, leading to 






2.5.3 Skeletal muscle mass 
There was no evidence of catabolic or anabolic properties associated with FO 
supplementation from the skeletal muscle mass measured in healthy animals from this 
study. This finding contrasts the demonstration of FO producing anabolic effects in 
healthy elderly subjects with (Da Boit et al., 2016) or without resistance training (Smith 
et al., 2015). However, the Control group in the study conducted by Smith et al. 2015, 
on average had a reduction of 1% thigh muscle volume, and the FO group showed an 
increase of 2%. The catabolic changes observed in the Control groups muscle volume 
were much greater (∼1% over six months) than what normally occurs with ageing 
(∼0.5%-1%/y) (Goodpaster et al., 2006). This made the overall muscle volume change 
effect between groups larger than if FO had only been compared to the group’s relative 
baseline levels.  
The evidence provided of an anabolic effect of FO supplementation in these studies is 
when the skeletal muscles are in a state of decay e.g., sarcopenia associated with ageing 
rather than a healthy state which is likely why they contrast to the current findings of 
this study. In fact, eight weeks of FO supplementation in healthy, resistance-trained 
males has been shown to have no effect on muscle protein synthesis (McGlory et al., 
2016). Several recent reviews have also come to similar conclusions that FO 
supplementation results in an anti-catabolic rather than an anabolic effect in skeletal 
muscle (Jeromson et al., 2015), particularly in older individuals (Molfino et al., 2014). 
A large-scale three-year cross-sectional study of elderly patients supplemented FO 
demonstrated protection against physical performance decline (Abbatecola et al., 2009). 
The maintenance of physical performance was likely due to attenuation of muscle mass 
loss rather than increased muscle protein synthesis. Animal studies have demonstrated 
that muscle mass loss is attenuated in the tibialis anterior during a cachetic cancer model 
(van Norren et al., 2009) and also in a burn injury model using the guinea pig 
(Alexander et al., 1986). Similarly, soleus muscle atrophy measured via muscle mass 
and myosin heavy chain levels was alleviated in an immobilisation protocol of rats fed a 
diet rich in FO (You et al., 2010). Lean body mass is also preserved in patients 
following oesophageal cancer surgery when EPA enriched enteral nutrition is used 
following the surgery (Ryan et al., 2009). When these findings are combined with 





induce an anabolic or catabolic effect in skeletal muscle. Dietary achievable FO doses 
may play a role in attenuating muscle loss in diseased conditions or conditions of 
muscle decline such as sarcopenia associated with ageing. However, further research is 
needed to understand whether it has a role in promoting anabolic actions in healthy 
skeletal muscle.   
2.5.4 Body weight management 
Both FO groups had gained significantly more weight than the Control group by week 
four of the feeding protocol, despite no increases in skeletal muscle mass and no 
changes observed in food intake. This indicates that FO did not restrict body weight 
gain in healthy lean animals following four weeks of supplementation with dietary 
achievable doses. This finding aligns with non-obesogenic aninmal studies which 
consistently demonstrate that there is no significant effect of FO on weight management 
when using dietary achievable, therapeutic and supra-therapeutical doses of FO, and 
feeding durations ranging from four weeks to thirty months (Table 2.14). However, 
these findings along with the findings from the current study are in contrast to some 
studies in rodents that have demonstrated an attenuation of body fat accumulation in 
growing (Baillie et al., 1999; Hainault et al., 1993) and adult (Belzung et al., 1993; 
Huang et al., 2004; Ruzickova et al., 2004) animals exposed to obesogenic high-fat 
diets incorporating supra-therapeutic doses of LC n-3 PUFA. The conflicting 
conclusions between studies investigating a weight management effect of FO can be 
explained by the trial design and dietary supplementation methods used.  
The anti-obesity effect is consistently attributed to reductions in visceral adipose tissue 
deposition (Baillie et al., 1999; Hainault et al., 1993; Huang et al., 2004; Ruzickova et 
al., 2004). Diets high in SFA promote fat deposition to visceral adipose tissue (Rosqvist 
et al., 2014). The diets used in this study contained 10% background fat made up by 5% 
animal fat (high in SFA), 2.5% SSO (high in n-6 PUFA) and 2.5% OO (high in MUFA, 
which was substituted to make FO diets) to replicate a typical Western-style dietary fat 
distribution. Importantly, the diets in this study did not exchange SFA out of the diet for 
increased amounts of FO as is commonly performed in obesogenic models (Baillie et 
al., 1999; Hainault et al., 1993; Huang et al., 2004; Ruzickova et al., 2004). It has also 





to weight reduction (Thorsdottir et al., 2007). However, there were no significant 
differences in food intake levels in FO supplemented animals in this study, in line with 
several other animal studies (Kamolrat et al., 2013; Peoples & McLennan, 2014).  
Interestingly, some human studies have also suggested that supplementing LC n-3 
PUFA to the diet has a weight loss effect (Couet et al., 1997; Kabir et al., 2007), 
particularly when supplementation occurs in combination with exercise training 
(Buckley & Howe, 2009, 2010). The results from the current study showing greater 
weight gain, aligns with evidence of increased oxygen efficiency following FO 
supplementation in animals (Pepe & McLennan, 2002; Pepe & McLennan, 2007) and 
humans (Hingley et al., 2017; Peoples et al., 2008). This suggests that there is no 
potential for FO alone to produce a weight reduction effect and perhaps its efficacy in 
conjunction with exercise is due in part to the ability of FO to increase exercise capacity 
through improved fatigue-resistance (Henry et al., 2015; Hingley et al., 2017; Peoples 
& McLennan, 2010). Therefore, it appears that in the presence of unchanged SFA 
intakes, dietary achievable and therapeutic FO doses alone do not produce a weight loss 
effect but may provide fatigue-resistance to enhance the weight loss effects attributable 
to exercise.      
2.5.5 Conclusions 
It is now well established that obesity may lead to the development of hypertension, 
type II diabetes and atherosclerosis which are all high-risk factors for cardiovascular 
disease (Yusuf et al., 2001). Collectively, previous epidemiology, intervention trials and 
animal research has demonstrated a cardio-protective effect of fish consumption (Burr 
et al., 1989; McLennan, 2014; Mozaffarian & Wu, 2011). It is well established that 
obesity is associated with CVD outcomes, as such it has been hypothesised that the 
ability of FO to aid weight loss in obesity may reduce the risk of obesity driven CVD 
outcomes (Buckley & Howe, 2010). However, this study showed results that FO doses 
achievable within a typical Western-style human diet did not have a weight reduction 
action. This suggests that FO at these doses has questionable relevance to weight gain 
management and is likely acting via another mechanism (anti-arrhythmic, heart rate 
lowering, improving heart rate variability) to provide protection from cardiovascular 





DHA phospholipid incorporation allows any altered cardiovascular function 
demonstrated in the proceeding chapters to be confidently related directly to higher 







   Table 2.14: Comparison of the effect of fish oil on body weight in animals from different studies. 
FO Dose Animal Duration of feeding Outcome Author 








12 weeks ↔ Energy intake, body weight or body weight gain (Slee et al., 2010) 
1.25  – 6%  Human therapeutic range (∼6 capsules/day – 28 capsules/day)  








12 weeks ↔ Energy intake, body weight or body weight gain (Slee et al., 2010) 
> 6%   Human supra-therapeutical range ( > 28 capsules/day)  
 Rat (Wistar) 8 weeks ↔  Food intake, body weight or muscle mass.  (Peoples & McLennan, 2014) 
 Rat (Wistar) 6 weeks ↔  Body weight, body size as indicated by tibia length or heart mass (Abdukeyum et al., 2008) 
 Rat (Wistar) 16 weeks ↔  Body weight (Pepe & McLennan, 1996) 
 Rat (Wistar) 4 weeks ↔ Final body weight and body weight gain. (Belzung et al., 1993) 
 Marmoset Monkey 30 months ↔ Body weight or heart mass (Abeywardena et al. 1991) 
 Rat (Wistar) 10 months ↔ Body weight (Charnock et al., 1992) 
 Rat (Wistar) 8 months ↔  Weight gain or food intakes (McIntosh et al., 1985) 















3.1 INTRODUCTION   
Cardiac function has been demonstrated to be positively influenced by FO 
supplementation in healthy populations (Macartney et al., 2014; Peoples et al., 2008) 
and is consistently associated with reduced CVD rates in epidemiological and cohort 
studies (Burr et al., 1989; Kagawa et al., 1982; Kromhout et al., 1985). Several meta-
analyses have provided evidence to support these observations (Mozaffarian et al., 
2008; Mozaffarian. et al., 2005; Xin et al., 2013), however some RCT (Galan et al., 
2010; Roncaglioni et al., 2013; Svensson et al., 2006) and meta-analyses (Alexander et 
al., 2017; Nestel et al., 2015) of studies using supplements have produced mixed results 
which do not support the notion that FO is acting in a cardio-protective manner. The 
discrepant findings produced in large scale clinical trials can be explained by poor 
design because of i) misunderstandings of the underlying mechanisms and/or ii) 
misunderstanding the doses of FO required to modify cardiac function and dysfunction 
and/or iii) failure to account for significant pre-existing DHA incorporation in control 
groups (Ip et al., 2017; McLennan & Pepe, 2015).   
Chapter two of this thesis demonstrated that supplementing dietary achievable FO doses 
to a typical Western-style diet in the rat caused robust and preferential incorporation of 
DHA into phospholipids of excitable tissue, most notably skeletal muscle 
phospholipids. It is well-established that incorporation of DHA into skeletal muscle 
phospholipids improves fatigue resistance during both normoxic (Henry et al., 2015; 
Peoples & McLennan, 2010, 2014) and hypoxic contractions (Peoples & McLennan, 
2017), even while using dietary achievable FO doses. However, there are no studies 
which have investigated the effects of myocardial phospholipid DHA incorporation 
attributable to dietary achievable FO doses on healthy and ischaemic cardiac 
physiological function. As such, the remaining studies in this thesis aim to characterise 
whether dietary achievable FO doses alter rested healthy cardiac function and confer 
protection to cardiac function during and directly following ischaemia and reperfusion 
injury of the heart. Such experiments will help establish the physiological relevance of 
any health benefits associated with supplementing dietary achievable FO doses to a 




Prior research has established the importance of physiological conditions, principally 
oxygenation and temperature (Henry et al., 2015; Peoples et al., 2013; Pepe & 
McLennan, 1993), in establishing real effects of altered cardiac and skeletal muscle 
phospholipid composition. Functional evaluation of the rat heart in vivo meets that 
requirement and is coupled with scaled down clinically relevant techniques to describe 
cardiac function in clinical terms and thereby optimise interpretation and translation of 
the findings into practice. Therefore, the primary objective of this study was to 
investigate the use of left ventricular pressure volume loops (PV-loops) for the 
assessment of cardiac performance and the optimisation of surgical protocols used to 
measure in vivo PV-loops in the rat heart.  
3.1.1 Left ventricular pressure volume loops  
To date, multiple techniques have been used to assess left ventricular cardiac 
haemodynamic performance such as ultrasonography, flow probes, micromanometers, 
magnetic resonance imaging (MRI), and more recently miniaturised conductance 
catheters (Burkhoff et al., 2005).  The use of conductance catheters allows for the 
generation of instantaneous pressure and volume measurements (Figure 3.1 &Figure 
3.2). Plotting instantaneous pressure against volume creates a two-dimensional 
representation of the cardiac cycle and generates a PV-loop. The PV-loop has long been 
recognised as an indicator of the work done by a system (the heart in this case) and the 
efficiency at which it completes this work. Although instantaneous pressure and volume 
measurements alone can provide valuable insights into the performance of the left 
ventricle, PV-loops provide a more powerful tool to assess left ventricular function. For 
these reasons, PV-loops provide a unique framework to assess a range of physiological 






Figure 3.1: Presentation of the Millar 6mm micromanometer conductance 
catheter along a longitudinal section of the left ventricle. 
Figure 3.1 notes: The catheter is placed along the longitudinal axis of a sliced rat left ventricle. 
The tip of the catheter sits at the apex of the ventricle and the proximal part runs through the 
aortic valve. Two conductance (volume) electrodes can be observed at the top (E1 & E2) and 
bottom (E3 & E4) of the catheter and the pressure transducer is found in between them. 
 
 
Figure 3.2: Representative instantaneous pressure and volume traces coupled 
with ECG. 
Figure 3.2 notes: This recording is an un-calibrated pressure and volume trace which was 
recorded in the left ventricle of a rat heart using the Millar 6mm micromanometer conductance 




The conductance catheter can be used to assess both in vivo and ex vivo cardiac function 
from large and small animals. The use of conductance catheters in animal models 
permits detailed characterisation of a range of invasive parameters which are not easily 
measured in human subjects for research purposes (Pacher et al., 2008). Using an 
animal model gives the researcher the ability to have precise nutritional control of the 
diet, ease of handling and housing, and control over a range of stimuli during 
experimentation which can influence cardiac function including temperature, 
anaesthesia and blood oxygenation concentrations (Pacher et al., 2008). As such, the rat 
in vivo and ex vivo heart model are commonly used in research laboratories, both of 
which offering their own set of advantages and disadvantages (Milani-Nejad & Janssen, 
2014). The ex vivo model allows direct conclusions to be made in regard to the heart 
itself as measurements are collected in the absence of confounding homeostatic 
feedback responses. The ex vivo model is preferred in some research settings 
investigating the effects of FO because it provides a highly reproducible preparation 
which allows easy access for measurement of oxygen consumption, cardiac workload 
and other coronary biochemistry (McLennan et al., 2012; Pepe & McLennan, 2002). 
However, Pepe & McLennan have suggested that using whole-blood perfusate to ensure 
adequate oxygenation is critical when using this model to draw accurate observations, 
particularly when considering mechanisms related directly to oxygen efficiency (Pepe & 
McLennan, 2002). Advances in technology such as the micro-conductance pressure-
volume catheters allow the in vivo heart model to provide a relatively easier and 
inexpensive method to measure clinically relevant indices of cardiac function. However, 
measurements can be confounded by factors such as preload, afterload and heart rate. 
The retention of autonomic control, neurohormonal influences on the heart and most 
importantly beat-to-beat whole blood perfusion of the heart via the coronary arteries, 
makes the measurements collected in vivo more physiologically relevant to this thesis. 
Therefore, using the conductance catheter in the rat in vivo heart was chosen to 
investigate the hypotheses in this thesis regarding identification of any cardiac 
physiological changes attributable to LC n-3 PUFA. This approach permits more 
confident extrapolation of observations made in the studies to human heart health. 
Consequently, the first focus of this study was to successfully reproduce relevant 




A PV-loop from a single cardiac cycle is illustrated in Figure 3.3, labelled according to 
key phases and events (Each point is labelled A-D). The following discussion will start 
from the bottom right corner of the loop (A) with the heart filled and about to contract. 
Point A of the loop represents completion of the diastolic filling phase. Closure of the 
mitral valve occurs as the left ventricle begins to contract and build pressure at this 
point but there is no movement of blood from the ventricle as the aortic valve is also 
closed at this point, this is known as the isovolumic contractile phase (A to B). Point B 
indicates the opening of the aortic valve, this occurs when the pressure in the left 
ventricle becomes higher than the pressure in the aorta. Increased left ventricular 
pressure forces the aortic valve open, allowing blood to travel down its pressure 
gradient from the left ventricle into the aorta; this is known as the ejection phase (B to 
C). Point C illustrates when ventricular pressure falls below aortic pressure as 
myocardial relaxation begins, causing aortic valve closure as blood begins to flow in a 
retrograde direction towards the left ventricle. Myocardial relaxation occurs before and 
following the closure of the aortic valve. Once both the mitral and aortic valves are 
closed, the isovolumetric relaxation phase occurs (C to D). At this point, no blood enters 
the ventricle and the ventricle relaxes causing a substantial decrease in pressure with no 
change in volume. Point D signifies completion of relaxation and the mitral valve opens 
again. When the mitral valve opens the left ventricle begins the next diastolic filling 
phase (D to A) which occurs passively as blood flows down its pressure gradient from 











Figure 3.3: Illustration of key phases and events in the left ventricle cardiac 





Commonly reported indices of cardiac physiological function are illustrated on a P-V 
loop in Figure 3.4. Point 1 represents end-diastolic volume and end-diastolic pressure; 
this shows the volume of blood which has filled the left ventricle during the diastolic 
filling phase and the resultant ventricular pressure. Physiologically, this point is 
synonymous with what is known as the ‘preload’ of the heart. Preload represents the 
extent to which myocardial sarcomeres are stretched at the time contraction commences. 
Thus, a greater end-diastolic volume produces increased distention of the ventricle, 
resulting in increased preload of myocardial sarcomeres, the opposite occurs with a 
reduced end-diastolic volume. In a healthy beating heart this is usually the lowest 
pressure reported between heart beats. The pressure at point 2 represents what is known 
as the ‘afterload’ of the heart. Afterload is an indirect representation of the tension that 
the left ventricular sarcomeres need to generate to overcome the resistance provided by 
aortic blood pressure. Changes in afterload are closely linked to the force-velocity 
relationship for cardiac myocytes. For example if afterload increases the velocity of 
myocyte shortening decreases, reducing the rate of volume ejection during the ejection 
phase, leaving more blood in the ventricle at the end of systole, the opposite occurs for 
decreases in afterload. The pressure measured at point 3 represents end-systolic pressure 
and the volume at point 3 represents end-systolic volume; this shows the volume of 
blood remaining in the ventricle after the ejection phase. The difference between end-
systolic pressure and end-diastolic volume is known as stroke volume. With analogy to 
a piston pump, this is the amount of blood pumped out of the ventricle in one heartbeat 









Figure 3.4: Illustration of common physiological indices measured in the left 
ventricular cardiac cycle as observed through a PV-loop. 
Abbreviations: 
SV = stroke volume; SW = stroke work; ESV = end-systolic volume; EDV = end-diastolic 
volume; ESP = end-systolic pressure; EDP = end-diastolic pressure. 
‘Preload’ = The extent to which myocardial sarcomeres are stretched at the time contraction 
commences.  
‘Afterload’ = An indirect representation of the tension that the left ventricle sarcomeres need to 





In addition to the physiological indices that can be measured directly from the PV-loop, 
there are a range of measurements which can be calculated from the PV-loop. Cardiac 
output can be calculated by multiplying the stroke volume with heart rate. Ejection 
fraction can be calculated using stroke volume as a proportion of end-diastolic volume 
(stroke volume/end-diastolic volume*100), this is an important measure for tracking 
pumping function of the left ventricle and in a healthy heart ejection fraction is usually 
fifty five percent or higher. The area within the loop can be calculated (shaded blue in 
Figure 3.4) and represents the stroke work completed by the left ventricle to eject 
blood into the aorta each cardiac cycle. The maximal rate of pressure rise (dP/dtmax) and 
maximum rate of relaxation (dP/dtmin) can also be calculated from the ventricular 
pressure measurements. The dP/dtmax calculated represents the maximal rate at which 
the heart generates pressure during the isovolumic contraction phase of each beat and is 
a good indicator of systolic function. The dP/dtmin calculated represents the maximal rate 
at which the heart relaxes during the isovolumic relaxation phase and is a good indicator 
of diastolic function. It can be appreciated that all aspects of the cardiac cycle can be 
intimately characterised through direct and calculated measurements made from the PV-
loop. Therefore, the PV-loop provides a unique framework to assess physiological 
relevant cardiac haemodynamic parameters and describe left ventricular performance. 
For these reasons, PV-loops are regarded as the gold standard for assessment of in vivo 
cardiac haemodynamic function in animals (Calligaris et al., 2013; Clark & Marber, 
2013; Pacher et al., 2008).  
3.1.2 The effect of anaesthetic on cardiac performance 
The use of anaesthetic for surgical protocols in animals is essential when investigating 
invasive measurements. However, anaesthetics can significantly alter baseline inotropic 
and chronotropic function of the cardiovascular system (Stein et al., 2007). As such, 
careful consideration of the anaesthetic used is needed when planning a study such as 
this, which aimed to measure cardiovascular performance. Sodium pentobarbital 
(pentobarbital) or a ketamine + xylazine mixture are amongst the most common 
anaesthetic agents used when measuring cardiovascular function in rats (Hanusch et al., 
2007).  
Pentobarbital is an oxybarbiturate that has been used for veterinary anaesthesia since the 




agonist at the GABAA receptor which is the principle inhibitory neurotransmitter in the 
central nervous system in mammals (Krasowski & Harrison, 1999). When given at 
higher doses in the anaesthetic relevant range, pentobarbital also acts to block excitatory 
glutamate receptors in the central nervous system and neuronal nAChR channels 
(Krasowski & Harrison, 1999). These mechanisms of action result in pentobarbital 
having a slightly depressive chronotropic and inotropic effect on the cardiovascular 
system (Saha et al., 2007), and it has been demonstrated that when used for prolonged 
periods of anaesthesia (+3hrs), cardiac output can be significantly reduced (Nash et al., 
1956).   
The pharmacology of ketamine is quite complex as it is known to interact with N-
methyl-D-aspartate (NMDA) receptors directly, opioid receptors, monoaminergic 
receptors, muscarinic receptors and voltage sensitive Ca2+ channels (Bergman, 1999). 
However, the main action of ketamine is through its non-competitive binding of NMDA 
receptors resulting in antagonism of the central nervous system. There is also some 
evidence that ketamine binds to α & β adrenergic receptors (Bevan et al., 1997). This 
results in ketamine having a sympathomimetic action on the cardiovascular system. As 
such, induction of anaesthesia with ketamine leads to increases in heart rate and 
increased systemic and vascular blood pressure. To diminish the effects of ketamine on 
the cardiovascular system, the concomitant administration of xylazine is commonly 
used. Xylazine is a α2-receptor agonist from the non-opioid group that blocks the release 
of catecholamine’s by sympathetic nerves, thereby reducing the sympathomimetic effect 
of ketamine alone (Sumitra et al., 2004).  
Both pentobarbital and ketamine offer a surgical grade of anaesthesia suitable for 
invasive measurements without pain to the animal. However, as just described, they are 
different classes of anaesthetic and act via different mechanisms of action to achieve 
this. Therefore, the secondary objective of this study is to compare these two anaesthetic 






3.2 AIMS AND HYPOTHESES 
This study aimed to optimise the reliability and reproducibility of the in vivo animal 
surgical model used to measure cardiac function and identify the most appropriate 
anaesthetic for cardiac measurements. 
Specifically, this experiment had the following aims: 
Aim 1: Optimise the surgical techniques and protocols required to measure cardiac 
haemodynamics with a conductance catheter in a physiologically stable in vivo model 
relevant to normal bodily cardiovascular function. 
Aim 2: Directly compare the effect of pentobarbital and ketamine + xylazine on 
cardiovascular haemodynamic function to determine which anaesthetic produces the 








3.3 METHODS  
3.3.1 Animals, ethical considerations & standardisation 
A primary cohort (cohort 1) of male rats (Sprague Dawley) were used in this study and 
ethical approval was completed (Section 2.3.1). Animals were housed and weighed 
according to procedures outlined in Section 2.3.2. Animals for this study were supplied 
lab chow and water ad libitum, but were not provided with dietary supplementation of 
FO.  
3.3.2 Groups 
Twenty-three (N=23) animals were randomly assigned to receive i.p injection of either 
pentobarbital (Hospira, Lyppards, SA, Aus) (n=11) or a mixture of ketamine + xylazine 
(Ceva brand Ketamine & Ilium brand Xylazine, Lyppards, SA, Aus) (n=12). 
Intraperitoneal injections of pentobarbital or ketamine + xylazine were chosen because 
of their ease of use when compared to gaseous anaesthetics which require specialised 
ventilation and gas extraction equipment.  
3.3.3 Experimental preparation 
Haemodynamic variables were obtained using a Millar pressure-volume single segment 
foundation system for animals connected to PowerLab 8/35 software (ADInstruments, 
Bella Vista, NSW, Aus) following established methods from previous studies (Abraham 
& Mao, 2015; Pacher et al., 2008). A 6mm miniaturised 2-French (2F) pressure-volume 
conductance catheter (SPR-638 Millar Instruments, Houston, USA) was used to assess 
in vivo left ventricular function in the animals. The sampling rate of the conductance 
catheter was set at 1kHz in PowerLab. The conductance catheter has four electrodes 
(E1, E2, E3 and E4) with a spacing of 6mm between electrode E2 and E3 which 
contained a 2F pressure transducer (Figure 3.1). To measure volume, the catheter emits 
a constant current to the blood inside the left ventricle from the two most outer 
electrodes (E1 & E4) and the voltage changes in the electrical field are then detected by 
the inner two electrodes (E2 & E3). Therefore, by Ohm’s law, the conductance of the 
blood surrounding the catheter in the left ventricle is inversely proportional to the 
measured electrical potential. A constant sinusoidal alternating current (0.02 mA root 




saline heated to 37°C for 30 minutes prior to experimentation to replicate the biological 
working environment and electronically calibrated before being used in the procedures.  
The catheter was connected to the Millar pressure volume suite (MPVS) ultra-control 
interface and the pressure and volume signals were electronically calibrated following 
the manufacturer’s instructions. This consisted of a two point electronic pressure 
calibration. The software output a pressure trace which was recorded at 0mmHg 
followed by 100mmHg and then the corresponding voltages were assigned to the trace. 
The electronic pressure calibration was confirmed using a manual mercury column 
sphygmomanometer calibration. The sphygmomanometer cuff port was fit with a 3-way 
stopcock. The transducer was carefully placed into a fluid filled (0.9% NaCl solution) 
haemostasis valve and gently secured. The haemostasis valve was then connected to the 
sphygmomanometer via the stopcock, and the sphygmomanometer was then inflated to 
100mmHg. The pressure measured via the MVPS software was then checked to 
determine if it matched the pressure in the inflated sphygmomanometer.  Volume was 
calibrated using the relative volume unit (RVU) method which converts conductance to 
RVU (Pacher et al., 2008). A volume tracing was output from the software and recorded 
at 119 RVU and 289 RVU and voltages were assigned to the corresponding volume 
traces. Volume measurements were then recorded throughout the experimental 
procedures as raw RVU (conductance). Further calibration was completed at the end of 
procedures to convert conductance into true volumes (mL).  
3.3.4 Surgical procedures 
3.3.4a Animal anaesthesia 
Animals were anaesthetised throughout all procedures to ensure physiological stability. 
Animals were weighed and then given an i.p injection of anaesthetic using a 1mL BD 
micro-fine insulin needle. Anaesthetic was dosed according to body weight 
(pentobarbital: 60mg/kg or ketamine 100mg/kg + xylazine 10mg/kg) using the 
formulary provided by the British small animal veterinary association (BSAVA) manual 
of practical animal care for small animal anaesthesia and analgesia. The depth of 
anaesthesia was confirmed prior to beginning procedures via monitoring of the foot 
withdrawal reflex to toe pinch and corneal reflex to touch (on average this was <15min). 




pinch reflexes for signs of inadequate anaesthesia. Additional doses (ketamine 25mg/kg, 
pentobarbital 20mg/kg) of anaesthetic were provided according to the standard practices 
on checking the animal’s reflex reaction responses (Hanusch et al., 2007).  
3.3.4b Temperature control 
Once anaesthetised, all surgical procedures and experimental protocols were performed 
with the animals placed on a heating mat (T-CAT 2 temperature controller, Braintree 
Scientific, MA, USA) which maintained animal core body temperature at 37oC as 
measured via a rectal probe (T-CAT 2 rectal probe, Braintree Scientific, MA, USA) 
throughout the procedures. Because of the automated nature of the heating mat with 
instantaneous feedback which ensured body temperature fluctuated from 37 oC only 
minimally at any time point, body core temperature was not recorded and is not reported 
in any of the studies conducted in this thesis. 
3.3.4c Electrocardiogram 
Electrical activity within the heart was monitored throughout surgical procedures and 
experimental protocols using the single lead surface electrocardiogram (ECG – lead I) 
method. This involved the placement of a positive electrode on the left fore-limb, a 
negative electrode on the right fore-limb and an earth electrode on the left hind-limb 
of the animal shortly after the animal was placed on the heating mat. Butterfly clip 
electrodes were attached to needles (27gx1/2, Terumo, Elkton, MD, USA) which were 
then placed through the superficial skin of the animals at each site. The surface ECG 
recorded at a frequency of 1000Hz to a computer with PowerLab software 
(ADInstruments Dual Bioamp, Bella Vista, NSW, Aus) and then saved for offline 
analysis. The ECG measurements record electrical activity of the heart, thus, tracing 
ventricular depolarisation periods. The ventricular depolarisation of the heart 
generates the R wave found in the QRS phase of the ECG recording of the cardiac 
cycle. Each QRS phase represents a new heart beat therefore the time between 





3.3.4d Tracheal, venous and arterial cannulation 
Following placement of electrodes and collection of baseline resting ECG 
measurements, a 3-4cm superior-inferior incision was made in the midline anterior 
neck of the animal and the trachea was bluntly dissected from the surrounding tissue. 
A small anterior incision was made between the c-shaped cartilage rings of the trachea 
to allow the placement of a 40mm polyethylene tube (Microtube Extrusions, North 
Rocks, NSW, Aus) into the trachea. Using blunt scissors and micro-curved forceps, 
the left internal jugular vein was then bluntly dissected away from the surrounding 
connective tissue just distal to where it merges with the left subclavian vein to form 
the left brachiocephalic vein. Two sterile siliconized (Dysilk, Dynek Pty Ltd, 
Australia) 6/0 silk sutures were loosely tied around the proximal and distal ends of the 
vein. The suture which was most distal (away from the chest) was then tightened and 
tied to stop blood flow returning from the head. A small transverse incision was then 
made in the vein using microsurgical scissors and a length of 0.96 x 0.58mm PE 
tubing was placed through the incision into the left internal jugular vein. The 
remaining suture at the proximal end (closer to the chest) was then pulled tight to 
secure the vein to the tubing. The distal suture was then also re-tied to the tubing to 
ensure it did not come loose during the procedures. The tubing was connected to a 
three-way valve to allow for the administration of physiological (0.9%) and 
hypertonic (30%) saline during experimental protocols.  
Following jugular vein cannulation, using blunt scissors and micro-curved forceps, the 
right common carotid artery was bluntly dissected away from the vagus nerve and 
surrounding connective tissue. Three sterile siliconized (Dysilk, Dynek Pty Ltd, 
Australia) 6/0 silk sutures were loosely tied around the artery, one in the proximal 
location and two distally. One of the distal sutures was then tightened and secured to 
occlude blood flow from the head. The proximal suture was held in a pair of hemostat 
scissors and then gently pulled and secured by clamping to the skin to occlude blood 
flow from the aorta. A small transverse incision was then made in the right common 
carotid artery using microsurgical scissors just in front of the distal suture. The pre-
calibrated miniaturised 2F pressure-volume conductance catheter was then advanced 
into the artery via the incision. The third suture was then secured to the catheter using a 
single loop knot and the proximal suture was released from the hemostat which 




be advanced through the right common carotid artery and into the aortic arch retrograde 
towards the heart. At this point the rodent ventilator system was turned on and artificial 
ventilation began. 
3.3.4e Artificial ventilation 
The tube placed into the trachea was attached to a rodent ventilator (Rodent Ventilator, 
Basile 7025, Italy) for the animal’s breathing to be maintained by machine (artificial 
ventilation); the rate and volume for ventilations were calculated using the following 
formula: Tidal Volume (Vt, ml) = 6.2M1.01 (M = animal mass, kg); Respiration Rate 
(RR, min-1) = 53.5 x M-0.26 (Pacher et al., 2008). For example, a rat weighing 400g 
would have a Vt = 2.4mL and an RR = 68. This ensured that the concentration of 
oxygen in the arterial blood remained high and constant, independently of the animal’s 
natural breathing cycle and depth throughout the experimental protocol. Additionally, 
controlling the respiratory rate maintains an adequate acid base balance during the 
experimental period. Changes in acid base balance can have a strong influence on the 
oxyhaemoglobin curve and unloading of oxygen (Stickland et al., 2011). Therefore, the 
primary role of the artificial ventilation was to deliver a standardised high level of 
arterial oxygen to all animals, and the secondary role was to maintain an adequate acid 
base balance which did not influence unloading of oxygen at the tissue. 
3.3.5 Experimental protocol and measurements 
Prior to surgery occurring heart rate was calculated from the ECG recording, using one 
(1) minute R-R interval averages. Following surgical procedures, the conductance 
catheter was placed in the aortic arch for baseline measurement of arterial pressures and 
heart rate was calculated from the ECG recording. Placement of the catheter in the 
aortic arch was confirmed in real time via the presence of the dicrotic notch in the 
pressure wave channel on PowerLab software (Figure 3.5). The catheter was then 
advanced across the aortic semilunar valve into the left ventricle of the heart via probing 
the valve with small to-and-fro movements of the catheter against the valve while 
rotating it, so the catheter tip moved across different parts of the valve. Once the 
catheter advanced past the aortic valve and entered the ventricle the pressure wave 
would drop from aortic pressure ranges (120mmHg – 80mmHg) to ventricular pressure 




left ventricle was confirmed via the pressure output channel in the Powerlab software 




Figure 3.5: Experimental pressure tracing showing the dicrotic notch which 




Figure 3.6: Experimental pressure tracing showing pressure drop as catheter 





Once catheter placement was confirmed in the left ventricle, animals were given fifteen 
minutes rest to allow stabilisation of left ventricular function, heart rate was calculated 
from the ECG at this stage. Resting cardiac haemodynamic function was then recorded 
for twenty minutes via the conductance catheter, the final five minutes of the recorded 
data was used for analysis of baseline resting cardiac haemodynamic function and PV-
loops, and heart rate was calculated from the ECG recording at this time point. The 
catheter was then withdrawn from the left ventricle into the aortic arch to measure aortic 
blood pressure. The catheter was then returned to the ventricle for saline calibration 
procedures.  
3.3.5a Saline calibration of the conductance catheter 
The current applied to the excitation electrodes on the catheter is conducted through the 
blood in the left ventricle, but also it flows through the surrounding ventricular tissue. If 
the conductance of the surrounding tissue is not accounted for, it can lead to an 
overestimation of the blood volume within the left ventricle . This is known as the 
parallel conductance of the ventricle (Gp). Therefore, a value for (Gp) was obtained by 
providing a bolus dose of hypertonic saline (30% NaCl) to the left ventricle via the right 
internal jugular vein at the end of experimental measurements. The saline was injected 
into the right internal jugular vein (Section 3.3.4d). The respirator was turned off for 
five seconds, and then 20-40mL of a 30% NaCl solution was injected into the right 
internal jugular vein until the PV loop visibly shifted to the right without a significant 
decrease in the pressure signal. This was conducted three times in each animal with 3-
5min rest periods between to allow the volume signal to recover between injections. 
Following completion of saline calibration procedures the conductance catheter was 
withdrawn into the aorta and remained there while the animals were euthanised via 
exsanguination and rapid removal of the heart. An overview of the experimental 












Figure 3.7: Overview of the surgical preparation and experimental protocol. 
1. Rodent ventilator 
2. Cannulation of left internal jugular vein for administration of saline 
3. Cannulation of right common carotid artery for entry of the conductance catheter 
4. Rectal temperature probe with automatic feedback loop to heat pad set at 37oC 
 
Abbreviations: HR = heart rate; BP = blood pressure; Xyl = xylazine. 
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3.3.6 Euthanasia & tissue collection 
All animals were euthanised without recovery from the anaesthetic using methods that 
were approved by the University of Wollongong’s animal ethics committee. Euthanasia 
was completed via removing the artificial ventilator and then rapid exsanguination and 
removal of the heart.  
3.3.6a Blood collection 
Exsanguination was completed using a 21-gauge needle (Terumo Europe, Leuven, 
Belgium) inserted into the bifurcation of the aorta at the common iliac artery. The blood 
was collected into a 5mL syringe containing 0.2mL of a 5,000 U/mL Heparin Sodium 
solution (Hospira, Lyypards, SA, AUS). The blood was then separated into 1mL 
EDTA-treated tubes. One tube of blood was used to complete cuvette calibration in 
order to calculate blood viscosity. The blood sample was immediately placed into a rat 
insulator-type calibration cuvette with known well diameters provided by the 
manufacturer (SPR-638 Millar Instruments, Houston, USA). The first five wells were 
filled with blood and the cuvette was placed on a heating pad at 37°C to keep the blood 
at biological temperature. The catheter was then placed into each of the five wells and 
held in the centre of each well while submerging all four electrodes by blood for 10-
15secs. The conductance changes were recorded in the volume channel in RVU via the 
PowerLab software (LabChart 8, PV Loop module, ADInstruments, Bella Vista, NSW, 
Aus). The remaining blood tubes were frozen at -80oC for further analysis.          
3.3.6b Cardiac tissue collection 
The heart was rapidly removed from the animal following exsanguination through a 
thoracic incision of the sternum. The major vessels were cut from the heart, and the 
heart was submerged into an ice cold perfusate to arrest beating. Excised hearts were 
then flushed with an ice cold 0.9% NaCl solution to remove any remaining blood. The 
great vessels were then dissected off the heart, and the heart was weighed. The atria 
were dissected off to obtain a ventricle weight, and the right ventricle was dissected off 
to obtain a left ventricle weight. The left ventricle was then sliced in 2mm diameter 
pieces and immediately frozen in liquid nitrogen, then stored at -80oC until fatty acid or 





3.3.7 Post-experimental conductance catheter calibration 
The recorded raw conductance data was converted to true volumes (mL) to allow for a 
more physiologically relevant assessment of ventricular work. Previously established 
cuvette and saline calibration calculations were completed using LabChart 8 PV loop 
software (Pacher et al., 2008). The conductance output collected in RVU during cuvette 
calibration was correlated with known volumes to develop a calibration curve that 
converted all recorded data from RVU into units of estimated volume (mL). However, 
these estimated volume recordings are still larger than expected due to the parallel 
conductance of the tissue surrounding the left ventricular blood volume. Therefore, 
parallel conductance was calculated using a series of linear equations. The LabChart 8 
PV-loop software calculated both of the linear equations; the first plotted the saline 
calibration data as the end-diastolic volume vs end-systolic volume. The second plotted 
end-diastolic volume = end-systolic volume, which represented the equivalent of a heart 
chamber devoid of blood. The value at the intersection between the two plotted lines 
was then used as a value to represent the parallel conductance of the left ventricular 
tissue. This value was then automatically subtracted from the estimated volumes 
calculated via the cuvette calibration curve. Following the cuvette and saline calibration 
calculations the recordings were in units of true volume (mL). This allowed for accurate 
and detailed assessment of the ventricular haemodynamics measured with the catheter 
in animals. 
3.3.8 Post-experimental data analysis 
3.3.8a Heart rate 
Offline analysis of the saved ECG recordings was completed using LabChart 8 
software. Files were visually inspected and filtered for the presence of ectopic beats, 
unusual electrical activity or interference. The ventricular depolarisation of the heart 
generates the R wave found in the QRS complex of the ECG recording of each cardiac 
cycle. Each QRS complex represents a new ventricular depolarisation therefore the time 





3.3.8b Left ventricular cardiac haemodynamics 
Resting cardiac haemodynamic function was analysed from the final five minutes of the 
recorded data collected. A smoothing filter (Triangular Barlett, window with 25 points) 
was applied to the volume channel due to regular noise which was distorting the 
channel and most likely due to the electrical network that the system was plugged into, 
the pressure signal was never filtered in order to maintain integrity of maximal and 
minimal rate of pressure development measurements (Pacher et al., 2008). Systolic and 
diastolic function was assessed via investigation of volume and pressure related indices 
measured and collated directly by the PowerLab software analysis tools. Analysis of 
pressure and volume indices was conducted on a minimum of thirty (30) consecutive 
cardiac cycles to create an average value for each animal.  
 3.3.8c Statistics 
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise 
stated. The effects of anaesthetic treatment on experimental outcomes were tested via 
ANOVA. Individual group means were compared using Bonferroni’s post-hoc analysis. 
All statistical analyses were performed in a blinded manner and completed using SPSS 






Anthropometric measures were collected on all animals. There were no statistically 
significant differences between the groups for age, body weight, respiratory rate and 
respiratory volume (Table 3.1). The pentobarbital group displayed a slightly larger 
total heart weight than the ketamine + xylazine group which approached significance (p 
=0.06). However, once heart weight was normalised to body weight, there was no 
statistical significant difference between the groups (p =0.17). 
 
Table 3.1: Anthropometric measurements between anaesthetic groups. 
 Ketamine + 
xylazine Pentobarbital Trend p 
Animals (N) 11 12  
Age (weeks) 13.8 (±0.2) 14.1 (±0.3) NS 
Body Weight (g) 505 (±8) 517 (±10) NS 
    
Ventilation    
Respiratory Rate (b/min) 63 (±2) 64 (±2) NS 
Respiratory Volume (mL) 3.1 (±0.1) 3.2 (±0.2) NS 
    
Tissue    
Heart Weight (mg) 1400 (±22) 1484 (±36) 0.06 
Heart/Body weight Ratio (mg/g) 2.78 (±0.04) 2.86 (±0.03) 0.17 










3.4.2 The effect of anaesthetic on in vivo cardiovascular function  
The heart rate of animals anaesthetised with ketamine + xylazine was significantly 
lower at all time points measured from the induction of anaesthesia until the end of the 
protocol when compared to animals anaesthetised with pentobarbital (Figure 3.8). 
Baseline resting heart rate was significantly lower in the ketamine + xylazine group 
compared to the pentobarbital group. Following surgery, heart rate of the ketamine + 
xylazine group (240 ±7 beats.min-1) had dropped further, whereas heart rate in the 
pentobarbital group remained stable (424 ±11 beats.min-1). At the beginning and end of 
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Figure 3.8: Heart rate (beats.min-1) calculations during different time points of 
the experimental protocol. 
Values are mean ± SEM (n = 11 – 12 per group). *p <0.05 vs Ketamine + xylazine 
(One-way ANOVA with Bonferroni post-hoc test). 
Figure 3.8 notes: Time 0 = Anaesthetic injection, Time 5 = Pre-surgery, Time 45 = Post-
surgery. Time 60 = Start of baseline measures following rest period, Time 80 = End of baseline 




The ketamine + xylazine group displayed a significantly lower systolic blood pressure, 
diastolic blood pressure and mean arterial pressure compared to the pentobarbital group 
at both measurement points (Table 3.2). Measurement of left ventricular function 
demonstrated cardiac output and heart rate to be significantly lower in the ketamine + 
xylazine group compared to the pentobarbital group. However, the stroke volume of the 
ketamine + xylazine group was significantly greater than the pentobarbital group. There 
were no significant differences between groups in any of the other haemodynamic 
measurements recorded including end-systolic volume, end-diastolic volume, end-
systolic pressure and end-diastolic pressure. Ejection fraction was significantly lower in 
the pentobarbital group compared to the ketamine + xylazine group, however there were 
no differences in any of the other systolic contractile indices measured including stroke 
work and dP/dtmax (Table 3.2). There was no difference in dP/dtmin between groups but 
the isovolumic relaxation constant Tau was significantly higher in the ketamine + 





Table 3.2: Haemodynamic parameters measured by conductance catheter in 
rats while anaesthetised with Pentobarbital or Ketamine + xylazine and 
expected normal range. 
 Ketamine + 
xylazine Pentobarbital Normal range
a 
Blood Pressure (mmHg)    
Systolic (Pre) 111(±2) 122(±3)*  
Systolic (Post) 115(±3) 127(±2)*  
Diastolic (Pre) 78(±3) 95(±3)*  
Diastolic (Post) 79(±2) 95(±3)*  
MAP (Pre) 92(±2) 107(±3)* 93 - 120 
MAP (Post) 94(±2) 108(±2)*  
Ventricular function    
Heart rate (beats.min-1) 285 (±25) 457 (±8)* 300 – 450 
SV (μL) 105 (±3) 95 (±4)* 101 – 154 
CO (mL.min-1) 26 (±3) 37 (±2)* 42 – 62 
bEstimated TPR 
(mmHg.min.ml-1) 
3.62 (±0.4) 2.92 (±0.3)*  
ESV (μL) 29 (±5) 44 (±7) 36 – 160 
EDV (μL) 117 (±10) 139 (±11) 170 – 266 
ESP (mmHg) 108 (±13) 132 (±9) 113 – 142 
EDP (mmHg) 13 (±1) 14 (±2) 1 – 7 
Systolic indices    
Stroke work (mmHg*μL) 8286 (±612) 8990 (±321) 12,800 – 21,000 
Ejection fraction (%) 89 (±3) 68 (±4)* 42 – 87 
dP/dtmax (mmHg.s-1) 9119 (±987) 8965 (±647) 7,600 – 11,500 
Diastolic indices    
dP/dtmin (mmHg.s-1) -7794 (±561) -7193 (±498) -5,970 – -9,970 
Tau (ms) 12.7 (±0.6) 10.4 (±0.4)* 10 – 13 
Values are mean ± SEM (n = 11 – 12 per group). *p <0.05 vs Ketamine + xylazine 
(One-way ANOVA with Bonferroni post-hoc test). 
a Values for normal range are obtained from experimental data provided by Pacher, P. et 
al., 2008. Data was collected from various rat strains anaesthetised with pentobarbital 
across years of experiments. b Estimated TPR calculated by dividing MAP (post) by 
CO.  
  
Abbreviations: SV = stroke volume; CO = cardiac output; ESV = end-systolic volume; EDV = 
end-diastolic volume; ESP = end-systolic pressure; EDP = end-diastolic pressure. 
Systolic indices: dP/dtmax = peak rate of pressure rise 
Diastolic indices: dP/dtmin = peak rate of pressure decline; Tau = relaxation time constant 





In this study, the surgical techniques and protocols for measuring in vivo left ventricular 
haemodynamics were optimised. The study demonstrated that using a conductance 
catheter to measure in vivo left ventricular haemodynamic performance, in animals 
anaesthetised with pentobarbital, produced sensitive and reproducible results which 
were comparable with previously described normative values (Pacher et al., 2008). 
Comparison of anaesthetic agents demonstrated that pentobarbital had less depressive 
influence on cardiac function than a ketamine + xylazine mixture. In fact, 
cardiovascular depression was evident directly following anaesthesia onset when using 
ketamine + xylazine and did not recover throughout the entire experimental protocol. In 
addition, anecdotal evidence observed of animal depth of anaesthesia during surgical 
procedures indicated that pentobarbital provided a more adequate grade of anaesthesia 
than ketamine + xylazine. Therefore, using pentobarbital as the anaesthetic was 
concluded to be more appropriate than the ketamine + xylazine mixture for surgical 
procedures and measurement of in vivo haemodynamic indices in the following FO 
studies.  
Compared to pentobarbital, the use of the ketamine + xylazine mixture slowed heart rate 
and increased systolic blood pressure. Heart rate, systolic blood pressure and the 
product of both, rate pressure product have been demonstrated to correlate strongly with 
myocardial oxygen consumption (Kitamura et al., 1972). Human and animal 
experimental studies consistently demonstrate FO supplementation to cause reductions 
in working myocardial oxygen consumption and heart rate (Macartney et al., 2014; 
Peoples et al., 2008; Pepe & McLennan, 2002). Heart rate and blood pressures 
measured in the pentobarbital group of this study were within the normal range and 
directly comparable to other studies using rats anaesthetised with barbiturates (Bal et 
al., 2005; Bátkai et al., 2004; Cingolani et al., 2004; Pacher et al., 2008) making it the 
more appropriate anaesthetic for assessment of these indices.  
Compared to the pentobarbital group, the use of ketamine + xylazine slightly resulted in 
a larger stroke volume, however cardiac output was smaller. Experimental studies have 
demonstrated FO supplementation to attenuate reductions in cardiac output in 
hypertrophic induced heart failure models (McLennan et al., 2012), therefore the use of 




for stroke volume and cardiac output to be 101-154 mL and 42-62mL.min-1 respectively, 
in rats anaesthetised with barbiturates. Stroke volume and cardiac output in the 
pentobarbital group of this study was slightly lower in comparison to the normative data 
reported by Pacher et al., 2008. However, it has been demonstrated that underestimation 
of stroke volume occurs as a result of the single volume segment present on four-
electrode conductance catheters (Bal et al., 2005). To correct this underestimation, flow 
probe measurements are commonly collected from the aorta to calculate a gain factor 
and calibrate volume readings from the conductance catheter (Pacher et al., 2008). Flow 
probe measurements were not collected in this study due to experimental constraints. It 
appears likely that this contributed towards a slight underestimation of stroke volume. 
In addition, the heart rate observed in this study was at the higher end of the normal 
range and therefore would not provide as much time for the diastolic filling phase, 
thereby contributing to a reduction in stroke volume.  
End-diastolic volume was higher in pentobarbital anaesthetised animals compared to 
ketamine + xylazine anaesthetised animals, but was slightly lower than values reported 
in other studies using barbiturates (Bal et al., 2005; Pacher et al., 2008). As stroke 
volume was similar between groups in this study, the greater end-diastolic volume 
contributed to a lower ejection fraction in pentobarbital anaesthetised animals compared 
to the ketamine + xylazine group. Importantly however, ejection fraction of the 
pentobarbital group was within the normal range and comparable to other studies 
(Cingolani et al., 2004; Pacher et al., 2008), whereas ejection fraction of ketamine + 
xylazine anaesthetised animals was beyond the upper limit of the normal range. 
Pressure derived indices (dP/dtmax and dP/dtmin) were within the normal range for both 
anaesthetic groups confirming that systolic and diastolic contraction and relaxation was 
not influenced by anaesthetic, however stroke work was lower than expected in both 
groups owing to the lower volumes observed.  
Overall, this study demonstrated that the Millar micromanometer conductance catheter 
is appropriate to collect accurate and detailed recordings of in vivo left ventricular 
haemodynamics, which were comparable with previously described normative 
physiological values. However, using the ketamine + xylazine mixture as the 
anaesthetic in the remaining studies of this thesis would make it considerably more 




attribute them to FO supplementation alone, rather than side-effects of anaesthesia. The 
minor differences observed between normative values and collected data for some 
indices measured may be dependent on differences in rat strain used between studies 
(Fisher vs Wistar vs Sprague-Dawley) and/or the effect of gender or anaesthetic dosing 
(Pacher et al., 2008). 
Research has demonstrated that cardiovascular depression is a common side-effect of 
ketamine + xylazine induced anaesthesia if it is not dosed precisely (Hart et al., 2001). 
Although not quantified with data in this study, the experimenter made anecdotal 
observations that dosing is especially difficult using the ketamine + xylazine mixture 
compared to pentobarbital. Animals dosed with the ketamine + xylazine mixture 
according to the formerly provided for body weight by the British small animal 
veterinary association took longer to reach the surgical plane of anaesthesia and 
required consistent additional doses to maintain this level. Whereas, the use of 
pentobarbital provided a faster onset of anaesthesia, a more satisfactory surgical grade 
of anaesthesia which continued for the entire 90 min with minimal additional doses 
required throughout the experiment. It is particularly important that the anaesthesia used 
for the FO studies performs in this manner as the experiments will run for an extensive 
time. Given the need for a surgical plane of anaesthesia, it is possible that the additional 
dosing was causing the cardio-depressive effects observed with ketamine + xylazine in 
this study. Importantly however, this study demonstrated that pentobarbital provides 
adequate long-term surgical grade anaesthesia.  
Previous research aiming to characterise the effect of FO on cardiac performance have 
predominately used isolated heart protocols with either a Langendorff or working heart 
perfusion system (Abdukeyum et al., 2008; McLennan et al., 2012; Pepe & McLennan, 
1996). As such, isolated heart measurements have been useful in describing changes to 
myocardial metabolic efficiency, inotropy, lusitropy and chronotropy associated with 
myocardial phospholipid DHA incorporation. These changes demonstrate many direct 
effects of FO in the myocardium and provide substantial evidence to support a 
mechanism of action for the cardio-protective effects associated with fish or FO intake. 
However, extension of these findings to humans is limited due to the isolation of the 
heart from a physiological system including neural feedback mechanisms, humoral 




Neural and humoral influences along with adequate oxygenation of the heart are 
essential for optimal cardiac performance in a working physiological system. In 
particular, maintaining oxygenation of the myocardium is critical for obtaining 
physiologically relevant measurements of cardiac function (Kuzmiak-Glancy et al., 
2015). Diminished cardiac function is attributed to the high oxygen demand required by 
the myocardium to complete physiological work as demonstrated by a linear 
relationship between mechanical energy and myocardial oxygen consumption (Suga, 
1979). In fact, inadequate oxygenation of the myocardium through the use of perfusate 
compared to erythrocytes in ex vivo models has been demonstrated to diminish cardiac 
function in the absence of injury (Pepe & McLennan, 1993) and has now been argued to 
be one of the biggest limitations to findings made in ex vivo research (Gutterman & 
Cowley, 2006; Kuzmiak-Glancy et al., 2015). The current study demonstrated that 
measurement of cardiac haemodynamic function indices using the conductance catheter 
is achievable in the in vivo model. This is important because the in vivo model together 
with artificial ventilation ensures high arterial oxygen concentrations are maintained 
throughout the experiment to allow oxygenation of the heart through beat-to-beat whole 
blood perfusion of the coronary arteries. Furthermore, the results exhibited in the study 
showed that the methods used are sensitive enough to identify minor changes of cardiac 
haemodynamic function and robust enough to allow reproducibility between animals to 
allow statistical comparisons. This will be particularly important for the characterisation 
of the effects of FO on cardiac haemodynamic function as the changes that will occur 
within the heart are hypothesized to be subtle functional shifts, particularly at rest, 
compared to the Control group.    
In conclusion, this study demonstrated the suitability of the surgical procedures and 
anaesthetic to use in order to attain physiologically stable measurements of in vivo left 
ventricular haemodynamic function in the FO studies. Chapter two of this thesis used 
precision dosing of FO and definitively separated dietary groups to succesfully describe 
phospholipid LC n-3 PUFA incorporation patterns between groups. As such, the 
following studies of this thesis used the conductance catheter and pentobarbital induced 
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4.1 INTRODUCTION   
4.1.1 Cardiovascular function 
The principal role of the cardiovascular system is to ensure all organs are constantly 
perfused with an adequate supply of oxygenated blood. To achieve this goal, the heart 
generates an arterial pressure wave via rhythmically contracting its muscular walls to 
propel blood into the vasculature and towards the organs. To ensure the metabolic needs 
of each tissue are met, cardiac function continually adjusts in response to a range of 
stimuli including stress, illness, trauma, hydration status, temperature, metabolic rate 
and physical activity levels (Degaute et al., 1991). Instantaneous cardiac function is 
controlled via a combination of mechanisms, which can be separated into two broad 
umbrella categories; 1) ‘Intrinsic control’ e.g. The Frank-Starling law of the heart 
(Starling & Visscher, 1927) and spontaneous depolarisation of pace-making cells 
(Mangoni & Nargeot, 2008) and 2) ‘Extrinsic control’ e.g. The autonomic nervous 
system and effect of circulating hormones (Abboud & Thames, 2011). Intrinsic control 
of the heart ensures that the volume of blood pumped into the arterial circulation (stroke 
volume) is equal to the volume of blood returning to the heart from venous circulation 
via changing myocardial contractility and beat rate. The autonomic nervous system 
including both vagal (parasympathetic) and sympathetic input also play an integral 
controlling role through feedback loops. Feedback integrates afferent inputs and 
transmits efferent signals to control beat rate and stimulate the release of hormones 
which can influence cardiac contractility. Although these mechanisms are categorised 
separately they work in synchrony throughout every heart beat in order to maintain 
optimal cardiac function. Investigation of acute and chronic cardiac function during 
rested conditions through measurement of parameters including and not limited to: heart 
rate, heart rate variability, cardiac contractility, systolic function indices, diastolic 
function indices, stroke volume and cardiac output are useful for identifying functional 
cardiac differences between intervention groups.  
4.1.2 Resting heart rate          
The relationship between heart rate and cardiovascular or all-cause mortality is of 
particular interest to researchers and clinicians, making investigation of such parameters 




prior cardiovascular disease, the role of heart rate may differ according to 
pathophysiological settings. Reducing a previously elevated resting heart rate in patients 
with CAD and left ventricular systolic dysfunction has been demonstrated to be 
associated with a small reduction in the risk of cardiovascular mortality and morbidity, 
the association strengthens in heart failure related outcomes (Fox et al., 2008). 
Furthermore, there is evidence that in patients with chronic heart failure reducing heart 
rate with ivabradine improves prognosis (Swedberg et al., 2010). Conversely, it has 
been shown that in patients with stable CAD without heart failure there is no 
improvement to prognosis when heart rate is reduced with ivabradine (Fox et al., 2014). 
The conflicting results suggest that elevated heart rate may be a risk factor in heart 
failure whereas elevated heart rate in the absence of heart failure is a risk indicator of 
other pathophysiological processes. This suggestion is supported by evidence from 
studies of the use of beta-blockers in heart failure that demonstrates the magnitude of 
resting heart rate reduction to be associated with the survival benefit, whereas the dose 
of beta-blocker is not (Cullington et al., 2012; McAlister, 2009).  
 
However, human studies stratified by resting heart rate have demonstrated that, in 
healthy population groups free from prior CVD, increased resting heart rate is 
associated with greater risk of cardiovascular and all-cause mortality (Hartaigh et al., 
2014; Zhang & Zhang, 2009). In particular, heart rate profiling during exercise and 
recovery has been demonstrated to be a powerful predictor of the risk of sudden cardiac 
death in healthy men (Jouven et al., 2005), and independent of fitness, levels resting 
heart rate is inversely associated with all cause-mortality in both men and women 
(Aladin et al., 2014). Increases in resting heart rate over five years has also been shown 
to be an independent predictor of mortality in a 20 year follow up period with healthy 
middle aged men free from clinically detectable CVD (Jouven et al., 2009). 
Furthermore, it has been demonstrated that higher resting heart rate is associated equally 
with both cardiovascular and all-cause mortality outcomes (Alhalabi et al., 2017). These 
findings are supported by a recent meta-analysis of eighty seven prospective studies that 
demonstrated a positive association between higher resting heart rate and the risk of 
coronary heart disease, sudden cardiac death, heart failure, stroke, CVD, total cancer 
and mortality (Aune et al., 2017). This highlights the important role of therapeutic 




could offer a favourable effect of slowing resting heart rate in the general population 
free from prior CVD. 
4.1.2a The effect of fish oil on heart rate 
The attributable advantage of DHA incorporation is a reduction in resting heart rate by 
up to 5 beats.min-1 in healthy and patient populations (Dallongeville et al., 2003; Geelen 
et al., 2005; Grimsgaard et al., 1998; Mozaffarian. et al., 2005) and across many animal 
species, including; rat (Abdukeyum et al., 2008; Lortet & Verger, 1995) rabbit (Verkerk 
et al., 2009); dog (Billman & Harris, 2011; Billman et al., 1999); pig (Hartog et al., 
1987) and horse (O’Connor et al., 2004). Heart rate has also been demonstrated to be 
reduced in athletes during exercising conditions without a compromise to peak heart 
rate (Buckley et al., 2009; Macartney et al., 2014; Peoples & McLennan, 2008) and 
heart rate recovery has been demonstrated to be faster in healthy males (Macartney et 
al., 2014) and in post myocardial infarction patients (O’Keefe et al., 2006). The 
combination of these observations suggests that DHA is acting to modify heart rate, 
however the doses of FO used in the vast majority of published research to date has 
been much higher than easily achievable from fish consumption in the diet. Therefore, 
the first objective of this study was to confirm whether dietary achievable FO doses 
cause slowing of resting heart rate in the rat.  
4.1.3 Left ventricular haemodynamics 
The left ventricle of the heart is responsible for the efficient pumping of oxygenated 
blood to the systemic circulation. To regulate mean arterial blood pressure, the 
myocardium must be able to relax and contract rapidly and adjust to acute and chronic 
influences to increase or reduce its pumping capacity (Abboud & Thames, 2011). Injury 
or degradation to the left ventricular myocardium can result in severe consequences 
including death. Therefore measurement of left ventricular cardiac performance is an 
important diagnostic and experimental tool in the assessment of cardiac performance. 
4.1.3a The effect of fish oil on left ventricular haemodynamics 
The intake of fish or FO is associated with reduced incidence of heart failure (Levitan et 
al., 2010; Mozaffarian et al., 2005b) and non-arrhythmic cardiac deaths (Valagussa et 
al., 1999) indicating that FO alters cardiac haemodynamic performance. Experimental 




model (McLennan et al., 2012), limit ischaemic cardiac damage, reduce oxygen 
consumption at any given work output and increase post-ischaemic contractile recovery 
(Abdukeyum et al., 2008; Pepe & McLennan, 2002). Ejection fraction of the left 
ventricle has been demonstrated to increase as a result of enhanced ventricular filling in 
the marmoset heart (McLennan et al., 1992a). Furthermore, isolated working heart 
studies in the rat using supra-therapeutical doses of FO have demonstrated improved 
haemodynamic function and the authors postulated that these effects should extend to 
lower doses (Pepe & McLennan, 2002; Pepe & McLennan, 2007). Cohort and 
experimental studies provide strong evidence that dietary FO supplementation can 
augment cardiac haemodynamics during diseased states, particularly when using 
therapeutic and supra-therapeutical doses. However, it is unknown if dietary achievable 
FO doses alters cardiac haemodynamics during rested conditions. Given the evidence of 
reductions in heart rate following FO supplementation, the second objective of this 
study was to determine whether cardiac haemodynamic performance changes are 
observed in parallel to ensure cardiac output is maintained. 
4.1.4 Heart rate variability 
Absolute heart rate cannot predict the balance of autonomic control pertaining to cardiac 
function. This is because, even during periods of rest when the heart rate is stable, the 
timing between consecutive heart beats fluctuates in order to maintain a stable cardiac 
output and mean arterial blood pressure. The speeding and slowing of the cardiac cycle 
between beats, as a result of vagal and sympathetic tone, is referred to as heart rate 
variability (HRV). Measurement of HRV can be categorised within time, frequency and 
non-linear domains in order to describe the oscillations between consecutive heart beats. 
Animal and human studies use HRV as a non-invasive surrogate assessment of 
autonomic control of the heart (Akselrod et al., 1981; Camm et al., 1996; Sztajzel, 
2004). Decreased HRV is strongly associated with sudden cardiac death in post-
myocardial infarction patients (Bigger Jr et al., 1992; Bilchick et al., 2002; Hull et al., 
1990). Furthermore, HRV has been demonstrated to independently predict 
cardiovascular disease mortality in populations with prior cardiovascular disease history 
(Carpeggiani et al., 2004; Galinier et al., 2000) as well as in healthy populations 





4.1.4a The effect of fish oil on heart rate variability 
The effect of FO on HRV is unclear and inconsistent. Traditionally high cardiac risk 
subgroups or post-myocardial infarction patient’s display reduced HRV, however, 
research has demonstrated some evidence that FO is associated with modest 
improvements in HRV indices in such patients (Christensen et al., 1999; Christensen et 
al., 2001; Mozaffarian et al., 2008; O’Keefe et al., 2006; Xin et al., 2013). However, 
some studies have demonstrated conflicting and inconsistent results when assessing the 
effect of DHA on time-domain (Dyerberg et al., 2004; O’Keefe et al., 2006) frequency-
domain (Billman & Harris, 2011; Carney et al., 2010; Ninio et al., 2008) and non-linear 
domain parameters (Macartney et al., 2014). However, a recent meta-analysis of human 
trials concluded that there is an association between short term consumption of FO with 
improved HRV, particularly frequency domain indices (Xin et al., 2013). Considering 
this evidence, the final objective of this study was to investigate any associations 
between HRV measures and resting heart rate following FO supplementation. 
In summary, there is strong evidence that demonstrates FO to have a direct cardio-
protective effect on the myocardium through slowing heart rate and altering cardiac 
haemodynamics. However, previous research has relied on therapeutical and supra-
therapeutical doses of FO and predominately ex vivo animal models to demonstrate 
these effects. Therefore, investigation of the physiological effects of dietary achievable 
FO doses, using a physiologically stable in vivo model, on resting cardiac function is 
warranted. Evidence-based observations of dietary FO altering cardiac haemodynamic 
performance and electrophysiology at these doses will help provide plausible 
physiological mechanisms of action of DHA on rested cardiac function. This will 
provide direct evidence and allow more confident extrapolation of findings from 
previous therapeutical and supra-therapeutical dose studies to explain the cardio-





4.2 AIMS AND HYPOTHESES 
This study investigated electrophysiological and haemodynamic function in the rested 
in vivo rat heart following supplementation of human dietary achievable FO doses to a 
typical Western-style diet (high SFA and n-6 PUFA).  
Specifically, these experiments had the following aims and hypotheses: 
Aim 1: Determine the influence of supplementing dietary achievable FO doses on 
‘intrinsic’ cardiac function. 
Hypothesis 1: Animals supplemeted with FO will have a slower resting heart 
rate than animals from the Control group. 
Hypothesis 2: Slower resting heart rate will be observed in direct 
relationship with modified cardiac haemodynamic performance in order to 
maintain cardiac output at rest. 
Aim 2: Determine the influence of supplementing dietary achievable FO doses on 
‘extrinsic’ autonomic control of cardiac function. 
Hypothesis 3: Slower resting heart rate will be associated with higher HRV. 










4.3 METHODS  
4.3.1 Animals, ethical considerations and standardisation 
Male rats (Sprague Dawley) were obtained and used under University of Wollongong 
ethical approval for this study (Section 2.3.1). Animals were housed and weighed 
according to procedures outlined in Section 2.3.2.  
4.3.2 Groups 
Sixty two (N = 62, cohort 2) animals were used supplied lab chow and water ad libitum 
for one week prior to dietary supplementation of FO beginning. Animals were then 
randomly split into three groups and supplied water and one of three pre-fabricated diets 
ad libitum for four weeks before experimentation. The diets contained different amounts 
of FO (Control – 0%: n = 22, LowFO – 0.31%: n = 20, ModFO – 1.25%: n = 20). 
4.3.3 Experimental preparation 
Left ventricular in vivo haemodynamic variables were obtained using a 6mm 
miniaturised 2-French (2F) Millar pressure-volume conductance catheter (SPR-638 
Millar Instruments, Houston, USA) for rats. ECG was also used to collect cardiac 
electrical activity, both the conductance catheter and ECG were connected to PowerLab 
8/35 software (ADInstruments, Bella Vista, NSW, Aus). Experimental preparation of 
the conductance catheter was completed according to the methods outlined in Section 
3.3.3. 
4.3.4 Surgical procedures 
Animals were prepared for experimental measurements according to the surgical 
procedures outlined in Section 3.3.4. Briefly, animals were removed from their cages, 
weighed and given an i.p injection of anaesthetic (Pentobarbital: 60mg/kg) before being 
returned to their cage and covered with a towel until they became non responsive to the 
toe pinch test. Animals were then placed on a heating pad and animal core temperature 
was maintained at 37oC via automated feedback loop from a rectal probe measuring 
core temperature. ECG was connected to the animal via the traditional three-lead 




the trachea, and cannulation of the right common carotid artery and the left internal 
jugular vein was completed to allow entrance of the conductance catheter and fluid lines 
respectively. The conductance catheter was prepared prior to each experiment and 
calibrated using the cuvette and saline calibration methods following the end of each 
experiment.  
4.3.4a Left ventricular load-independent haemodynamics 
To collect load-independent measurements using the pressure-volume conductance 
catheter the inferior vena cava was transiently occluded after resting haemodynamics 
had been collected. The abdominal wall was opened via a transverse incision just 
inferior to the xiphoid process and diaphragm. The coronary ligament of the liver was 
cut and removed using micro surgical scissors and the liver was held inferiorly to allow 
access to the inferior vena cava. A cotton tip applicator was then used to apply pressure 
on the inferior vena cava against the diaphragm and occlude it for four to six seconds, 
reducing venous return to the heart and allowing load-independent indices to be 
measured. Occluding the vena cava for short time frames leads to a reduction in venous 
return and thereby reduces end-diastolic volume and preload. The typical response 
observed in the PV-loop during vena cava occlusion is a shift of the loop towards the 
left and drop in the left ventricular pressure developed (Figure 4.1). Measuring end-
systolic and end-diastolic pressure-volume relationships allows assessment of cardiac 
contractility and diastolic relaxation. The passive tension filling curve for the ventricle 
is known as the end-diastolic pressure-volume relationship (EDPVR), the slope of this 
curve is the reciprocal of ventricular compliance. Increases in EDPVR indicate impaired 
diastolic relaxation or ‘stiffness’ in the left ventricle myocytes. The end-systolic 
pressure-volume relationship (ESPVR) describes the maximal pressure that the ventricle 
can generate at any given left ventricular volume. The ESPVR is analogous to the total 
tension that the ventricle can generate as the PV-loop cannot cross the ESPVR under a 
given inotropic state. Therefore, ESPVR is a useful indicator of left ventricular systolic 
contractile function. The ability to measure left ventricular cardiac parameters 
independently from loading conditions is particularly important for the assessment of 
acute changes in left ventricular performance (Pacher et al., 2008) and emphasises the 
importance of the current model. 











Figure 4.1: Representation of the effect of inferior vena cava occlusion on PV-
loops to calculate the ESPVR and EDPVR.  
ESPVR = End systolic pressure-volume relationship  





4.3.5 Experimental protocol and measurements 
Once animals were sufficiently anaesthetised and ECG was connected, animals were 
left to rest for five minutes before baseline resting ECG recording was collected for 
fifteen minutes. Baseline resting heart rate and HRV analysis of data collected via the 
ECG was completed in the last five minutes of recording. Upon completion of ECG 
measurements surgical procedures began. Following surgical procedures animals were 
given ten minutes rest while anaesthetised with the conductance catheter in the left 
ventricle of the heart. Resting cardiac function and PV-loops were then recorded via the 
conductance catheter for ten minutes, the last five minutes of the recorded data was used 
far analyses. The abdominal cavity was then opened and load-independent indices were 
measured via occlusion of the inferior vena cava on three separate occasions for each 
animal with five minutes recovery between each occlusion. An overview of the 















Figure 4.2: Overview of the resting in vivo cardiac function experimental protocol carried out. 
Groups: Control, LowFO – 0.31% fish oil & ModFO – 1.25% fish oil 































































































Resting cardiac function tests 
 
Dietary supplementation 




4.3.6 Post-experimental data analysis 
4.3.6a Heart rate and heart rate variability 
Offline analysis of the saved ECG recordings was completed on the final five minutes 
of data using LabChart 8 software to investigate heart rate (Section 3.3.8a) and HRV. 
LabChart 8 was used to detect R waves and calculated 512 RR interval time periods 
from the cleanest segment of the five minute recording for HRV analysis. Data sets of 
512 RR intervals were chosen as this length has been recommended to be the best 
compromise between the need for a large time series in order to achieve frequency 
domain accuracy and the practicality of shorter time periods (Kuwahara et al., 1994). 
The data sets were converted into a text file and exported into Kubios HRV analysis 
program (Version 2.2, Department of Physics of the University of Kuopio, Finland). 
The recordings were placed through an automatic filter set to low which is part of the 
Kubios program. The filter was used to remove any artefacts and/or ectopic beats and 
leave only normal beats. This allowed the remaining data to be referred to as NN 
intervals rather than R-R intervals as they are all normal beats. HRV measures analysed 
included time, frequency and nonlinear indices.  
Time domain heart rate variability 
Time domain parameters measured included the mean NN interval (R-R time between 
successive beats), the standard deviation of NN intervals and the root mean square of 
differences of successive NN intervals (Figure 4.3). The standard deviation of NN 
reflects cyclic elements responsible for the variability in the corresponding period of 
recording; therefore standard deviation of NN represents long term HRV (Camm et al., 
1996). The standard deviation of NN captures short term changes in variability of the 
heart and has been shown to be an acceptable index of vagal (parasympathetic) 






Figure 4.3: Representative ECG recorded cardiac cycle from a rat showing the 
P wave, QRS complex and T wave and measurement of beat to beat differences 
between consecutive RR intervals. 
 
Frequency domain heart rate variability 
Frequency domain analysis was used to calculate power spectrum density estimates 
present in the recordings. The RR interval series recording was detrended prior to 
analysis using the smoothness priors method with regularization parameter (λ) set to 
500 and a cubic spline interpolation technique described previously (Tarvainen et al., 
2002). Power spectrum density estimates were calculated using the fast fourier 
transformation. RR interval series were resampled at 4Hz and fast fourier 
transformation window length of 256 samples was used. The frequency-domain 
measures calculated were low frequency and high frequency power in normalised units 
and as a percentage of overall power. The frequency bands identified for analysis were: 
low frequency (0.04 - 0.8Hz) which represented both sympathetic and parasympathetic 
activity and high frequency (0.8 – 1.5Hz) which is considered an index of cardiac vagal 
control.   
Non-linear domain heart rate variability 
Sample entropy and approximate entropy were assessed via non-linear domain analyses. 
In terms of HRV analysis, accurate long period data sets can be hard or impossible to 




acceptable to allow the measure of regularity from shorter recordings. Additionally, 
Poincaré plots were used for quantitative and qualitative beat-to-beat analysis of HRV. 
The Poincaré plot is a scattergram of all NN intervals in which each NN interval is 
plotted as a function of the previous one (Figure 4.4). As the RR interval lengthens 
progressively to its maximum then shortens progressively to minimum repeatedly, the 
shape of the plot allows the fit of an ellipse, which can be used to quantify SD1 and 
SD2. SD1 represents dispersion of the points perpendicular to the line of identity and is 
thought to be an index of instantaneous (parasympathetic) beat-to-beat variation (Camm 
et al., 1996). SD2 represents dispersion of the points along the line of identity, and 
represents the slow variability (sympathetic) of the heart (Camm et al., 1996). 
Additionally, the ratio of SD1:SD2 was calculated which represents the randomness in 
the HRV time series recording (Camm et al., 1996).  
 
 
Figure 4.4: Representation of a Poincaré plot measured in a rat during rested 
cardiac function. 
Figure 4.4 notes: The identity line divides the Poincaré plot into two areas, decelerations are 
located above and accelerations below this line. As described the variance of the projection of 
the Poincaré plot points along the identity line is the short-term variability SD1 and 




4.3.6b Left ventricular cardiac haemodynamics 
Resting left ventricular cardiac haemodynamic function was analysed from the post-
surgery measurements in the final five minutes of the recording period. This gave each 
animal time to stabilise following surgery and reduced the chance of surgical procedures 
influencing the haemodynamic measurements collected. Analysis was completed 
following the methods outlined in section 3.3.8b. Load-independent indices were 
analysed at each inferior vena cava occlusion and the average of all three measurements 
were used to assess the ventricular systolic and diastolic function of dietary groups. 
4.3.6c Statistics 
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise 
stated. The effects of dietary treatment were tested via ANOVA. A Bonferroni post-hoc 
test for comparison between group means was then used to identify differences. A 
Dunnett’s T-test was used for comparison of individual diets against the Control group. 
A repeated measures ANOVA (Dietary treatment*time) was completed to investigate 
changes in heart rate between the groups during three time points across the experiment. 
All statistical analyses were performed in a blinded manner and completed using SPSS 





Sixty two (N=62) animals were used for the experimentation following dietary 
supplementation (Figure 4.5). Two (2) animals in the Control and one (1) animal in the 
LowFO groups died directly following injection of the anaesthetic. During surgery a 
further three (3) animals in the LowFO and two (2) animals in the ModFO groups died, 
likely caused by surgical damage to the conduction pathways, surgical complication 
resulting in cardiogenic shock or anaesthetic overdose. Separate to these, the 
conductance catheter was unable to be guided into the left ventricle of two (2) animals 
in Control group and one (1) animal in the LowFO group; this meant only ECG 
measurements were collected from these animals at the post-surgical stage of the 
experiment. Final group numbers for resting ECG and HRV measurements were n = 19 
- 20 respectively and resting left ventricle cardiac haemodynamic measurements were 














Figure 4.5: Overview of animal group numbers throughout experimentation.  
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4.4.1 The effect of fish oil supplementation on resting heart rate 
Resting heart rate was analysed (n = 16 – 20) at three different time points during the 
experiment including baseline, pre-surgery and post-surgery (Figure 4.6). Baseline, 
pre-surgical and post-surgical resting heart rate of the Control group was between 447 –
454 beats.min-1. The FO groups displayed a dose-related slowing in baseline resting 
heart rate compared to the Control group. The LowFO group (429 – 445 beats.min-1) 
trended slower at all time points but was only significantly slower during baseline 
measures compared to the Control group (p <0.01). Whereas, resting heart rate of the 
ModFO group (420 – 426 beats.min-1) was significantly slower at all three time points 






























Figure 4.6: The effect of fish oil on resting heart rate (beats.min-1) calculated 
at different times throughout experimentation. 
Values are mean ± SEM. (n = 16 – 20) *p <0.05 vs Control **p <0.01 vs Control †p 






4.4.2 The effect of fish oil supplementation on resting heart rate variability 
Time domain, frequency domain and non-linear domain HRV parameters were analysed 
during the pre-surgery measurements after fifteen minutes of rest. Both FO groups 
displayed a dose-related higher mean NN interval time than the Control group (Control: 
134 ±2, LowFO: 140 ±2, ModFO: 145 ±3ms) compared to the Control group (p 
=0.015). This mirrored the slowed heart rate previously discussed. There were no 
significant differences displayed in either the SDNN or RMSSD between any of the 
groups (Table 4.1). Fast fourier transformation (FFT) analysis displayed high frequency 
band dominance (77 - 83% of total power) compared to low frequency (16 - 22% of 
total power) during the recording period regardless of dietary group. However, there 
were no statistical differences observed between dietary groups for any frequency 
domain measures calculated.  
Non-linear domain parameters SD1, SD2, the ratio of SD1:SD2, approximate entropy 
and sample entropy were calculated from the Poincaré plots produced (Figure 4.7). 
The Control group displayed a SD1/SD2 ratio of 0.520 ±0.01, sample entropy of 1.154 
±0.04 and approximate entropy of 0.940 ±0.02. The SD1/SD2 ratio was demonstrated to 
be significantly higher in the LowFO (0.566 ±0.01) and ModFO (0.580 ±0.01) groups 
compared to the Control group (Table 4.1). Sample entropy was significantly higher in 
the ModFO group compared to the Control group (p <0.05). Approximate entropy 
trended higher in the LowFO and ModFO groups but did not reach significance (p 
=0.103). However, pooled analysis of both FO groups showed a significantly higher 








Table 4.1: The effect of fish oil on heart rate and heart rate variability indices 
during pre-surgical measurements. 
 
Control LowFO ModFO Trend p 
Time domain        
Mean HR (b.min-1) 447 (±7) 430 (±6) 425 (±6)* 0.017 
STD (b.min-1) 5 (±1) 5 (±1) 4 (±1)  
Mean NN (ms) 134 (±2.2) 140 (±2.1) 145 (±3.6)* 0.015 
SDNN (ms) 1.3 (±0.4) 1.4 (±0.4) 1.2 (±0.3)  
RMSSD (ms) 1.3 (±0.4) 1.4 (±0.4) 1.3 (±0.4)  
        
Frequency domain        
FFT        
LF Power (%) 16.4 (±2.4) 21.5 (±3.6) 21.1 (±3.7)  
LF Power (nu) 16.4 (±2.4) 21.5 (±3.6) 21.2 (±3.7)  
HF Power (%) 83.2 (±2.4) 78.2 (±3.7) 78.4 (±3.8)  
HF Power (nu) 83.4 (±2.4) 78.3 (±3.6) 78.6 (±3.7)  
LF/HF 0.22 (±0.1) 0.35 (±0.09) 0.36 (±0.09) 0.32 
Pooled LF/HF 0.22 (±0.04) 0.35 (±0.06) 0.15 
        
Non-linear domain        
SD1 (ms) 0.94 (±0.3) 1.02 (±0.3) 0.93 (±0.2)  
SD2 (ms) 1.68 (±0.5) 1.76 (±0.6) 1.48 (±0.3)  
SD1/SD2 0.52 (±0.1) 0.56 (±0.01) 0.58 (±0.01)* 0.031 
SampEn 1.15 (±0.1) 1.30 (±0.1) 1.42 (±0.1)* 0.033 
ApEn 0.94 (±0.02) 0.99 (±0.1) 1.03 (±0.1) 0.10 
Pooled ApEn 0.94 1.02 (±0.02)* 0.035 
Values are mean ± SEM (n = 19 – 20). *p <0.05 vs Control diet (One-way ANOVA 
with Dunnett’s T-test vs Control group). Pooled analysis compared both FO diets 
combined vs Control. 
Abbreviations: SDNN = standard deviation of NN intervals; RMSSD = root mean square 
standard deviation of NN intervals; FFT = fast fourier transformation; LF = low-frequency 
power; HF = high-frequency power; SD1 = standard deviation of points perpendicular to the 
axis; SD2 = standard deviation of points along the axis of line-of-identity; ApEn = approximate 












Figure 4.7: Representative Poincaré plots from a Control and ModFO animal 





4.4.3 The effect of fish oil supplementation on resting cardiac haemodynamics 
Resting aortic blood pressure was analysed from data following the surgery but before 
the catheter had been advanced into the left ventricle. No significant differences were 
observed in diastolic pressure, systolic pressure or MAP between any of the groups (p 
>0.05). Resting left ventricular cardiac haemodynamics and preload-independent 
indices were analysed from the post-surgery measurements in the final five minutes of 
the recording. The average heart rate, stroke volume and cardiac output were 451 
±8beats.min-1, 100 ±7µL and 44 ±3mL.min-1 respectively in the Control group. Average 
heart rate in the ModFO group was significantly slower than the Control group (Table 
4.2). The slower heart rate observed in the ModFO group was accompanied with a non-
significant elevation of stroke volume compared to both the other groups. No significant 
differences were observed in cardiac output between any of the groups (p >0.05). 
Furthermore, there were no significant differences in systolic (ejection fraction – EF, 
maximal rate of pressure change – dP/dtmax) or diastolic function (Isovolumic relaxation 






Table 4.2: The effect of fish oil on resting cardiac haemodynamics measured 
post-surgery with a pressure volume conductance catheter. 
 
Control LowFO ModFO 
Variable    
Diastolic BP (mmHg) 94 (±4) 90 (±3) 93 (±3) 
Systolic BP (mmHg) 122 (±6) 125 (±6) 127 (±4) 
MAP (mmHg) 103 (±5) 101 (±4) 104 (±4) 
HR (beats.min-1) 451 (±8) 446 (±6) 426 (±8)* 
SV (µL) 88 (±7) 90 (±8) 108 (±9) 
CO (mL.min-1) 39 (±3) 40 (±3) 46 (±4) 
CI (mL.min-1 x kg) 23 (±2) 23 (±2) 25 (±2) 
ESV (µL) 65 (±10) 56 (±9) 71 (±10) 
EDV (µL) 153 (±9) 145 (±12) 179 (±16) 
ESP (mmHg) 139 (±7) 132 (±4) 140 (±5) 
EDP (mmHg) 13 (±1) 12 (±1) 10 (±1) 
DFP (sec) 0.068 (±0.001) 0.070 (±0.002) 0.078 (±0.002)* 
Ea (mmHg/µL) 1.5 (±0.2) 1.5 (±0.2) 1.2 (±0.1) 
Systolic indices    
EF (%) 67 (±5) 70 (±4) 63 (±4) 
dP/dtmax (mmHg.sec-1) 8688 (±441) 8796 (±288) 8537 (±401) 
Diastolic indices    
dP/dtmin (mmHg.sec-1) -7735 (±483) -7773 (±364) -7440 (±313) 
Tau (ms) 10.0 (±0.3) 9.6 (±0.4) 10.0 (±0.4) 
Values are mean ± SEM (n = 15 – 18). *p <0.05 vs Control diet (One-way ANOVA 
with Bonferroni post-hoc test). 
Abbreviations: HR = heart rate; SV = stroke volume; CO = cardiac output; CI = cardiac index, 
CO/Body weight; ESV = end-systolic volume; EDV = end-diastolic volume; ESP = end-systolic 
pressure; EDP = end-diastolic pressure; Ea = arterial elastance (measure of ventricular 
afterload).  
Systolic indices: EF = ejection fraction; dP/dtmax = peak rate of pressure rise. 
Diastolic indices: dP/dtmin = peak rate of pressure decline; Tau = relaxation time constant 
calculated by Glantz method (regression of dP/dt versus pressure). 
Table 4.2 notes: Two (2) animals in the ModFO group were removed from the analysis due to 
bradycardia associated with atrioventricular block, without preceding arrhythmia. This was 
most likely caused by surgical damage to the conduction pathways, surgical complication 




Left ventricular cardiac haemodynamics during inferior vena cava occlusions were 
analysed to assess preload-independent changes of systolic and diastolic function. There 
were no statistical differences present between dietary groups for the slope calculated of 
the ESPVR, PRSW and dP/dtmax – EDV relationships (Figure 4.8). Pooled analysis of 
FO vs Control animals did not show any statistical differences either but the trend 
became stronger (Table 4.3).   
 
Table 4.3: The effect of fish oil on preload-independent indices of left 
ventricular function during inferior vena cava occlusion. 
 Control LowFO ModFO Trend p 
Systolic indices     
SW (mmHg*µL) 10933 (±963) 9693 (±744) 10226 (±917)  
ESPVR 2.11 (±0.21) 2.14 (±0.18) 2.28 (±0.14)  
- Pooled  2.22 (±0.11) 0.637 
PRSW (mmHg) 115 (±8) 120 (±8) 124 (±7)  
- Pooled  122 (±5) 0.498 
dP/dtmax – EDV 
(mmHg.s-1 ml-1) 46 (±8) 49 (±8) 55 (±6)  
- Pooled  53 (±5) 0.517 
Diastolic indices     





Values are mean ± SEM (n = 9 – 12). Pooled analysis completed with both FO diets 
combined vs Control. 
Abbreviations:  
Systolic indices: SW = stroke work; ESPVR = end-systolic pressure volume relation; PRSW = 
preload recruited stroke work (slope of stroke work−EDV relationship); dP/dtmax−EDV = 
dP/dtmax−end diastolic volume relation.  


























Control = 46.92 (±8.87)
LowFO = 49.51 (±8.07)


















Control = 115.68 (±8.73)
LowFO = 120.94 (±8.92)
ModFO = 124.5 (±7.61)
EDV (mL)
 
Figure 4.8: Typical PRSW and dP/dtmax – EDV relationship from one animal in 
each dietary group. 
 
*Regression lines shown are from one (1) animal per group, mean slope is calculated from 





This study demonstrated that supplementing FO doses achievable within a typical 
Western-style human diet (high SFA and n-6 PUFA) modified in vivo resting cardiac 
function. Physiologically, resting heart rate was slowed in a dose-related manner, 
cardiac output was maintained despite the slower heart rate and non-linear domains of 
vagal tone were higher in FO supplemented animals. The dietary achievable FO doses 
used in this study, for the first time, provide a compelling physiological link to explain 
the consistent observation of fish or FO intake being associated with lower heart rates in 
humans (Dallongeville et al., 2003; Geelen et al., 2005; Grimsgaard et al., 1998; 
Mozaffarian. et al., 2005). The ability of FO to reduce resting heart rate in healthy 
populations is likely associated with its consistently demonstrated cardio-protective 
effect in previous epidemiology, intervention trials and animal research (Burr et al., 
1989; McLennan, 2014; Mozaffarian & Wu, 2011). Importantly, the physiological 
measurements collected in all dietary groups using the conductance catheter in this 
study were consistent with previous values reported in Chapter 3, and within the 
normative physiological range outlined in a separate study (Pacher et al., 2008). Thus, 
the in vivo experimental model used in this study provides a strong platform to examine 
the differences observed in rested cardiac function between dietary groups. 
4.5.1 Resting blood pressure, heart rate and cardiac haemodynamics 
No differences were found for resting blood pressures following supplementation. 
Blood pressure acts to maintain perfusion of oxygen and essential nutrients to the 
organs, tissues and cells of the body. Thus, in a healthy population, the cardiovascular 
system acts to control contributing cardiac factors such as heart rate and stroke volume 
(cardiac output) and vascular factors such as total peripheral resistance in order to 
maintain mean arterial blood pressure. Dietary supplementation of fish oil has only been 
shown to reduce blood pressure in hypertensive subjects in a dose-dependent 
relationship, but/and only in supra-therapeutic doses (Appel et al., 1993; Kris-Etherton 
et al., 2009; Morris et al., 1993). Considering the normotensive blood pressures of the 
animals in the current study, it would be counterproductive if fish oil acted to reduce 




heart rate is slowed by ∼20 – 40beats.min-1 in a dose-related manner in the rat heart 
which has been supplemented with dietary achievable FO doses. 
Previously, animal studies have demonstrated that DHA confers the ability to reduce 
heart rate in rats (Abdukeyum et al., 2008; Lortet & Verger, 1995; Pepe & McLennan, 
1996), exercising conditioned horses (O’Connor et al., 2004) pigs (Hartog et al., 1987), 
and dogs (Billman & Harris, 2011). Additionally, FO supplementation has been 
reported to slow resting heart rate in generally healthy but untrained humans 
(Mozaffarian. et al., 2005), similar to the slowed resting heart rate associated with 
regular physical activity (Scheuer & Tipton, 1977). Heart rate has also been shown to be 
reduced by FO supplementation during cardiac induced stress from exercise protocols 
(Buckley et al., 2009; Macartney et al., 2014; Ninio et al., 2008; Peoples & McLennan, 
2008). However, slowed heart rates in animal models have only been associated with 
the delivery of therapeutical and supra-therapeutical FO doses. Likewise, human studies 
demonstrating slowed resting or exercise heart rate have provided supplementation of 
FO doses in the therapeutic range (Mozaffarian. et al., 2005).  
Physiologically, slowing of the heart rate in the ModFO group resulted in ∼40 
beats.min-1 less than Control animals, this equates to approximately 2400 less heart 
beats per hour. This slowing of heart rate is important when related to myocardial 
oxygen demand (MVO2) of the heart. Cardiac MVO2 is an index of the oxygen 
consumption and energy used by the heart for a given workload. Basal myocardial 
energy metabolism accounts for approximately 25% of myocardial MVO2, myocardial 
wall tension, rate of contraction and contractility are the other primary factors 
determining MVO2. Factors that enhance tension development by myocytes, such as the 
rate of tension development (systolic blood pressure), or the number of tension 
generating cycles (heart rate) will increase MVO2. The importance of MVO2 was 
highlighted almost a century ago in Ernest Starling’s laboratory which demonstrated 
that the heart is an aerobic organ which cannot develop an oxygen debt except for very 
brief periods (Evans & Ogawa, 1914). Dietary achievable FO doses slowed heart rate 
thereby leading to favourable reductions in MVO2.  
Slowed resting heart rate leads to increased myocardial perfusion time due to an 
increased time period of the diastolic phase in the cardiac cycle. Blood flow to the 




compressed due to the higher pressures associated with systole (Spaan et al., 2008). 
Diastolic filling period was demonstrated to be approximately ten milliseconds longer in 
the ModFO group compared to the Control group and the LowFO group also showed a 
slightly longer diastolic filling period. Given that the resting heart rate observed in the 
ModFO group was 425 beats.min-1 and diastolic filling period was approximately 10 
milliseconds longer for each heartbeat, this would result in cardiac perfusion time to 
myocardial membranes increasing by almost four and a half minutes per hour 
(425beats.min-1 * 0.01sec [diastolic filling period] * 60sec).  
Cardiac efficiency is improved when diastolic filling period is longer because more 
volume enters the ventricle leading to a greater end-diastolic volume. The Frank-
Starling law of the heart demonstrates that a greater end-diastolic volume otherwise 
referred to as ‘preload’ allows more myocardial stretch which results in a stronger 
contraction at a lower energy cost (Starling & Visscher, 1927). This phenomenon helps 
demonstrate how stroke volume is acutely adjusted when preload is changed in order to 
maintain forward movement of blood volume throughout the cardiac cycle. During 
periods of increased preload cardiac myocytes are stretched, this causes two processes 
to occur: (i) troponin C Ca2+ binding sites to become more sensitive to Ca2+ allowing 
increased rates of actin and myosin cross-bridge attachment and detachment (ii) the 
amount of Ca2+ supplied to the cardiac myocytes is increased (Allen & Kentish, 1985). 
Together this causes the myocyte to generate a stronger contraction when stretched. 
Stroke volume was not statistically different between any of the groups in this study. 
However, the ModFO group displayed the greatest stroke volume which is likely 
closely linked to the greater end-diastolic volume observed and the Frank-Starling law 
of the heart.  
Previously, FO supplementation in animal models has shown associations with 
increased left ventricular ejection fraction in healthy hearts (McLennan et al., 1992a) 
and increased myocardial contractility in models of hypertrophic heart failure 
(McLennan et al., 2012) and ischaemia and reperfusion (Pepe & McLennan, 2002). 
Taken in combination, these findings suggest improved contractile properties of the 
myocardium following incorporation of DHA. Although this study did not identify any 




cardiac output despite slowed resting heart rate suggests that contractile function was 
modified.  
4.5.2 Heart rate variability 
The intrinsic control of heart rate is modulated by the spontaneous depolarization of 
pacemaker cells in the sino-atrial node. Moment by moment changes in heart rate are 
then further mediated through the vagal nerve as part of the parasympathetic nervous 
system (PNS). Acetylcholine acts on muscarinic receptors to slow heart rate with high 
vagal tone, whereas vagal withdrawal causes heart rate to increase. Sympathetic nervous 
system (SNS) stimulation acts via noradrenaline on β1-adrenergic receptors to increase 
heart rate and force, whereas sympathetic withdrawal acts to decrease heart rate and 
force. However, the SNS acts much slower than the PNS to modify heart function 
(Nicolini et al., 2012). The influence of the PNS or SNS over heart rate is generally 
evaluated through heart rate variability (HRV) measurements and analyses (Camm et 
al., 1996).   
This study demonstrated higher sample entropy and a high SD1:SD2 ratio in both FO 
groups compared to the Control group. Entropy is defined as the rate of generation of 
new information over a large data set, or the regularity of the data, e.g. it is a measure of 
how likely an RR interval will repeat itself (Richman & Moorman, 2000). Thus, higher 
entropy suggests a more irregular heart rate (increased HRV) during the recording 
period. Higher SD1:SD2 has been proposed to indicate stronger vagal tone (Camm et 
al., 1996), suggesting that vagal tone in this study was higher in FO supplemented 
animals and may have facilitated the slowed resting heart rate. In contrast, high 
frequency power which is thought to represent vagal tone (Pomeranz et al., 1985), 
trended lower in both FO groups, implying decreased vagal tone. The conflicting nature 
of the non-linear and frequency domain measures analysed in this study makes it 
difficult to draw direct conclusions of autonomic tone slowing resting heart rate in this 
study. Nevertheless, the demonstration of higher sample entropy and a higher SD1:SD2 
ratio aligns with conclusions drawn from previous studies that describe therapeutical 
and supra-therapeutical doses of FO to increase HRV, particularly vagal tone (Billman 




Despite the great awareness of HRV and its association with autonomic control of heart 
rate, the analysis and relation of HRV to autonomic control is still controversial 
(Karemaker, 2006). Animal and human studies use HRV as a non-invasive surrogate 
assessment of autonomic control of the heart (Akselrod et al., 1981; Camm et al., 1996; 
Sztajzel, 2004). However, it has also been demonstrated that HRV is primarily a non-
linear surrogate of heart rate itself, making it inappropriate to draw conclusions on the 
autonomic nerve activity controlling the heart (Bolea et al., 2016; Monfredi et al., 2014; 
Rocchetti et al., 2000; Zaza & Lombardi, 2001). Furthermore, it has been demonstrated 
that variability in the beat rate remains in the human transplanted heart that cannot be 
attributed to sympathetic or parasympathetic nervous influences (Camm et al., 1996; 
Fallen et al., 1988; Sands et al., 1989). This variability in beat rate exists even in 
isolated rabbit hearts (Janoušek et al., 2010), isolated myocytes (Zaniboni et al., 2014) 
and isolated cardiomyocytes derived from human stem cells in culture (Mandel et al., 
2012). As such, variability in beat rate is likely influenced by both autonomic tone and 
intrinsic mechanisms within the sino-atrial node of the heart.  
The evidence for modified autonomic tone in this study was conflicting and did not 
allow conclusions to be drawn in relation to what caused the slowing of resting heart 
rate. Nevertheless, several studies have demonstrated slowed heart rate in cardiac 
transplant patients (Harris et al., 2006b) and in rat isolated hearts following FO 
supplementation (Abdukeyum et al., 2008; Pepe & McLennan, 1996, 2002), both of 
which would be void of neural inputs. Interestingly, resting heart rate has been 
demonstrated to remain unchanged despite a trending reduction in vagal tone which 
should increase heart rate, following supplementation of dietary achievable FO doses to 
healthy young males (Macartney et al., 2014). The same study also described a faster 
recovery of heart rate towards resting rates following intense exercise with an associated 
decrease in vagal tone. Given these observations in addition to the evidence from 
transplant and isolated heart studies, it is likely that slowing and variation of beat by 
beat rate is related to an intrinsic mechanism of action of DHA at the pacemaker region 
of the heart, rather than altered autonomic tone. 
4.5.3 Conclusions 
In a dose-related manner, in vivo resting heart rate was slowed in animal’s 




autonomic tone or intrinsic regulation of HRV is responsible for the slower heart rate 
described in this study requires further investigation. Slower resting heart rate has been 
associated with reduced risk of cardiovascular related mortality and morbidity (Ivanović 
et al., 2012; Palatini & Julius, 2004). In fact, clinical evidence has demonstrated that a 
reduction of resting heart rate by approximately 1.6 beats.min-1 is estimated to represent 
a 5% decrease in the risk of developing cardiovascular disease (Mozaffarian. et al., 
2005). Therefore, the evidence of slowed resting heart rate provided in this study 
supports the notion that increased fish or FO intake reduces the risk of cardiovascular 
disease. Given these findings the next chapter will explore whether supplementing 
dietary achievable FO doses provides protection from arrhythmias during brief periods 









Investigating arrhythmias during 
ischaemia and reperfusion following 
supplementation of human dietary 





5.1 INTRODUCTION   
5.1.1 Background 
The coronary arteries carry oxygenated blood and nutrients to the myocardium and are 
essential for healthy functioning of the heart. A common cause of cellular dysfunction, 
damage or death within the myocardium is via the temporary blockage (ischaemia) and 
return (reperfusion) of blood flow in one or more of the vessels supplying the 
myocardium. In cardiac patients, this is known as coronary or ischaemic heart disease. 
Coronary heart disease can present clinically as either an acute coronary syndrome or as 
angina, which is persistent chest pain. The heart can function during this disease 
process, and it is not uncommon for people to live for prolonged periods of time without 
a diagnosis. However, if left untreated the myocardial cells in the ischaemic area will 
undergo necrosis and a myocardial infarction will develop. Therefore, reperfusion of 
blood flow to the ischaemic area is necessary to preserve the viability of myocardial 
cells. Unfortunately, it has been demonstrated that reperfusion can lead to accelerated 
and additional damage to the myocardium beyond what was generated by the initial 
ischaemia (Moens et al., 2005). For this reason, reperfusion has been referred to as a 
‘double edged sword’ because it causes further damage to previously ischaemic tissue, 
when it should attenuate damage (Braunwald & Kloner, 1985).  
Of particular relevance to this study is the evidence which demonstrates a close link 
between ischaemia and reperfusion of the myocardium and the manifestation of 
electrical instability (arrhythmia) in the heart (Gaudron et al., 2001; Gorenek et al., 
2015). Arrhythmias can originate from the atria or ventricle of the heart and have 
significant consequences on the hemodynamic functioning of the cardiovascular system. 
If the arrhythmia is of atrial origin, cardiac output can be significantly reduced, 
particularly when the heart is working at higher rates (>140beats.min-1) resulting in 
exercise intolerance (Lee et al., 2005). However, arrhythmia of ventricular origin is 
much more serious as it can result in sudden cardiac death (SCD) in the absence of rapid 
medical intervention (Gorenek et al., 2015). In fact, in 20-25% of patients with 
myocardial ischaemia, the first clinical manifestation may be SCD (Luqman et al., 
2007) and it has been reported that in most cases, the mechanism of onset is ventricular 




5.1.2 Myocardial damage attributable to brief episodes of ischaemia and reperfusion 
During ischaemia there is insufficient blood flow to maintain adequate oxygenation of 
the tissue and sustain healthy metabolism within myocardial cells. Myocardial 
ischaemic episodes as short as five minutes lead to depletion of energy stores and the 
production of reactive oxygen species and their oxidation products within the 
myocardium. The heart has very little energy stored in the form of ATP, yet very high 
energy demands (Lopaschuk et al., 2010). In fact, in a contracting human heart the 
entire pool of ATP is turned over six to eight times in a minute (Lopaschuk et al., 
2010). Therefore, synthesis of ATP required by the healthy heart is primarily generated 
by aerobic mitochondrial oxidative metabolism of substrates including fatty acids, 
glucose, ketones, lactate, amino acids and pyruvate (Lopaschuk et al., 2010). During 
ischaemia the coronary vessels dilate up to three to five times in order to maintain 
oxygen delivery for aerobic metabolism (Spaan et al., 2008). However, if oxygen 
supply to the myocardium is not adequate even with this compensation, ATP 
concentrations cannot be maintained using anaerobic pathways and will rapidly deplete 
(Stanley et al., 2005). In addition, the alternative use of anaerobic metabolism to 
maintain ATP production creates an excess of intracellular hydrogen (H+) ions. 
Increased H+ ions and decreased washout of lactate and other metabolites associated 
with anaerobic metabolism leads to a reduction in the tissue pH (Moens et al., 2005).  
The combination of oxidative stress due to increased reactive oxygen species, ATP 
depletion and changes in tissue pH lead to altered membrane integrity, lipid 
peroxidation, impaired functioning of membrane-bound proteins, ion pumps, channels, 
receptors, altered electrolyte balances and damage to DNA (Bolli, 1988; Bolli, 1990; 
Ferrari et al., 1998). These cellular changes lead to mechanical dysfunction of cardiac 
myocytes and functional abnormalities, particularly electrical instability even in the 
absence of cell necrosis. Intracellular Ca2+ concentrations are closely linked to these 
changes, as Ca2+ movement out of the cell is inhibited by the failure of ATP-reliant ion 
transporters. Therefore intracellular Ca2+ concentrations overload the cells. Calcium 
overload within the cell can cause the generation of further reactive oxygen species and 
the activation of a range of Ca2+ dependant enzymes including ATPase’s and 
phospholipases (Moens et al., 2005). The impaired ability to sequester Ca2+ can 




instability resulting in premature ventricular beats (PVB), ventricular tachycardia (VT) 
and ventricular fibrillation (VF) (Luqman et al., 2007; Pogwizd & Corr, 1986). 
However, the abnormalities of myocardial functioning in the absence of tissue necrosis 
usually recover in the proceeding 24 - 48 hours, hence the term “stunned myocardium” 
has been coined to describe the acute abnormalities observed (Bolli, 1992). The return 
of blood flow allows restoration of glucose and free fatty acids concentrations, which 
are essential for generating ATP via aerobic metabolism, and allows the recruitment of 
inflammatory cells to the damaged region. 
The rapid reactivation of aerobic pathways is associated with an overload of reactive 
oxygen species due to Ca2+ sensitive proteases in the mitochondrial respiratory chain 
(Kitakaze, 2010). Furthermore, the return of blood flow causes metabolites and ions 
which have accumulated in the ischaemia area to be redistributed throughout the 
extracellular space (Moens et al., 2005). As such, when blood flow is restored to the 
ischaemic region there is rapid normalisation of the tissue pH but also overload of 
intracellular Ca2+ concentration gradients (Sanada et al., 2011). The rapid normalisation 
of extracellular H+ concentrations which occurs upon reperfusion leads to the activation 
of the Na+ - H+ exchanger to extrude H+ to the interstitium in exchange for sodium 
(Na+) influx to the cytosol. It has been postulated that this generates an excess of Na+ 
within the cell upon reperfusion (Tani & Neely, 1989), however, some studies have 
been unable to demonstrate increased Na+ concentrations (Pike et al., 1990) or have 
reported decreased Na+ concentrations (Emous et al., 2001). Increased intracellular Na+ 
activates the Na+ - Ca2+ exchange to remove Na+ in exchange for Ca2+ into the cell. 
However, Ca2+ concentrations within the cell are already high as Ca2+ movement out of 
the cell during ischaemia was inhibited. The combination of accumulated intracellular 
Ca2+ and increased Ca2+ flux from activation of the Na+ - Ca2+ exchange leads to much 
higher than normal intracellular Ca2+ concentrations. 
Ischaemia also induces an inflammatory response that leads to the production of a range 
of endogenous eicosanoids and other fatty-acid membrane derived bioactive 
compounds. These compounds are formed from membrane bound AA, EPA and DHA 
cleaved by phospholipases and then by cyclooxygenase enzymes (Serhan & Petasis, 
2011). The eicosanoid end products derived mainly from AA include prostaglandins, 




associated with a pro-inflammatory response and have been the target of many 
pharmacological interventions including aspirin (inhibits COX-2 mediated production 
of prostaglandins), which inhibit their production. They cause the recruitment and 
amplification of cytokines (TNF-α), interleukins (IL-1β, IL-6) and chemokines to the 
myocardium (Nah & Rhee, 2009). This inflammatory response is amplified and 
accelerated when the myocardium is reperfused allowing better access for inflammatory 
cells (Frangogiannis et al., 2002). The localized inflammation process is an integral part 
of the recovery for the myocardium as it mediates the removal of necrotic cells and 
debris and promotes tissue repair and scar formation (Nathan, 2002). However, a 
sustained, exacerbated or uncontrolled inflammatory response can impede the recovery 
process and lead to further damage of the ischaemic and surrounding areas. In addition, 
the presence of inflammation has been demonstrated to be associated post-operative 
arrhythmias (Bruins et al., 1997) and atrial fibrillation (Aviles et al., 2003). As such, the 
combination of rapid reactivation of aerobic metabolism, inflammatory cascades and the 
presence of catecholamines during reperfusion often facilitates the rapid generation 
(∼15 seconds) of VT which frequently degenerates into fatal VF upon reperfusion of the 
myocardium (Brooks et al., 1995; Pogwizd & Corr, 1986; Sanada et al., 2011).  
5.1.3 The anti-arrhythmic action of fish oil during ischaemia and reperfusion 
Research has established a range of actions of FO on the cardiovascular system, which 
may contribute to the observed cardio-protective effects. These include an anti-
thrombotic (Connor, 2000), anti-atherogenic (Balk et al., 2006) and an anti-
hypertensive effect (Geleijnse et al., 2002). However, the most significant effect of FO 
appears to be its anti-arrhythmic action (McLennan, 2014). This effect has been 
observed at lower doses of FO than most other established effects with the 
consequences potentially being of more relevance to the cardio-protective action 
observed in populations which regularly consume fish (Harris et al., 2009). 
Several large human based trials have demonstrated that consumption of FO leads to a 
reduction in SCD. The Diet and Reinfarction observational Trial (DART) followed the 
post-myocardial infarction recovery (secondary prevention) of over 2000 men and 
revealed that men who consumed fish regularly (2-3 meals/week) had a 52% reduction 
in the risk of SCD (Burr et al., 1989). The Gruppo Italiano per lo Studio della 




investigated more than 11,000 post-myocardial infarction patients (secondary 
prevention) and also demonstrated a 45% reduction in the risk of SCD with the 
consumption of supplements containing 850mg/day of EPA + DHA (Valagussa et al., 
1999). Additonally, doses as low as 180mg/day have been demonstrated to reduce the 
risk of primary cardiac arrest in a population-based case-control study of adult females 
and males free from prior clinical heart disease (Siscovick et al., 1995). As such, it has 
been suggested that there is sufficient evidence to show FO reduces the incidence of 
SCD in humans, however it is still unclear what dose is required and wether the 
background diet influences the cardio-protective action (Reiffel & McDonald, 2006). 
Physiological evidence of the direct anti-arrhythmic action of FO has been provided by 
studies using both paced and unpaced in vivo and ex vivo rat, monkey and pig hearts 
(Table 5.1).  
In summary, it is still unknown if the anti-arrhythmic effect of FO demonstrated in 
animal studies is relevant to the observational and cohort studies of diet and SCD, 
because of the use of FO doses not relevant to human nutrition. Studies which have 
used dietary achievable FO doses have not supplied a typical Western-style background 
diet high in SFA and n-6 PUFA. Therefore, extrapolation of the findings from such 
studies must be used with caution to explain reductions of SCD observed in 
epidemiological and cohort trials, where arrhythmia prevention is ascribed to fish 
intake. As such, the objective of this study was to establish whether supplementing 
human dietary achievable FO doses to a typical Western-style diet protects against 
ischaemic and reperfusion generated arrhythmias. The surgical model which will be 
used in the present study to induce regional ischaemia and reperfusion was a 
modification of a technique first described in 1960 (Selye et al., 1960). The clinical 
relevance of this model to acute coronary syndrome has allowed it to be extensively 
used in the literature to investigate arrhythmia generation in both pharmaceutical anti-
arrhythmic therapies (Altug et al., 1999; Walsh et al., 2010) and the investigation of 
anti-arrhythmic actions of FO (Abdukeyum et al., 2008; Charnock et al., 1989; 




Table 5.1: Comparison of animal interventions investigating fish oil and arrhythmia generation. 
Fish oil dose 
(% wt/wt) Type of oil Animal Model Outcome Author 
12% 
 
DHA-rich tuna oil Rat In vivo 
 
↓ Vulnerability to I & R induced VT and VF McLennan. P.L et al. 
(1988) 
12% Purified EPA-rich 
Shaklee oil 
Rat In vivo ↓ Incidence of I & R induced VF McLennan. P.L. (1993) 
12% Purified EPA-rich 
Shaklee oil 
Rat Ex vivo 
(paced) 
Prevented reperfusion-induce VF and ↓ ischaemia induced arrhythmias Pepe. S. et al. (1996) 




↑ Threshold to stimulated VF and ↓ VF incidence  
(and during ischaemia) 
McLennan. P.L. (1992b) 
7% DHA-rich tuna oil Rat Ex vivo ↓ Arrhythmia during I & R Abdukeyum. G.G. et al. 
(2008) 
5% DHA-rich Menhaden 
oil 
Rat In vivo ↓ Incidence and severity of VF and VT during I & R Hock. C.E. et al. (1990) 
4.5% Mackerel oil Pig In vivo ↓ Incidence of reperfusion-induced arrhythmias  Hartog. J.M. et al. (1987) 




↑ Threshold to stimulated VF  
(and during ischaemia) 
McLennan. P.L et al. 
(1993) 
3% Purified EPA-rich 
Shaklee oil 
Rat Ex vivo 
(paced) 
↓ Incidence of arrhythmias during 15min ischaemia Pepe. S. et al. (2007) 
1%  DHA-rich tuna oil Rat In vivo ↓ Episodes and duration of VF during reperfusion Abeywardena. M. et al. 
(2016) 
0.4-1.1% Purified EPA or DHA 
rich oil 
Rat In vivo Purified DHA ↓ VF incidence but Purified EPA did not McLennan. P.L. et al. 
(1996) 
1.25 & 0.31% DHA-rich tuna oil Rat In vivo ?? Present study 
Abbreviations: VT = ventricular tachycardia; VF = ventricular fibrillation; I = ischaemia; R = reperfusion. 
Fill represents historically common supra-therapeutical doses of FO. 
Fill represents dietary achievable doses of FO. 
 




5.2 AIMS AND HYPOTHESES 
This study aimed to investigate arrhythmia generation, during a clinically relevant 
(acute coronary syndrome) ischaemia and reperfusion protocol, following 
supplementation of dietary achievable FO doses to a typical Western-style diet (high 
SFA and n-6 PUFA). 
Specifically, this experiment had the following aims and hypotheses: 
Aim 1: Determine the influence of supplementing dietary achievable FO doses on 
ischaemic generated arrhythmias. 
Hypothesis 1: The severity, duration and incidence of ischaemic arrhythmias 
will be reduced by FO supplementation. 
Hypothesis 2: The risk of fatality from arrhythmia will be reduced by FO 
supplementation. 
Aim 2: Determine the influence of supplementing dietary achievable FO doses on 
reperfusion generated arrhythmias. 
Hypothesis 3: The severity, duration and incidence of reperfusion generated 
arrhythmias will be reduced by FO supplementation. 









5.3 METHODS  
5.3.1 Animals, ethical considerations and stadardisation 
The male rats (Sprague Dawley) from cohort 2 were used in this study. Directly 
following the end of experimental procedures described in Chapter 4 the experimental 
procedures for this study began.  
5.3.2 Groups 
Animals were supplied water and randomly assigned to one of three pre-fabricated diets 
ad libitum for four (4) weeks before experimentation. The diets contained different 
amounts of FO (Control – 0%: n = 18, LowFO – 0.31%: n = 15, ModFO – 1.25%: n = 
18 (%wt/wt)). 
5.3.3 Experimental preparation 
Preparation of the 6mm miniaturised 2-French (2F) Millar pressure-volume 
conductance catheter (SPR-638 Millar Instruments, Houston, USA) and 
electrocardiogram (ADInstruments, Bella Vista, NSW, Aus) was completed (Section 
3.3.3). 
5.3.4 Surgical procedures 
Animals were anaesthetised, and surgery conducted to allow cardiac measurements 
including: ECG, ventricular pressure and volume and aortic blood pressure (Chapter 4). 
Following this an established surgical technique which has been used extensively for 
the production of arrhythmias in the in vivo heart was completed (McLennan et al., 
1988; Selye et al., 1960).  
5.3.4a Thoracotomy  
A 3-4cm superior-inferior midline incision was made in the chest and at the inferior end 
of the incision a 2-3cm transverse incision was to made towards the left mid-axillary 
line to allow the skin to be bluntly dissected and reflected back to reveal the 
musculature and ribs of the left thoracic cavity. Blunt scissors were inserted between the 
pectoralis major and minor muscles in order to break the fascia and allow retraction of 




the superficial thoracic vein during this step as injury to this vessel causes significant 
bleeding. Once the ribs were visible the chest was then opened at the fourth intercostal 
space using blunt surgical scissors to tear the intercostal muscles and make a 1-2cm 
transverse incision. The incision was made 3-4mm laterally from the sternum to avoid 
damaging the internal thoracic artery which results in heavy bleeding that is very 
difficult to control. The fourth rib was then sectioned using surgical scissors 
approximately 2-3mm from the sternum and blunt scissors were then used to increase 
the space of the incision via opening the scissors at an oblique angle to the ribs. The 
heart then became visible encased in the pericardium. The pericardium was grasped 
with curved forceps and opened using blunt scissors to avoid damage to the 
myocardium, once opened it would slide behind the heart and remain there making the 
heart freely accessible.    
5.3.4b Exteriorisation of the heart and suturing of the LAD coronary artery 
The heart was exteriorised via placing a scoop spatula with a small amount of 0.9% 
NaCl on it underneath the heart inside the thoracic cavity and then applying a small 
amount of external pressure on the superior and right chest wall. The LAD runs 
obliquely over the anterior surface of the left ventricle from the left coronary artery 
branch with the left circumflex artery towards the apex of the heart along the 
interventricular sulcus. Once the heart was exteriorised it was held between the left 
thumb and forefinger with the apex facing towards the right of the animal and slightly 
superiorly. A size 6-0 braided silk suture attached to a 12mm atraumatic taper needle 
(Dynek Pty Ltd, Australia) was placed under the LAD using curved tip hemostat 
scissors in the right hand. The LAD sits within the myocardium which makes it difficult 
to directly locate visually. Therefore the left auricular appendage and pulmonary cone 
were used as guides for insertion and exit points respectively of the suture. The heart 
was then replaced in the chest and the animal was allowed to recover for ten minutes. 
This entire process takes roughly ten to fifteen seconds. 
5.3.5 Experimental protocol and measurements 
Animals were checked for depth of anaesthesia (Section 3.3.3) directly following 
surgical procedures being completed and prior to experimental protocols and 




to the thoracic cavity, each animal was allowed ten minutes recovery for stabilisation of 
cardiac function before commencing the ischaemia and reperfusion protocol (Figure 
5.3).  
5.3.5a LAD coronary artery occlusion and reperfusion 
The suture was drawn through a 3mm length of polyethylene tubing with a small slit 
made in the side at one end of the tubing. The tubing was allowed to slide down the 
suture to come into contact with the heart where the LAD sits. The LAD was occluded 
via applying tension to the suture and the tension was maintained by drawing the suture 
down the slit in the tubing (Figure 5.1). Occlusion of the LAD was confirmed by 
checking for visible blanching of the anterior wall of the left ventricle after a few 
seconds and via confirming depression of the ST segment and elevation of R wave on 
the ECG (Figure 5.2). The LAD was occluded for fifteen minutes of ischaemia while 
arrhythmia generation was measured via ECG. The fifteen minutes ischaemic duration 
was used because the occurrences of arrhythmias induced by regional ischaemia in the 
rat peak between five to ten minutes and usually finish before fifteen minutes (Curtis et 
al., 1987). The suture was released from the slit in the tubing and tension relieved after 
fifteen minutes of ischaemia, allowing reperfusion of the heart following occlusion. 
Reperfusion arrhythmias peak in the first five minutes but can also still be observed up 
to fifteen minutes after release of the occlusion (McLennan et al., 1988), therefore 













Figure 5.1: Post-experimental isolated heart showing surgical LAD coronary 
artery occlusion via placing tension on a piece of tubing over the artery & 
Indian dye stained ischaemic/non-ischaemic tissue. 
Figure 5.1 notes: The tubing places pressure on the area of myocardium where the LAD is 
located whilst the suture places pressure from below in order to occlude it. The tubing is held in 
place with tension generated from a suture being held in a slit of the tubing. Ischaemic region 
(non-stained) and non-ischaemic region (stained black) can also be observed after perfusion of 
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Figure 5.2: Example of typical ECG trace from an animal as the LAD coronary artery occlusion is begun. 
Figure 5.3 notes: The occlusion of the LAD artery was confirmed via sighting of elevation of the R wave and ST-segment depression along with blanching of the 
ventricular wall.
LAD occluded 
Normal ST segment Depressed ST segment 















Figure 5.3: Overview of the experimental protocol used to investigate the effect of fish oil on arrhythmia generation. 
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5.3.6 Post-experimental data analysis 
5.3.6a Classification and scoring of arrhythmias 
Arrhythmia classification was completed according to the Lambeth conventions 
(Walker et al., 1988). Measurement of PVB was completed through identifying a QRS 
complex which occurred earlier than would be expected in the ECG tracing of regular 
sinus rhythm. Because PVB originate from the ventricle they are identifiable on the 
ECG as a QRS complex without a preceding P wave (Figure 5.4A), which is why they 
are also commonly referred to as Ventricular Ectopic Beats (VEB). Classification of VT 
was defined as four or more consecutive PVB, and VF was defined as indistinguishable 
QRS deflections where no rate could be measured along with accompanied drop in 
blood pressure, torsade de pointes was also classified as VF (Figure 5.4B). 
Identification of the arrhythmias allowed a previously established scoring scale to be 
used to rank the severity of the arrhythmias and allow comparison between groups 
(Curtis et al., 1987). This is achieved by taking into account the number of PVB, the 
duration and type of arrhythmia, the timing of the arrhythmia in relation to the 
ischaemic and reperfusion period and whether and when the animal spontaneously 
reverted to sinus rhythm or the arrhythmia resulted in death. The scale is from zero to 
nine with scores between zero and five indicating that the animal survived the entire 
ischaemia or reperfusion protocol. However, an animal which scored five would have 
had more incidents and/or duration of arrhythmia and/or more serious arrhythmia e.g., 
more VF than VT compared to an animal which scored one. Scores between six and 
nine are given to animals which did not survive the ischaemia, the difference in scoring 
for these animals is dependent upon the time that the fatal VF started, with a higher 
score given for fatal VF starting earlier in the ischaemia or reperfusion (Table 5.2). The 
scale was slightly modified to quantify reperfusion induced arrhythmias following an 
established method in a previous study with similar design and measurement outcomes 
to this one (McLennan et al., 1988). The modified scale was used to take into account 
the shorter time course of reperfusion arrhythmias. Using a scoring index to represent 
the severity and incidence of arrhythmias occurring is of particular value in aiding 






Table 5.2: Scoring index used to quantify arrhythmias. 
Ischaemia Reperfusion 
0 = 0-49 PVB 0-49 PVB 
1 = 50-499 PVB 50-249 PVB 
2 = >499 PVB and/or 1 episode of spontaneously reverting VT or VF >250 PVB and/or 1 episode of spontaneously reverting VT or VF 
3 = >1 episode of VT or VF or both (<60 s total combined duration) >1 episode of VT or VF or both (<20 s total combined duration) 
4 = VT or VF or both (60-119 s total combined duration) VT or VF or both (20-59 s total combined duration) 
5 = VT or VF or both (>119 s total combined duration) VT or VF or both (>60 s total combined duration) 
6 = fatal VF starting >15 min after occlusion fatal VF starting at >5 min after reperfusion 
7 = fatal VF starting between 4 and 14 min 59 s after occlusion fatal VF starting between 4 and 5 min after reperfusion 
8 = fatal VF starting between 1 and 3 min 59 s after occlusion fatal VF starting between 20 s and 2 min after reperfusion 
9 = fatal VF starting  <1 min after occlusion fatal VF starting  <20 s after reperfusion 
 
Abbreviations: PVB = premature ventricular beats; VT = ventricular tachycardia; VF = ventricular fibrillation.  









Figure 5.4: Example experimental ECG (Pink) and aortic blood pressure (Red) 
traces showing PVB (A), VT and VF (B). 
A: Premature ventricular beat (PVB). It can be observed that the QRS complex occurs prior to 
the P wave and then a compensatory pause before next QRS complex.  
B:          Highlights a run of premature ventricular beats (PVB) leading into an episode of 
ventricular tachycardia (VT:       ) and an episode of torsade de pointes (ventricular fibrillation 






















































All results are expressed as mean ± standard error of the mean (SEM) unless otherwise 
stated. The effects of diet treatment were tested via ANOVA. A Bonferroni post-hoc 
test for comparison between group means was then used to identify differences. The 
incidence of VT or VF was expressed as the percentage (%) of animals in which at least 
one episode was observed. Percentage incidence data was then tested using chi-square 
with Fischer’s exact test. All statistical analyses were performed in a blinded manner 
and completed using SPSS 21 for Windows (SPSS Inc, Chicago, IL, USA). Alpha was 







Forty-nine (N = 49) animals were used for the analysis of ischaemic arrhythmias. Two 
(2) animals in the ModFO group were removed from the analysis due to bradycardia 
associated with atrioventricular block, without preceding arrhythmia. This was most 
likely caused by surgical damage to the conduction pathways, surgical complication 
resulting in cardiogenic shock or anaesthetic overdose. The final group numbers 
included in the analysis of each group were as follows: Control (n = 18), LowFO (n = 
15) and ModFO (n = 16). Of the forty nine (49) animals that underwent LAD coronary 
artery occlusion only twenty-eight (28) animals survived the complete occlusion. 
Ischaemic induced arrhythmias were most pronounced between five and eight minutes 
after the occlusion had been drawn tight. Animals which did not die from fatal VF 
during the ischaemia had predominantly reverted to normal sinus rhythm after ten 
minutes of ischaemia. Twenty-one (21) animals died (44%) due to VF prior to the 











Figure 5.5: The total survivors/deaths during fifteen minutes LAD coronary 
artery occlusion. 
*Two (N=2) animals in the ModFO group were removed from the analysis due to bradycardia 
(Abnormally low heart rate prior to the occlusion occurring) without preceding arrhythmia.   
Total Animals (N=51) 
15min coronary LAD occlusion induced ischaemia 
Control (N=18) LowFO (N=15) ModFO (N=16*) 
11 deaths 6 deaths 4 deaths 




5.4.1 The effect of fish oil supplementation on ischaemia generated arrhythmias  
Nearly all the animals in the Control (94%) and LowFO (91%) group experienced at 
least one VT episode during the ischaemia (Figure 5.6A). Significantly less animals 
experienced at least one incidence of VT in the ModFO (31%) group compared to both 
of the other groups (p <0.001). The mean total duration of VT in animals which 
experienced ≥ one episode was significantly shorter in both FO groups compared to the 






































Figure 5.6: The effect of fish oil on the incidence and duration of ventricular 
tachycardia during LAD coronary artery occlusion induced ischaemia of the left 
ventricle. 
Values are mean ± SEM (n = 15 - 18). * p <0.05 vs Control diet, † p <0.05 vs LowFO 
diet (% Incidence analysed via chi-square with Fischer’s exact test, Duration analysed 





Almost all animals in the Control group (89%) experienced at least one VF episode 
during ischaemia. Less animals in the LowFO (60%) group experienced at least one 
episode of VF which trended toward significance (p =0.052). In the ModFO (50%) 
group, a significant difference in the number of animals which experienced at least one 
episode of VF was evident (Figure 5.7A). There were no significant differences 
between groups in the mean number of VF episodes per animal which did experience 
VF during the ischaemia (Table 5.3). A trending reduction in cases of fatal VF during 
ischaemia in animals from the LowFO group (6/15 animals [40%]) compared to the 
Control (11/18 animals [61%]) was evident. Whereas, cases of fatal VF in the ModFO 
group (4/16 animals [25%]) were significantly less than the Control group. The mean 
total duration of VF in animals which experienced ≥ one episode of VF was not 





































Figure 5.7: The effect of fish oil on the incidence and duration of ventricular 
fibrillation during ischaemia of the left ventricle induced by occlusion of the 
LAD coronary artery. 
Values are mean ± SEM (n = 15 - 18). * p <0.05 vs Control diet (% Incidence analysed 
via chi-square with Fischer’s exact test, Duration analysed by One-way ANOVA with 





The arrhythmia score was significantly lower in a dose-related manner, the Control 
group displaying the highest score followed by the LowFO and the ModFO groups 
(Figure 5.8A). The FO supplemented groups spent significantly more time in normal 
sinus rhythm compared to the Control group throughout the entire fifteen minutes of 
ischaemia (Figure 5.8B). Furthermore, during the fifteen minutes of ischaemia both 
FO groups had less PVB than the Control group (Table 5.3). The ModFO group had an 
almost three-fold reduction in PVB which was significantly less compared to the 










































Figure 5.8: The effect of fish oil on arrhythmia score and time spent in normal 
sinus rhythm during ischaemia of the left ventricle induced by occlusion of the 
LAD coronary artery. 
Values are mean ± SEM (n = 15 -18).* p <0.05 vs Control diet (One-way ANOVA with 
Bonferroni post-hoc test). Arrhythmia score was calculated according to Curtis. M.J. et 






5.4.2 The effect of fish oil supplementation on reperfusion generated arrhythmias 
Twenty-one (N = 21) animals died of arrhythmias during the ischaemic period of the 
ischaemia and reperfusion protocol. This resulted in twenty-eight (28) animals being 
used for the analysis of reperfusion-induced arrhythmias. The final group numbers for 
analysis were: Control (n = 7), LowFO (n = 9) and ModFO (n = 12). Reperfusion 
induced arrhythmias were most pronounced between fifteen seconds and one minute 
after the LAD coronary artery occlusion had been released. Animals which did not have 
an arrhythmia during this time period predominantly would not have any arrhythmias 
during the remaining reperfusion time. Animals that did have non-fatal arrhythmias 
during this time had usually spontaneously reverted to normal sinus rhythm before five 
minutes of reperfusion. Of the twenty-eight (28) animals that underwent reperfusion of 













Figure 5.9: The total survivors/deaths during fifteen minutes LAD coronary 
artery reperfusion.  
Total Animals (N=28)  
15min coronary reperfusion induced ischaemia 
Control (N=7) LowFO (N=9) ModFO (N=12) 
1 death 0 deaths 0 deaths 
Control (N=6) Survival: LowFO (N=9) ModFO (N=12) 
Control (n=18) 
6/15 






All the animals in the Control and LowFO group experienced at least one VT episode 
during reperfusion (Figure 5.10A). Significantly less animals experienced at least one 
incidence of VT in the ModFO (33%) group compared to both of the other groups (p 
<0.001). The mean total duration of VT in animals which experienced ≥ one episode 









































Figure 5.10: The effect of fish oil on the incidence and duration of ventricular 
tachycardia during reperfusion of the LAD coronary artery. 
Values are mean ± SEM (n = 7 - 12). * p <0.05 vs Control diet, † p <0.05 vs LowFO 
diet (% Incidence analysed via chi-square with Fischer’s exact test, Duration analysed 





Almost all animals in the Control group (86%) experienced at least one VF episode 
during reperfusion. Significantly less animals in the LowFO (22%) and ModFO (8%) 
group experienced at least one episode of VF compared to the Control group (Figure 
5.11A). Total mean number and duration of VF episodes per animal which did 
experience VF during reperfusion were unable to be statistically analysed due to the 
small number of animals in the ModFO (n=1) and LowFO (n=2) which experienced VF 
(Table 5.3). However, anecdotal observation shows that the duration of VF in the 
animals that did experience at least one case was dramatically lower in the ModFO and 





































Figure 5.11: The effect of fish oil on the incidence and duration of ventricular 
fibrillation during reperfusion of the LAD coronary artery. 
Values are mean ± SEM (n = 7 - 12). * p <0.05 vs Control diet (% Incidence analysed 
via chi-square with Fischer’s exact test, Duration analysed by One-way ANOVA with 





The arrhythmia score was significantly lower in a dose-related manner across the FO 
groups compared to Control during reperfusion (Figure 5.12A). Additionally, the FO 
supplemented groups spent significantly longer in normal sinus rhythm compared to the 
Control group throughout the entire fifteen minutes of reperfusion (Figure 5.12B). 
There was one fatal VF episode in the Control group but there were no fatal VF 
episodes in the FO groups. During the fifteen minutes of reperfusion both FO groups 
had an approximately three-fold reduction in PVB compared to the Control group (p 




Figure 5.12: The effect of fish oil on arrhythmia score and time spent in normal 
sinus rhythm during reperfusion of the LAD coronary artery. 
Values are mean ± SEM (n = 7 – 12).* p <0.05 vs Control diet, † p <0.05 vs LowFO 
diet (One-way ANOVA with Bonferroni post-hoc test). Arrhythmia score was 




Table 5.3: The effect of fish oil on arrhythmia indices in the left ventricle during fifteen minutes ischaemia induced by occlusion of the 
LAD coronary artery and fifteen minutes reperfusion.  
 Ischaemia Reperfusion 
 
Control LowFO ModFO Trend p = Control LowFO ModFO Trend p = 
Animals (n) 18 15 16  7 9 12  
Time in NSR (Max = 900s) 716 (±13) 794 (±24)* 798 (±25)* 0.005 795 (±34) 884 (±5)* 895 (±2)* <0.001 
PVB 114 (±27) 78 (±17) 43 (±9)* 0.050 155 (±36) 58 (±15)* 59 (±14)* 0.006 
Animals experienced VT (n) 17 14 5  7 9 4  
VT incidence 94% 93% 31%*† <0.001 100% 100% 37%*† <0.001 
VT episodes 7 (±2) 5 (±2) 4 (±3)  6 (±1) 2 (±1)* 2 (±1) 0.01 
VT duration 64 (±14) 26 (±15)* 25 (±16)* 0.043 32 (±8) 13 (±5)* 10 (±8)* 0.04 
Animals experienced VF (n) 16 9 8  6 2 1  
VF incidence 89% 60% 50%* 0.042 86% 22%* 9%* <0.001 
Fatal VF 61% 40% 25%* 0.045 14% a 0% a 0%  
VF episodes 1.4 (±0.3) 1.7 (±0.4) 1.1 (±0.5)  1.6 (±0.4)  a 1 a 1  
VF duration 124 (±16) 122 (±22) 110 (±23)  85 (±33) a 9 a 7  
Arrhythmia score 6.1 (±0.4) 4.6 (±0.5) 3.1 (±0.7)* 0.0026 4.6 (±0.3) 3.1 (±0.3)* 1.3 (±0.3)*† <0.001 
Values are mean ± SEM. * p <0.05 vs Control diet † p <0.05 vs LowFO diet, a too few numbers to complete statistical comparisons (% Incidence 
analysed via chi-square with Fischer’s exact test, Duration analysed by One-way ANOVA with Bonferroni post-hoc test).  
 
Abbreviations: NSR = normal sinus rhythm; PVB = premature ventricular beats; VT = ventricular tachycardia; VF = ventricular fibrillation; Incidence = 
percentage of animals which experienced at least one episode; Fatal VF = percentage of animals which died from VF; Episodes = mean number of arrhythmic 
episodes per animal; Duration = mean total time in arrhythmia of animals having ≥ one episode.  
 
Ischaemic arrhythmia score was calculated using previously outlined and established methods (Curtis et al., 1987). Reperfusion arrhythmia score was calculated 
using previously outlined and established methods (McLennan et al., 1988). 





This study, for the first time, demonstrated that supplementing FO doses achievable 
within a typical Western-style human diet (high SFA and n-6 PUFA) provides 
protection against ischaemia and reperfusion induced arrhythmias in the in vivo heart. 
Arrhythmia generation, including fatal arrhythmias, were reduced by both FO diets in a 
dose-related manner, suggesting that optimal cardiac electrophysiology is intimately 
linked with myocardial phospholipid DHA concentrations. However, during ischaemia 
anti-arrhythmic effects were not observed across all indicators in the LowFO diet, 
suggesting that it may be close to the threshold dose required for protection. Whereas, 
during reperfusion there were few statistically significant differences between the two 
FO doses, suggesting that the threshold for effectiveness may be even lower. The 
demonstration of reduced fatal ischaemia and reperfusion generated arrhythmias 
provides strong evidence, for the first time, to rationalise how FO can prevent sudden 
(arrhythmic) cardiac death (Burr et al., 1989; Valagussa et al., 1999). This finding 
underpins the importance of increasing fish or FO intake in a typical Western-style diet 
containing high amounts of SFA and n-6 PUFA. 
5.5.1 Generation of arrhythmias via ischaemia and reperfusion model 
Arrhythmias were successfully generated during the transient regional ischaemia and 
reperfusion periods induced by the surgical occlusion and release of the LAD coronary 
artery. During the ischaemic period approximately 60% of the Control group died due 
to fatal VF. The incidence of fatal VF in the Control group is very similar to the 
mortality rate displayed in Control groups of other studies using the same or very 
similar surgical methods for the induction of arrhythmias in the rat (Abeywardena et al., 
2016; McLennan, 1993). This confirms the reliability of the surgical model used to 
induce ischaemic arrhythmias in this study. Reperfusion of the myocardium is also a 
very strong stimulus for arrhythmia generation (Manning & Hearse, 1984). It has been 
suggested however that the preceding ischaemic period can lead to biased outcomes 
(Balke et al., 1981). When LAD ligation induced ischaemia is limited to five minutes, 
the proceeding reperfusion produces VT in virtually all cases and VF in approximately 
80%; less cases are generated with both shorter and longer periods of ischaemia 




five and eight minutes of ischaemia and animals usually spontaneously reverted to 
normal sinus rhythm for the remainder of the fifteen minute occlusion. During 
reperfusion the occurrence of VT was usually observed in all animals very rapidly after 
reperfusion began. The Control group incidence of VF was 86% and one case 
progressed into fatal VF. Therefore, the use of a fifteen minute ischaemic period did not 
seem to influence the occurrence of reperfusion VT or VF but did reduce the expected 
cases of fatal VF. A possible explanation for this observation is that the ischaemic 
period was sufficient enough to cause fatal VF in animals susceptible to it; therefore the 
animals which reached reperfusion were more likely to not die of fatal VF upon 
reperfusion. Importantly, compared to the Control group, the FO supplemented groups 
were protected from the arrhythmic stimulus throughout ischaemia and reperfusion.  
5.5.2 Arrhythmia protection attributable to human dietary achievable fish oil doses  
The current study has demonstrated, for the first time, that the anti-arrhythmic action of 
FO is present in animals when using human dietary achievable doses, equivalent to 
what could be achieved in the human diet, and in the presence of a background 
Western-style diet high in SFA and n-6 PUFA. This finding extends the demonstration 
of FO anti-arrhythmic action in previous studies (Abdukeyum et al., 2008; 
Abeywardena et al., 2016; Hartog et al., 1987; Hock et al., 1990; McLennan et al., 
1988; McLennan et al., 1993; McLennan et al., 2007) using therapeutic and supra-
therapeutical doses of FO. Importantly, for the first time this study has demonstrated 
that the anti-arrhythmic action of FO remains present at a dose (LowFO) equivalent to 
two 100g serves of fish per week or one average sized salmon fillet (≈250g) (Slee et al., 
2010). Only one other study has described an anti-arrhythmic action of FO while using 
a comparable dose to the ModFO group (Abeywardena et al., 2016). The study 
completed by Abeywardena et al., 2016, supplemented 1% FO and induced in vivo 
arrhythmias via the same surgical protocol used in this study. The reduction in fatal VF 
episodes observed in the ModFO (1.25%) supplemented rats was comparable to the 
mortality rate demonstrated in rats supplemented 1% FO by Abeywardena et al., 2016. 
In combination, these findings provide strong evidence that infers the anti-arrhythmic 
action of FO is present using doses in the rat equivalent to what could be easily 




at similar doses, different background diets were used. This suggests that variations in 
background diet do not exert any influence on the anti-arrhythmic action of FO. 
The anti-arrhythmic action of FO first described several decades ago using a whole 
animal model (McLennan et al., 1988) appears to be intimately linked to myocardial 
phospholipid DHA concentrations. In line with this observation, studies consistently 
demonstrate the anti-arrhythmic action of FO via only altering dietary LC n-3 PUFA 
intake. For example, initial research demonstrated that crossover to a supra-
therapeutical FO diet reversed the arrhythmogenic effects of prolonged high SFA intake 
(McLennan et al., 1990). Further to this, addition of supra-therapeutical doses of FO to 
a diet high in SFA has been demonstrated to reduce the vulnerability of the rat heart to 
ischaemic arrhythmia, whereas the addition of n-6 PUFA to the high SFA diet did not 
show the same protection (Charnock et al., 1991). Similarly, ventricular fibrillation 
threshold has been demonstrated to be modulated by addition of supra-therapeutical 
doses of FO to a high SFA diet but it is not modified by the addition of sunflower seed 
oil (n-6 PUFA) in the marmoset heart (McLennan et al., 1993). More recently, 
ischaemic induced arrhythmias have been demonstrated to be inhibited by the addition 
of therapeutic and supra-therapeutical doses of FO to a high SFA-enriched diet in rats 
(Pepe & McLennan, 2007). It has been postulated that it is essential to change dietary 
intakes of both LC n-3 PUFA and n-6 PUFA (reduce the n-6:n-3 ratio) to observe 
cardiovascular benefits (Lands, 2003; Rupp et al., 2004; Simopoulos, 2008), based on 
the notion that phospholipid incorporation of LC n-3 PUFA only occurs when the n-6:n-
3 ratio is reduced (Hulbert et al., 2005). However, there is significant evidence that 
indicates that dietary n-6 PUFA intake does not affect LC n-3 PUFA incorporation, 
particularly when preformed EPA+DHA are provided (Slee et al., 2010; Stark et al., 
2007a; Stark et al., 2007b). The current research supports this by demonstrating that 
phospholipid concentrations of LC n-3 PUFA are closely associated with absolute 
amounts of LC n-3 PUFA provided, regardless of background SFA or n-6 PUFA levels. 
In addition, the current research has now demonstrated an anti-arrhythmic action 
without modifying SFA or n-6 PUFA concentrations in the diet, supporting clinical 
evidence which demonstrates that only LC n-3 PUFA levels need to be changed in the 




Previously studies have relied upon therapeutic and supra-therapeutical doses of FO to 
demonstrate an anti-arrhythmic action; however, background diets has varied 
considerably between studies (Charnock et al., 1991; McLennan, 1993; McLennan et 
al., 1988, 1990; Pepe & McLennan, 2007). The only other study to demonstrate anti-
arrhythmic effects of FO with similar doses to this study used a diet which was rich in 
n-6 PUFA and monounsaturated fatty acids but did not contain large amounts of SFA 
(Abeywardena et al., 2016). In contrast, the monounsaturates portion (olive oil) of the 
diets used in this study was substituted for FO to ensure high levels of both SFA and n-6 
PUFA were present in the FO diets. The variation in SFA between this study and the 
study completed by Abeywardena et al., 2016 is important as long term feeding with 
SFA has been demonstrated to be arrhythmogenic (McLennan et al., 1990). As such, 
this study provides novel evidence to demonstrate that the anti-arrhythmic action of FO 
is not inhibited by the normally arrhythmogenic stimulus associated with high amounts 
of dietary SFA, typical to the Western-style diet. In addition, it demonstrates that 
variations in the background diet do not appear to exert any influence on the anti-
arrhythmic action of FO. Rather, the anti-arrhythmic action is closely linked to the 
absolute FO intake, regardless of background SFA and n-6 PUFA intake. 
Several key changes in the arrhythmic indices measured from FO supplemented animals 
help explain the overall anti-arrhythmic action observed. During ischaemia, FO 
supplemented animals spent approximately one to one and a half minutes longer in 
normal sinus rhythm compared to Control animals, and during reperfusion this 
increased towards two minutes longer. The FO groups had a reduced total number of 
PVB compared to the Control group and in the case of the ModFO group the reduction 
observed was almost three-fold. Increased time in normal sinus rhythm and less PVB in 
FO supplemented animals is important as PVB have been demonstrated to be associated 
with the initiation of VT which can progress into fatal VF in patients with and without 
heart disease (Haïssaguerre et al., 2003; Haïssaguerre et al., 2002). As such, reduced 
PVB in FO animals provides plausible physiological evidence to describe the lower 
incidence and shorter mean duration of VT and VF observed in FO supplemented 
animals during ischaemia and reperfusion. Human clinical investigations have 
demonstrated that as the duration of VF increases, the defibrillation threshold required 
to revert out of VF becomes larger (Gradaus et al., 2002). Furthermore, 




threshold in the marmoset heart (McLennan et al., 1993). Unlike the human heart, the 
rat heart can spontaneously defibrillate (Manoach et al., 1980). As such, it is likely that 
the observation of reduced fatal VF cases in animals supplemented FO is due in part, to 
the smaller mean duration of time spent in VF, and modification of the ventricular 
fibrillation threshold improving the chances of the heart spontaneously defibrillating.   
There has been evidence that suggests dietary FO does not protect against arrhythmias 
and may even act in a pro-arrhythmic manner (Billman et al., 2012; Billman et al., 
2010; Mączewski et al., 2016). However, several reasons can be made for the 
conflicting evidence provided in these studies and the findings described in this study. 
The study conducted by Mączewski et al., (2016) investigated arrhythmias occurring 
between the sixth and ninth hour of ischaemia. Arrhythmias investigated in the present 
study and in the majority of previous work completed (Abdukeyum et al., 2008; 
Abeywardena et al., 2016; Hartog et al., 1987; Hock et al., 1990; McLennan, 1993; 
McLennan et al., 1988; McLennan et al., 1993) were generated during the first minutes 
of ischaemia. Arrhythmia which occur within minutes of the ischaemic onset are caused 
by different pathogenic mechanisms to arrhythmias which occur after hours (Opitz et 
al., 1995), making a comparison between the results of the Mączewski et al., 2016 study 
and others challenging. The studies completed by Billman et al., (2010 & 2012) 
demonstrated a pro-arrhythmic effect when supplementing supra-therapeutical FO doses 
to dogs. However, despite supplementing extraordinary doses of FO to dogs (1,2, 4g/d 
(840mg; 1680mg; 3360mg EPA+DHA/d to 20kg dogs), their erythrocyte EPA+DHA 
phospholipid concentrations were only 3.0% (1g); 3.7% (2g); and 6.7% (4g). This 
highlights that the dog is much less amenable to phospholipid LC n-3 PUFA 
incorporation following dietary FO supplementation than the rat and even humans 
(700mg/d EPA+DHA in 80kg males has been shown to produce phospholipid 
EPA+DHA concentrations of 6.3% (Macartney et al., 2014)). Furthermore, there is 
evidence to describe that the dog model used by Billman does not fit with other studies 
in the rat, mouse and human when investigating the effect of vagal tone on exercise 
induced bradycardia (Boyett et al., 2017b). Likewise, the evidence of pro-arrhythmic 
effects shown in dogs does not fit with the consistent anti-arrhythmic effect 
demonstrated in other animal models (Matthan et al., 2005) and humans (Reiffel & 




generation does not seem appropriate, whereas, this study used a more physiologically 
relevant in vivo rat model. 
5.5.3 Linking reduced risk of sudden cardiac death and fish oil 
The reduction in mortality associated with FO is usually attributed to reduced risk of 
SCD caused by fatal arrhythmia. Research shows that myocardial ischaemia and 
spontaneous reperfusion is linked to more than 80% of all fatal arrhythmias (Huikuri  et 
al., 2001). During regional myocardial ischaemia caused by blockage of a coronary 
artery there is redistribution of a number of ions (H+, Na+, Ca2+, K+) (Rubart & Zipes, 
2005), increased production of reactive oxygen species (Bolli, 1992), depletion of ATP 
stores (Stanley et al., 2005) and overload of intracellular Ca2+ concentrations throughout 
cells in the ischaemic area (Moens et al., 2005; Rubart & Zipes, 2005). The culmination 
of these cellular changes leads to slowed conduction, altered refractory periods and 
ultimately electric instability of the ischaemic zone which can trigger episodes of VT 
and/or VF (Rubart & Zipes, 2005; Zipes & Wellens, 1998). Paradoxically, reperfusion 
of the ischaemic area further propagates the rapid generation of VT and/or VF and is 
closely linked to SCD (Wit & Janse, 2001). Ischaemia and reperfusion was induced 
experimentally by occlusion of the LAD coronary artery in this study. In humans, pre-
existing coronary artery disease is a common pathology which can produce episodes of 
ischaemia and spontaneous reperfusion of the myocardium, triggering cardiac 
arrhythmias and SCD. However, even in the absence of coronary artery disease, there 
are other pathologies including: acute coronary artery spasms, unstable angina and 
exercise induced ischaemia which can trigger spontaneous reperfusion induced fatal 
arrhythmias and SCD (Zipes & Wellens, 1998).  
The unpredictable nature of these events makes it difficult to identify patients at risk of 
SCD and therefore preventative prophylactic drug therapy is not possible and usually 
only treatable with implantable defibrillation devices. For this reason, the evidence of 
FO reducing experimentally induced fatal ischaemic and reperfusion generated 
arrhythmias in this study, provides strong evidence to underpin the importance of 
including dietary FO as part of a balanced diet to help prevent SCD. The hypothesis of 
FO acting to prevent SCD rates through an anti-arrhythmic action is supported by 
evidence from human trials also. Two prominent large scale trials have demonstrated 




cause a reduction in cardiovascular related mortality (Burr et al., 1989; Valagussa et al., 
1999). Interestingly, these trials demonstrated that the incidence of SCD was 
significantly reduced but the incidence of new ischaemic events was not significantly 
reduced. Furthermore, it has been demonstrated that a 1% increase in the omega-3 index 
(red blood cell EPA + DHA concentrations expressed as weight percentage of total 
phospholipid fatty acids) in humans, reflects a 58% reduced risk of VF during the 
ischaemic phase of acute myocardial infarction caused by coronary artery disease 
(Aarsetoey et al., 2011; Aarsetoy et al., 2008). Taken in combination with the evidence 
provided in this study suggests that FO acts directly on the heart in an anti-arrhythmic 
manner rather than on vascular related outcomes influencing the initiation of acute 
coronary syndrome. Ex vivo research supports this notion via demonstrating that the 
anti-arrhythmic effect is independent of the circulating fatty acid concentrations (Pepe 
& McLennan, 1996). These findings provide a physiological plausible mechanism to 
assist in explaining the reduced cardiovascular mortality rates observed amongst 
populations that habitually consume fish in their diet (Kromhout et al., 1985).  
5.5.4 Conclusions 
For the first time, the anti-arrhythmic action of FO was demonstrated using a dose of 
FO equivalent to approximately two serves of fish per week in the human diet. The 
protection was evident despite animals consuming a typical Western-style background 
diet high in SFA and n-6 PUFA, suggesting that the anti-arrhythmic action of FO is 
intimately linked to absolute intake of FO. Reduced fatal ischaemic and reperfusion VF 
events strongly warrant the inference that FO is acting to reduce SCD outcomes, rather 
than on vascular outcomes influencing the occurrence of ischaemia (acute coronary 
syndrome). In view of these findings the next chapter explored whether supplementing 
dietary achievable FO doses protects the haemodynamic integrity of the heart during 
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ischaemic in vivo cardiac 
haemodynamics following 
supplementation of human dietary 





6.1 INTRODUCTION   
6.1.1 Background 
In contrast to brief periods of ischaemia, the primary outcome of prolonged ischaemia is 
myocardial tissue necrosis which can develop into a myocardial infarct. This leads to 
progressive left ventricle remodelling including dilation and hypertrophy of the 
myocardium and haemodynamic dysfunction (Sutton & Sharpe, 2000). There is strong 
evidence demonstrating that sudden cardiac death commonly occurs in patients with or 
without pre-existing infarct evident, showing that the significance of arrhythmic 
outcomes (Chapter 5) is not necessarily correlated to the extent of tissue necrosis 
(Huikuri  et al., 2001). However, haemodynamic dysfunction is correlated with the 
extent of the tissue necrosis (Bolli, 1990) and evidence has highlighted that in the 
decade following their myocardial infarction, more than one third of patients will 
develop heart failure (Hellermann et al., 2003; Kenchaiah et al., 2004). The degree of 
tissue necrosis varies, depending on the duration of the ischaemia, the presence or 
absence of collateral circulation in the ischaemic zone, whether the occlusion is 
complete or incomplete and the individual demands of the myocardial cells for oxygen 
and nutrients (Thygesen et al., 2007).  
6.1.2 The phenomenon of myocardial ischaemic pre-conditioning 
Ischaemic pre-conditioning is a phenomenon in which submitting the myocardium to 
brief periods of ischaemia and then reperfusion prior to prolonged ischaemia protects 
and improves the recovery of the heart (Przyklenk & Kloner, 1998). Ischaemic pre-
conditioning has been shown to significantly reduce arrhythmia generation and infarct 
size (Abdukeyum et al., 2008; Shiki & Hearse, 1987), attenuate post-ischaemic 
myocardial dysfunction (Efstathiou et al., 2001; Lasley et al., 1993; Przyklenk & 
Kloner, 1998) and improve the recovery of rate pressure product during reperfusion 
(Lasley et al., 1993). Additionally, hypoxic pre-conditioning before regional cardiac 
ischemia has been demonstrated to lead to preservation of ejection fraction and preload 
recruitable stroke work, indicating improved systolic function (Van der Mieren et al., 
2008). The protection afforded by ischaemic pre-conditioning occurs in two stages. The 




few hours and repeated applications causes desensitisation (Qiu et al., 1997). The 
second ‘late’ stage occurs after twenty four hours and can be invoked repeatedly to 
provide prolonged cardio-protection (Qiu et al., 1997).  
Identification of the cellular mechanisms contributing to the physiological outcomes 
observed with ischaemic pre-conditioning is of interest to researchers due to the 
potential clinical uses in the treatment of ischaemia and reperfusion injury. It has been 
demonstrated that the early stage protection offered by ischaemic pre-conditioning is 
caused by the production of free radicals and reactive oxygen species, creating oxidative 
stress (Yellon & Downey, 2003). However, because the stimulation is only for brief 
periods, the myocardial oxidative stress generated actually leads to the production and 
up-regulation of a range of antioxidant systems including: nitric oxide synthase, 
superoxide dismutase and heat-shock proteins (Lin et al., 2011) which in turn induce 
resistance to subsequent more prolonged ischaemic episodes (Das & Das, 2008). 
Whereas, late stage protection is thought to be mediated by changes in the expression of 
genes leading to altered inflammatory processes and mediation of excessive Ca2+ influx 
and opening of mitochondrial K+ ATP channels during subsequent ischaemic episodes 
(Das & Das, 2008; Yellon & Downey, 2003). Despite the extensive interest in research 
surrounding ischaemic pre-conditioning, the unpredictable onset of 
ischaemic/reperfusion injury and invasive methods required to implement remote or 
ischaemic pre-conditioning make it impractical in clinical practice (Iliodromitis et al., 
2007).  
6.1.3 Other potential methods to exert a pre-conditioning effect  
There is evidence for other methods which are more clinically applicable to replicate the 
cardio-protection observed with ischaemic pre-conditioning. These approaches include 
exercise, remote and post ischaemic conditioning, heat stress, oxidative stress, stretch 
and some pharmacological interventions (Kharbanda et al., 2002; Kharbanda et al., 
2009; Staat et al., 2005; Taylor & Starnes, 2003). Typically, the conditioning provided 
involves toxic stimuli acting directly at the heart that raise defences in anticipation of an 
upcoming event and the protection is persistent even after the initial agent has washed 
off. However, exercise and remote ischaemic conditioning are particular interesting 
therapeutic candidates because they do not require toxic stimuli to be applied directly to 




Staat et al., 2005). This suggests the mechanism involves the release of protective 
agents into the circulation which can produce persistent protective effects. Specifically, 
studies reveal that chronic endurance exercise training protects the heart against 
arrhythmias, contractile dysfunction, oxidative injury, mitochondrial damage and cell 
death (Lennon et al., 2004; Liu et al., 2000). The mediators responsible for the cardio-
protection offered by exercise and remote conditioning have not yet been fully 
explained, however studies have shown that upregulation of antioxidant enzymes plays 
a critical role in protecting the myocardium against I/R injury (Hamilton et al., 2003; 
Kavazis, 2009; Liu et al., 2000; Powers et al., 1993). 
Supplementation of FO appears to offer similar cardio-protective features as to those 
observed when using other forms of conditioning. However, like remote and exercise 
conditioning, FO supplementation results in the upregulation of antioxidant enzymes 
within the myocardium without subjecting the heart to a toxic stimuli (Abdukeyum et 
al., 2016). The unsaturated nature of DHA makes it prone to oxidation; therefore 
increasing myocardial DHA concentrations elevates the peroxidation potential of 
membrane phospholipids in the myocardium (Serhan et al., 2004; Song et al., 2000), 
indirectly generating a toxic stimulus. In addition to this upregulation of antioxidant 
systems, it is well-established that FO acts in an anti-arrhythmic manner at therapeutic 
doses (Matthan et al., 2005; McLennan, 2014), and now at dietary achievable doses 
(Chapter 5). It has also been demonstrated that MVO2 is reduced without diminishing 
work output, suggesting the heart is also using oxygen more efficiently following 
supplementation of therapeutic FO doses (Pepe & McLennan, 2002). Furthermore, early 
post-ischaemic contractile recovery of heart function is augmented (Pepe & McLennan, 
2002), there is reduced production of ischaemic damage biomarkers and infarct size is 
attenuated (Abdukeyum et al., 2008; Pepe & McLennan, 2002; Pepe & McLennan, 
2007).  
As such, it appears that supplementing therapeutic FO doses promotes the upregulation 
of antioxidants and produces similar physiological outcomes to other well researched 
forms of conditioning. Importantly, the upregulation of antioxidant enzymes, anti-
arrhythmic and improved ischaemic and post-ischaemic contractile actions of FO are 
on-going without the need for daily intake. It has been demonstrated that the most 




dose of FO (Ghasemifard et al., 2015). As such, FO supplementation, like remote and 
exercise conditioning offers a more lifestyle applicable, sustainable and effective form 
of cardio-protection referred to by Abdukeyum et al., 2008 as ‘nutritional pre-
conditioning’. However, previous studies investigating conditioning of the myocardium 
by FO supplementation have relied upon therapeutic and supra-therapeutical doses and 
ex vivo experimental models to describe changes. Therefore, the objective of this study 
was to evaluate the conditioning efficacy of human dietary achievable FO doses in a 





6.2 AIMS AND HYPOTHESES 
This study investigated whether supplementing dietary achievable FO doses to a typical 
Western-style diet (high SFA and n-6 PUFA) provides ‘nutritional pre-conditioning’ of 
the heart during prolonged regional ischaemia and reperfusion, in a similar manner to 
ischaemic pre-conditioning, remote pre-conditioning and exercise training.  
 
Specifically, this experiment aimed to test the following hypotheses: 
Aim 1: Determine the influence of supplementing dietary achievable FO doses on 
ischaemic haemodynamic function. 
Hypothesis 1: Cardiac haemodynamic dysfunction induced by ischaemia, 
particularly changes to heart rate, will be attenuated by supplementation of 
FO. 
Aim 2: Determine the influence of supplementing dietary achievable FO doses on post-
ischaemic haemodynamic recovery. 
Hypothesis 2: Post-ischaemic haemodynamic recovery of the left ventricle as 








6.3 METHODS  
6.3.1 Animals, ethical considerations and stadardisation 
The male rats (Sprague Dawley) from cohort 2 were used in this study. Directly 
following the end of experimental procedures described in Chapter 5 the experimental 
procedures for this study began.  
6.3.2 Groups 
Animals were supplied water and randomly assigned one of three pre-fabricated diets ad 
libitum for four weeks before experimentation. The diets contained different amounts of 
FO (Control – 0%: n = 6, LowFO – 0.31%: n = 9, ModFO – 1.25%: n = 12). 
6.3.3 Experimental preparation 
Preparation of the 6mm miniaturised 2-French (2F) Millar pressure-volume 
conductance catheter (SPR-638 Millar Instruments, Houston, USA) and 
electrocardiogram (ADInstruments, Bella Vista, NSW, Aus) was completed (Section 
3.3.3). 
6.3.4 Surgical procedures 
Animals were anaesthetised, and surgery conducted to allow cardiac measurements 
including: ECG, ventricular pressure and volume and aortic blood pressure (Chapter 4). 
An established surgical technique was used to create an ischaemia and reperfusion 
model within the in vivo heart via occluding and reperfusing the LAD coronary artery 
(Chapter 5). 
6.3.5 Experimental protocol and measurements 
Following completion of the in vivo acute ischaemia and reperfusion experimental 
protocol and arrhythmia generation measurements (Chapter 5), animals were checked 
for depth of anaesthesia prior to experimental protocols and measurements being 
collected for this study. After depth of anaesthesia was confirmed, measurements of 
heart rate and aortic systolic blood pressure were collected as pre-ischaemic reference 




for forty five minutes to generate a prolonged ischaemic episode, followed by the 
release of tension from the ligature, allowing reperfusion of the myocardium (Figure 
6.1). During ischaemia the catheter was placed in the aorta to monitor arterial blood 
pressure, heart rate was also collected. Following the ischaemia, the myocardium was 
reperfused for forty five minutes before the conductance catheter was moved into the 
left ventricle and post-ischaemic cardiac function was measured for fifteen minutes. 
Upon completion of post-ischaemic cardiac function measurements, the inferior vena 
cava was occluded for four to six seconds using a cotton tip applicator. Three separate 
occlusions were completed for each animal with five minutes recovery between each 
occlusion, this allowed measurement of post-ischaemic load-independent cardiac 
function. Saline calibration procedures (Section 3.3.5a) were completed with the 
conductance catheter and then animals were euthanased. 
6.3.5a Euthanasia and tissue collection 
Following the completion of experimental procedures all animals were euthanased 
without recovery from the anaesthetic via removing the artificial ventilator and then 
rapid exsanguination and removal of the heart. During exsanguination, blood was 
collected into a 5mL syringe containing 0.2mL of a 5,000 U/mL Heparin Sodium 
solution (Hospira, Lyypards, SA, AUS). The blood was then used to fill the wells of 
calibration cuvette and then placed on a heating pad set to 37 oC for calibration of the 
pressure volume transducer (Section 3.3.7). Hearts were rapidly removed from animals 
following exsanguination, weighed and snap frozen in liquid nitrogen (Section 2.3.5a). 
Following exsanguination and removal of the heart, a pre-determined selection of 
skeletal muscles were dissected from the upper thigh and lower leg of the left hind-limb, 

















Figure 6.1: Overview of the experimental protocol which occurred during the prolonged ischaemia and subsequent reperfusion. 
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6.3.5b Zone at risk measurement 
The heart was arrested and flushed with ice cold saline and the zone at risk was 
delineated according to previously established methods (McLennan et al., 1988). A 
5mL plastic syringe filled with an Indian-dye solution was inserted into the aorta and 
the aorta was tightly bound to the syringe via suture. The coronary arteries were then re-
occluded and pressure was placed on the syringe in order to cause retrograde perfusion 
of Indian dye into the aorta and coronary arteries. The ischaemic zone at risk was then 
delineated via staining of the perfused (non-ischaemic) and non-perfused (ischaemic) 
tissue. The heart was then weighed (total weight, total left + right ventricular weight and 
left ventricle weight only) and cut into five transverse sections (Figure 6.2). The slices 
were then separated into non-ischaemic and zone at risk and weighed again. The zone at 
risk was calculated as % of total wet left ventricle weight. Tissue was then snap frozen 
and stored at –80°C for future biochemical analysis following weight and zone at risk 




Figure 6.2: An isolated heart slice showing ischaemic/non-ischaemic 
ventricular tissue following Indian dye tissue staining.  
Figure 6.2 notes: Ischaemic region (non-stained) and non-ischaemic region (stained black) can 










6.3.6 Post-experimental data analysis 
Average heart rate was calculated (Section 3.3.8a) at five minute intervals during 
ischaemia and reperfusion from the saved electrocardiogram recordings in parallel with 
measurements of systolic blood pressure. Rate pressure product was calculated from 
these measurements at the corresponding time points. In vivo left ventricular cardiac 
haemodynamic function was analysed in the final five minutes of the recordings 
collected by the conductance catheter during post-ischaemic measurements. Analysis of 
haemodynamic indices was completed following the methods outlined in section 3.3.8b. 
Load-independent indices were analysed at each inferior vena cava occlusion and the 
average of all three measurements were used to assess the ventricular systolic and 
diastolic function of dietary groups. 
6.3.6a Statistics 
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise 
stated. The effects of dietary treatment during ischaemia and post-ischaemia were tested 
via ANOVA. A Bonferroni post-hoc test for comparison between group means was then 
used to identify differences. A Dunnett’s T-test was used for comparison of individual 
diets against the Control group. All statistical analyses were performed in a blinded 
manner and completed using SPSS 21 for Windows (SPSS Inc, Chicago, IL, USA). 






Six (6) animals died during the forty five minute ischaemia period due to cardiogenic 
shock and diminished mean arterial pressure. Therefore, final group numbers for 
comparisons of ischaemic cardiac function and recovery were n = 6 – 8. Zone at risk 
measurements showed that on average ∼39 – 45% of the left ventricle wall across all 
animals was ischaemic during the LAD occlusion and at risk of becoming infarcted 
(Figure 6.3). There were no statistical significant differences in the zone at risk 
between any groups. 
 
Figure 6.3: The effect of fish oil on the percentage wet weight of left ventricle 
wall at risk of ischaemia following prolonged LAD coronary artery occlusion. 
Values are mean ± SEM (n = 6 – 8 per group). No statistical significant differences 





6.4.1 The effect of fish oil supplementation on ischaemic cardiac function 
There were no significant differences between any of the groups in pre-ischaemic heart 
rate, systolic blood pressure and rate pressure product. Five minutes after the onset of 
ischaemia heart rate and systolic blood pressure had dropped in all groups resulting in 
decreased rate pressure product (Cross hatch red, Figure 6.4). Ten minutes after the 
onset of ischaemia heart rate and systolic blood pressure returned toward pre-ischaemic 
levels in the ModFO group but remained depressed in the Control and LowFO groups. 
The recovery of heart rate and systolic blood pressure in animals from the ModFO 
group generated a significantly higher rate pressure product then the Control and 
LowFO group. The ModFO maintained the significantly higher rate pressure product 
for the remaining time in ischaemia. Five minutes after the onset of reperfusion, rate 
pressure product remained significantly higher in the ModFO group compared to the 
Control and LowFO group (Cross hatch green, Figure 6.4). There were no further 
significant differences between any of the groups for the remaining time in reperfusion. 
All groups displayed a recovery towards pre-ischaemic heart rate, systolic blood 





Figure 6.4: The effect of fish oil on heart rate, aortic systolic blood pressure 
and rate pressure product throughout ischaemia and subsequent reperfusion of 
the left anterior descending coronary artery. 
Values are mean ± SEM (n = 6 – 8 per group). *p <0.05 vs Control diet (One-way 
ANOVA with Dunnett’s T-test vs Control)  
Notes: ‘Pre’ measurements are taken directly prior to ischaemia occurring and are not 
equivalent to baseline measurements shown in Figure 6.5 which were collected prior to any 
surgery being completed.   




6.4.2 The effect of fish oil supplementation on post-ischaemic cardiac haemodynamic 
function 
Heart rate was significantly slower during post-ischaemic measurement when compared 
to baseline measurements in the Control and LowFO groups, whereas the post-
ischaemic heart rate of the ModFO group returned towards its resting baseline 
measurement (Figure 6.5).  
 
Figure 6.5: The effect of fish oil on resting heart rate (beats.min-1) following 
ischaemia and reperfusion.  
Values are mean ± SEM (n = 6 – 8 per group). *p < 0.05 within group, vs baseline 
measurements (One-way ANOVA with Bonferroni post-hoc test). †p < 0.05 between 
group, vs Control diet (One-way ANOVA with Bonferroni post-hoc test). 
Notes: ‘Baseline’ resting heart rates are the measurements reported in Chapter 4 (Table 4.2) 







Stroke volume and cardiac output were lower in all groups, but the reductions did not 
reach statistical significance (Table 6.1). Compared to baseline, the Control group 
displayed a significantly lower end-systolic pressure and a significantly greater end-
systolic and end-diastolic volume. Compared to baseline, both FO groups displayed a 
significantly lower end-systolic pressure, there were no other changes in the LowFO 
group but the ModFO group also showed a significantly greater end-diastolic pressure. 
As a result of these changes there was a clear downward shift of the PV-loop on the y-
axis for all groups. However, rightward shifting along the x-axis was only reflected in 
the Control PV-loop (Figure 6.6). Comparison of calculated haemodynamic variables 
showed all groups to have a significantly lower dP/dtmax and significantly higher 





Figure 6.6: Representative in vivo baseline and post-ischaemic left ventricular 
PV-loops following FO supplementation.  
Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p <0.05 vs baseline 
(One-way ANOVA comparing within diet conditions with Bonferroni post-hoc test). 
Abbreviations: ESP = end-systolic pressure; ESV = end-systolic volume; EDP = end-diastolic 




Table 6.1: The effect of fish oil on baseline resting and post-ischaemic left ventricular measured haemodynamic variables. 
 
Control LowFO ModFO 
Variable Baseline Post ∆  Baseline Post ∆ Baseline Post ∆  
HR (beats.min-1) 451 (±8) 
382* 
(±17) 
-69 445 (±6) 
388* 
(±15) 
-57 421 (±8) 
410 
(±10) -11 

































ESV (µL) 65  (±10) 
115*  
(±15) 







EDV (µL) 154  (±9) 
184*  
(±36) 







ESP (mmHg) 139  (±7) 
84*  
(±7) 
-55 132  (±4) 
96*  
(±9) 
















Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p < 0.05 vs baseline (One-way ANOVA comparing baseline vs post-ischaemic 
measures within diet conditions using a Bonferroni post-hoc test). 
 
Abbreviations: HR = heart rate; SV = stroke volume; CO = cardiac output; CI = cardiac index, CO/Body weight; ESV = end-systolic volume; EDV = end-diastolic 









Table 6.2: The effect of fish oil on baseline resting and post-ischaemic left ventricular calculated haemodynamic variables. 
 Control LowFO ModFO 
Variable Baseline Post ∆  Baseline Post ∆ Baseline Post ∆ 
Systolic indices          











EF (%) 65  (±5) 
38*  
(±10) 












-4633 8796  (±288) 
4845* 
(±724) 










4661 -7773  (±364) 
-4351* 
(±882) 




Tau (ms) 10.0  (±0.3) 
15.0* 
(±2.0) 
5 9.6 (±0.4) 
14.4* 
(±1.9) 




Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p < 0.05 vs baseline (One-way ANOVA comparing baseline vs post-ischaemic 
measures within diet conditions using a Bonferroni post-hoc test). 
 
Abbreviations:  
Post = post ischaemia; ∆ = difference between baseline and post-ischaemia. 
Systolic indices: Ea = arterial elastance; EF = ejection fraction; dP/dtmax = peak rate of pressure rise.  




6.4.3 The effect of fish oil supplementation on post-ischaemic preload-independent 
cardiac function 
All groups displayed a significant reduction in stroke work compared to baseline resting 
measurements (Table 6.3). There were no significant changes to the ESPVR, preload-
recruitable stroke work and dP/dtmax – end-diastolic volume relationships following 
ischaemia when they were calculated for all groups. In addition, there were no clear 
changes observed within any of the groups when the slope of the diastolic index 







Table 6.3: The effect of fish oil on baseline and post-ischaemia left ventricular preload-independent haemodynamic function. 
 Control LowFO ModFO 
Systolic indices Baseline Post ∆ Baseline Post ∆ Baseline Post ∆ 
SW (mmHg*µL) 10933 (±963) 
4559* 
(±1020) 
-6374 9693 (±744) 
5276* 
(±879) 









































Diastolic indices          











Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p < 0.05 vs baseline (One-way ANOVA comparing baseline vs post-ischaemic 
measures within diet conditions using a Bonferroni post-hoc test). 
 
Abbreviations:  
Post = post ischaemia; ∆ = difference between baseline and post-ischaemia. 
Systolic indices: SW = stroke work; ESPVR = end-systolic pressure volume relation; PRSW = preload recruited stroke work (slope of stroke work−EDV 
relationship); dP/dtmax−EDV = dP/dtmax−end diastolic volume relation  





The current study demonstrated that supplementing FO doses achievable within a 
typical Western-style human diet (high SFA and n-6 PUFA) modified in vivo ischaemic 
and post-ischaemic cardiac function. Importantly, a physiologically and clinically 
relevant ischaemic episode induced by regional blood flow restriction was used, typical 
of major vessel disease and myocardial infarction. Previously, the effects of FO on 
cardiac haemodynamic function during ischaemia and reperfusion have generally been 
restricted to ex vivo models and relied upon therapeutic and supra-therapeutical doses 
(Abdukeyum et al., 2008; Goo et al., 2014; Herrera et al., 2015; McLennan et al., 2012; 
Pepe & McLennan, 2002). Furthermore, with the exception of the study completed by 
Abdukeyum, et al., 2008; ischaemia has been induced by globally restricting blood flow 
to the entire coronary circulation. As such, findings from this study offer novel and 
clinically relevant evidence to demonstrate that dietary achievable FO doses are 
associated with cardio-protective physiological actions akin to the protection provided 
by regular exercise training and remote or ischaemic pre-conditioning.  
6.5.1 Fish oil effects on cardiac dysfunction induced by regional ischaemia 
Shortly after the onset of the regional ischaemic stimulus before cellular necrosis 
occurred, cardiac function was depressed in a manner which fits with the previously 
described physiological outcomes of non-infarcted ischaemic damage to the 
myocardium (Indolfi & Ross, 1993; Moens et al., 2005). Physiologically, this was 
observed as acute reductions to heart rate, systolic blood pressure and as a consequence 
of these changes, rate pressure product was lower. Supplementation of dietary 
achievable FO doses did not influence this initial reduction to heart rate, systolic blood 
pressure or rate pressure product. However, at the onset of ischaemia, the decline in 
cardiac function observed across all groups is a normal compensatory mechanism. 
During ischaemia, myocardial substrate and oxygen supply is reduced, it is well 
established that in an attempt to compensate the reduced sub-endocardial perfusion, 
reductions in transmural wall thickening or segment shortening occur (Canty & Suzuki, 
2012). This is often referred to as ‘perfusion-contraction matching’ (Indolfi & Ross, 
1993; Ross, 1991) or ‘hibernation’ of the myocardium (Heusch et al., 1997). This 




myocytes and delay the occurrence of myocyte necrosis by maintaining substrate 
availability. A major factor influencing transmural blood flow and ultimately substrate 
availability is heart rate. Sub-endocardial perfusion only occurs during diastole when 
coronary vasodilation is maximal (Spaan et al., 2008). For this reason, using beta-
blockers to reduce heart rate is a common therapeutical intervention during ischaemia 
(López-Sendó et al., 2004) and during heart failure (Cullington et al., 2012) based on 
the rationale of indirectly modulating MVO2 during periods of mismatched oxygen 
supply and demand to reduce myocyte necrosis. Therefore, the initial reduction in heart 
rate, systolic blood pressure and rate pressure product observed across all groups at the 
onset of ischaemia was a normal intrinsic cardiac mechanism for maintaining 
myocardial perfusion-contraction matching. Heart rate slowing also reflects another 
mechanism to maintain cardiac output by increasing the diastolic filling phase between 
beats. As such, FO modification of cardiac function, particularly heart rate during this 
response would be detrimental to the preservation of viable myocytes during ischaemia. 
Within ten minutes of the onset of ischaemia heart rate, systolic blood pressure and rate 
pressure product started recovering in all groups and this gradual recovery continued 
throughout the remainder of ischaemia towards pre-ischaemic levels. The recovery in 
cardiac function observed during ischaemia in this study highlights some important 
differences between in vivo regional ischaemia and ex vivo global ischaemia 
experimental models. The typical ex vivo response to global ischaemia can be 
understood by detailed experiments completed using a erythrocyte-perfused isolated 
working heart model (Pepe & McLennan, 1993). The experiments demonstrated 
external work, heart rate and the pressure-time integral per heart beat (dP/dtmax) to be 
significantly reduced after five minutes of ischaemia, similar to the physiological 
changes observed in this study. In contrast to this study, these indices of cardiac 
function remained depressed or progressively deteriorated following twenty minutes of 
global ischaemia in the ex vivo model (Pepe & McLennan, 1993). This highlights the 
dubious physiological relevance of using ex vivo global ischaemia models to assess 
cardiac interventions or treatments. 
Global ischaemia models have no non-ischaemic tissue capable of compensatory 
responses during ischaemia. Whereas, the region at risk of becoming infarcted due to 




Importantly, zone at risk was not different between any of the groups, indicating an 
equivalent ischaemic insult and the proportion of ventricular wall that was ischaemic 
was comparable to previous studies using similar surgical protocols (Abdukeyum et al., 
2008; Curtis et al., 1987; Ertracht et al., 2011; Spadaro et al., 1980; Xue et al., 2016). 
Interestingly, the location of staining consistently demonstrated that the free left 
ventricular wall was at risk of ischaemia rather than the interventricular septum (Figure 
6.2). In humans the LAD coronary artery usually (90%) supplies the anterior two-thirds 
of the interventricular septum. However, there is evidence to demonstrate that in the rat 
the interventricular septum is supplied by a branch that originates close to the origin of 
the left coronary artery (Spadaro et al., 1980). Thus, occlusion of the LAD coronary 
artery in the rat would not obstruct flow to the interventricular septum and explains why 
staining consistently showed that the free wall of the left ventricle was at risk of 
ischaemia.    
Cardiac function in ex vivo models are devoid of neural, humoral and blood pressure 
feedback regulatory mechanisms. Thus, the heart’s response to decreased perfusion 
during ischaemia in an isolated system is to depress contractile function in order to 
preserve myocardial tissue while oxygen supply is not adequate. Whereas, the recovery 
in heart rate and systolic blood pressure observed across all groups in this study are 
linked to the important regulatory role of the baroreceptor reflex in maintaining 
physiological homeostasis. The baroreceptor reflex acts to maintain mean arterial 
pressure at all times, to do so it exerts potent control over the heart and vasculature 
(Cowley et al., 1973). The sudden decrease in arterial blood pressure at the onset of 
ischaemia triggers the baroreceptors to stimulate the medulla leading to vagal 
withdrawal and increased sympathetic nervous tone to the heart. This response explains 
how heart rate and systolic blood pressure partially recovers in the in vivo heart during 
ischaemia but not in the ex vivo heart. This makes the in vivo experimental model used 
in this study more clinically relevant and provides a strong basis to assess the effects of 
FO on cardiac function during ischaemia. 
The current study demonstrated, for the first time, that there was a distinct accelerated 
recovery of heart rate, systolic blood pressure and rate pressure product in the ModFO 
group compared the Control group. Chapter 4 of the current thesis demonstrated dietary 




Lortet & Verger, 1995) and ex vivo research (Abdukeyum et al., 2008; Pepe & 
McLennan, 1996). Interestingly, in contrast to the slowed resting heart rate consistently 
observed with FO, this study demonstrated that heart rate rapidly recovered to pre-
ischaemic rates and remained stable for the duration of the ischaemic episode in the 
ModFO group. This provides evidence to suggest that FO does not act solely to slow 
heart rate. Rather, it appears FO acts in a manner to adjust contractile function of the 
heart to a physiologically appropriate rate and force. Further support for this notion is 
found in a study which demonstrated that slowing of heart rate driven by oxygen 
deficits during ischaemia were attenuated by FO in blood perfused isolated hearts 
devoid of neural feedback (Pepe & McLennan, 1996).  
The rapid recovery of heart rate and systolic blood pressure in the ModFO group 
facilitated a higher rate pressure product. Heart rate, systolic blood pressure and the 
product of both, rate pressure product have been demonstrated to correlate strongly with 
in vivo MVO2 (Kitamura et al., 1972), but this correlation was unable to be shown in ex 
vivo hearts (Aksentijevic et al., 2016). However, it is likely that the inability to 
demonstrate a correlation in the ex vivo model is because low-oxygen carrying perfusate 
was used instead of whole-blood leading to altered oxygen conductance. Therefore, the 
higher rate pressure product demonstrated in vivo in the current study indirectly 
suggests that MVO2 is greater in the ischaemic heart following FO supplementation. 
Interestingly, during ex vivo ischaemia, it has been demonstrated that FO lowers MVO2 
when the heart is electrically paced to maintain a uniform beat rate, and left ventricular 
preload and afterload are strictly controlled, ensuring the same amount of work was 
conducted (Pepe & McLennan, 2002). In contrast, the present study demonstrated a 
faster heart rate and higher systolic blood pressure, indirectly suggesting a greater 
MVO2 and indicative of greater cardiac work. The indirect observation of greater MVO2 
in this study in contrast to lowered MVO2 in the study conducted by Pepe et al., 2002 
demonstrates the important role FO plays in the efficient use of oxygen rather than 
exclusively as a depressor of oxygen use. This further highlights a role of FO in 
maintaining cardiac muscular contractile function, via the efficient use of available 
oxygen during ischaemia, in a similar manner to what has been demonstrated in skeletal 




It has been demonstrated that during ischaemia, MVO2 can remain paradoxically high in 
the presence of abnormal wall motion and decreased contractile function in the canine 
heart (Dean et al., 1990) emphasizing the normal inefficient increases of MVO2 during 
ischaemia. The current study demonstrated that dietary achievable FO doses instigated 
productive increases of myocardial MVO2 during ischaemia. That is, when the heart is 
adapting to adverse conditions, FO enables ongoing function. Contradictory recent 
research has declared that FO does not improve the oxygen efficiency or mechano-
energetic performance of the ex vivo working heart (Goo et al., 2014). The conflicting 
evidence described from the study conducted by Goo et al., 2014 and the current one 
can be clarified by comparing the experimental models used. The study conducted by 
Goo et al., 2014 used an ex vivo heart at low temperature (32°C), perfused with a tyrode 
solution bubbled with 100% oxygen, which despite very high PO2 carry much less 
oxygen than blood (Pepe & McLennan, 1993). In contrast, this study used an in vivo 
model where the heart was perfused by the animals own blood, core temperature was 
maintained at 37°C and all physiological feedback mechanisms remained intact. Neural 
and humoral influences, temperature regulation and most importantly, adequate 
oxygenation of the heart, are essential for optimal cardiac performance in a working 
physiological system (Kuzmiak-Glancy et al., 2015). Inadequate oxygenation of the 
myocardium through the use of red blood cell-free perfusate in ex vivo models has been 
demonstrated to diminish cardiac function, even in the absence of injury (Pepe & 
McLennan, 1993). It has been suggested that whole blood perfusate provides superior 
preservation of myocardial function during ex vivo heart preparations where in vivo 
methods are not available (White et al., 2015). This clarifies why whole blood perfused 
ex vivo models consistently demonstrate improved cardiac (Pepe & McLennan, 2002; 
Pepe & McLennan, 2007) and skeletal (Henry et al., 2015; Peoples & McLennan, 2010, 
2017) muscle contractile function with FO supplementation that contrast the findings of 
Goo et al., 2014. It is therefore likely that the conflicting evidence demonstrated by Goo 
et al., 2014 is driven by the low temperature that experiments were conducted in and 
inadequate oxygenation of the heart as a result of non-whole blood perfusate being used 
in their ex vivo heart model.    
Another factor which may have increased apparent oxygen consumption in the ModFO 
group is the possibility that there were more viable myocardial cells during the 




research has demonstrated that therapeutic and supra-therapeutical doses of FO can 
reduce infarct size in the rat heart (Abdukeyum et al., 2008; Pepe & McLennan, 2002; 
Pepe & McLennan, 2007). Less extensive damage resulting in a greater proportion of 
viable cells within the ischaemic region would also help explain why the ventricle was 
able to generate greater contractile function than the other groups during ischaemia. 
Contractile function has previously been demonstrated to improve in isolated hearts 
supplemented supra-therapeutical doses of FO (Abdukeyum et al., 2008; Pepe & 
McLennan, 2002). Although measured indirectly as systolic blood pressure, this study is 
the first to demonstrate improved contractile function during ischaemia in a clinically 
relevant in vivo model coupled with dietary achievable FO doses. The comparison of 
systolic blood pressure to left ventricular contractile function is appropriate in this study 
as the catheter was sitting in the aorta directly outside the left ventricle which is 
representative of the afterload or ‘tension’ generated by the left ventricle. 
6.5.2 Fish oil effects on post-ischaemic cardiac dysfunction 
Assessment of Control post-ischaemic in vivo pressure and volume relations, 
demonstrated the typical contractile dysfunction associated with the loss of viable 
myocardium caused by ischaemia. Acutely, myocardial ischaemia reduces total 
contractility (Pfeffer, 1995; Yang et al., 2004); this was reflected in Control animals by 
lower end-systolic pressure and the PV-loop shifting downwards on the y-axis. Reduced 
force of ventricular contraction results in decreased ventricular emptying and a greater 
end-systolic volume. Increased end-systolic volume means the diastolic filling phase of 
the cardiac cycle starts at a greater volume, therefore normal venous return added to an 
already partially filled ventricle results in a greater end-diastolic volume (preload). This 
is reflected by significant rightward shifting of PV-loops acutely following ischaemia in 
rats (Pfeffer et al., 1991). In comparison to their baseline PV-loop, the post-ischaemic 
Control PV-loop shifted rightwards on the x-axis, reflecting greater end-systolic volume 
and end-diastolic volume. Acutely, increased stretch of the myocytes caused by a 
greater end-diastolic volume generates a stronger contraction via the Frank-Starling law 
to ensure stroke volume is maintained and the increased blood volume in the ventricle is 
ejected into circulation rather than pooling within the ventricle (Glower et al., 1985). 
Although post-ischaemic stroke volume is maintained by this compensation, ejection 




The degree of post-ischaemic ventricular haemodynamic dysfunction has been 
demonstrated to be directly related to the extent of viable myocardium loss (Pfeffer et 
al., 1979). Together, the zone at risk measurements collected and the haemodynamic 
dysfunction observed confirms that the ischaemic episode was sufficient to cause 
typical post-ischaemic contractile dysfunction, consistent with what has been described 
in other studies. Therefore, the alterations observed between the Control baseline and 
post-ischaemic in vivo PV-loop provided a suitable basis to assess whether 
supplementing FO doses achievable within a typical Western-style human diet modified 
haemodynamic function after ischaemia. 
Post-ischaemic stroke volume and cardiac output was decreased by ∼15 - 20% and ∼25 - 
30% respectively across all groups compared to baseline measures. However, 
supplementation of dietary achievable FO doses maintained PV-loop integrity leading 
to attenuated declines in left ventricular ejection fraction, despite the decrease in stroke 
volume. Ejection fraction has been demonstrated to be increased as a result of enhanced 
ventricular filling in the resting in vivo marmoset heart following supra-therapeutical 
FO doses (McLennan et al., 1992a). This is the first study to show preservation of 
ejection fraction following ischaemia while using dietary achievable FO doses. 
Diastolic function was impeded in all groups indicated by increases in the relaxation 
constant Tau and the maximal rate of relaxation (dP/dtmin). The myocardium commonly 
becomes stiff and slower to or less able to relax during and following ischaemia 
resulting in impaired diastolic filling (Varma et al., 2003). Nevertheless, this study 
demonstrated post-ischaemic dP/dtmin to be ∼1000mmHg.sec-1 faster in the FO 
supplemented animals compared to the Control group. This reflects observations made 
in an ex vivo study which also demonstrated supra-therapeutical doses of FO to improve 
maximum rate of ventricular relaxation (Abdukeyum et al., 2008). Therefore, it is likely 
that this in part contributed to the maintenance of left ventricular ejection fraction 
observed in FO supplemented animals of this study.  
The lower stroke volume and cardiac output were likely related to the reductions in the 
maximal rate of pressure development (dP/dtmax) observed across all groups. This 
indicates the left ventricle was in a weakened systolic inotropic state following 
ischaemia (Kass et al., 1989). However, this study demonstrated that dP/dtmax was 




In addition, although not statistically significant, end-systolic pressure in FO 
supplemented animals was ∼10-15mmHg higher during post-ischaemic measurements. 
These findings reflect a study which demonstrated supra-therapeutical doses of FO to 
preserve in vivo systolic heart function twenty four hours after permanent ligation of the 
LAD in the rat (Lescano de Souza Junior et al., 2017). Furthermore, findings from this 
study support an ex vivo study which demonstrated that during reperfusion left 
ventricular developed pressure (equivalent to end-systolic pressure) is increased in 
hearts supplemented supra-therapeutical doses of FO (Abdukeyum et al., 2008). As a 
result of these changes, the time for ejection would be greater, allowing stroke volume 
to be maintained and stopping rightward shift of the PV-loop. These changes were 
similar to an in vivo sheep heart model assessing the effect of ischaemic pre-
conditioning on global ischaemia (Tanoue et al., 2002). The PV-loops of Control groups 
in both studies shifted downwards and rightwards compared to baseline. The FO 
supplemented group in this study and the ischaemic pre-conditioned group in the study 
conducted by Tanoue et al., 2002 did not show any rightward shifting compared to their 
baseline loops. The remarkable resemblance of the effects of human dietary achievable 
FO doses on cardiac function to the effects demonstrated with ischaemic pre-
conditioning suggests they share a similar mechanism of action to provide cardio-
protection. Such changes indicate that post-ischaemic left ventricular contractile 
function was improved independent of the Frank-Starling law. The Frank-Starling 
compensation observed in the Control group during post-ischaemic function would be 
causing increased contractility to maintain stroke volume. Therefore, systolic contractile 
dysfunction in the Control group may have been masked by the powerful Frank-Starling 
compensation, meaning the differences between groups could become more evident 
over longer time frames when the compensation diminishes. 
6.5.3 Conclusions 
Ischaemia and reperfusion induced cardiac dysfunction characterised by reduced rate 
pressure product during ischaemia and reduced post-ischaemic ejection fraction, was 
largely prevented by prior feeding with FO. The moderate dose was more effective than 
the low dose but many effects were observed with both indicating that the addition of 
FO doses achievable within a typical Western-style human diet can protect against 




of FO was only demonstrated while using therapeutic and supra-therapeutic doses not 
nutritionally relevant to the human diet. Furthermore, the cardio-protective actions 
demonstrated mimicked both the potent ‘early’ phase and the long lasting ‘late’ phase 
protection previously only attributable to ischaemic pre-conditioning. The modification 
of ischaemic and post-ischaemic cardiac function described in this study, together with 
the demonstration of slowed resting heart rate and reduced arrhythmia generation, 
provides novel evidence to support increasing fish or FO intake for nutritional pre-














7.1 GENERAL DISCUSSION 
Pharmacological and therapeutic strategies aimed at reducing and treating 
cardiovascular disease are important to improve patient quality of life. The majority of 
studies to advance cardiovascular outcomes are pharmacologically based. 
Notwithstanding the success such treatment has on decreasing the impact of 
cardiovascular disease on healthcare systems,  research targeting modification of 
lifestyle related risk factors, such as diet and exercise (Eckel et al., 2014), are just as 
essential in reducing mortality and morbidity rates and underpinning the prevention of 
disease burden. Regular fish intake is consistently associated with a cardio-protective 
action in human population based studies (Bang & Dyerberg, 1972; Burr et al., 1989; 
Hirai et al., 1980; Kagawa et al., 1982; Kromhout et al., 1985). Now for the first time, 
this thesis provides physiological evidence of heart rate slowing, reduced arrhythmia 
generation and attenuated post-ischaemic contractile dysfunction, all of which would 
contribute to reducing the risk of cardiovascular disease (Fox et al., 2008; Gorenek et 
al., 2015). Importantly, the modification of in vivo heart function was attributable to 
supplementing FO doses achievable within a typical Western-style human diet (high 
SFA and n-6 PUFA). This highlights that in the typical Western-style diet which 
contains very small amounts of LC n-3 PUFA (Micha et al., 2014), as also could be 
implied from global erythrocyte EPA+DHA levels (Stark et al., 2016), and high 
amounts of SFA and n-6 PUFA, the cardiovascular benefits of FO can be produced 
solely through increasing LC n-3 PUFA intake without the need to concurrently reduce 
n-6 PUFA intake as previously postulated by Simopoulos, A.P., 2008, Lands, E.M., 
2003 & Rupp et al., 2004. As such, this research emphasises the importance of 
nutritional interventions aimed at increasing fish or FO intake in the Western-diet for 
optimal cardiac function and provides further support for the recommendation to 
establish a dietary reference intake (Flock et al., 2013). 
7.1.1 Direct effect of dietary achievable fish oil doses on heart function 
The heart is remarkably adaptive to both acute and chronic stimuli. This research 
demonstrated that the preferential incorporation of DHA into myocardial phospholipids 
influences both chronotropic and inotropic heart function. Specifically, the 




well-defined autonomic tone changes, suggestive of an intrinsic mechanism, ii) less 
severe and reduced incidence of arrhythmias (including fatal) during simulated acute 
coronary syndrome and iii) improved left ventricular post-ischaemic contractile 
function. 
7.1.1a Heart rate 
In each cardiac cycle, the beat to beat interval is controlled, along with stroke volume 
and together they are responsible for cardiac output. Control of cardiac output is 
essential as it contributes to maintaining mean arterial pressure for the adequate 
perfusion of organs and tissues in the body. This research demonstrated that 
supplementing FO to a typical Western-style diet slows resting heart rate, in a similar 
fashion to exercise training (Blomqvist & Saltin, 1983; D’Souza et al., 2015b). 
Previously heart rate slowing had only been demonstrated in animals using FO doses in 
the therapeutic or supra-therapeutical range (McLennan, 2014). The dietary achievable 
doses used in this series of projects provides a compelling physiological link to explain 
the consistent observation of FO supplementation being associated with lower heart 
rates in humans (Dallongeville et al., 2003; Geelen et al., 2005; Grimsgaard et al., 
1998; Mozaffarian. et al., 2005). Increased resting heart rate in patient and healthy 
populations is associated with a greater risk of CVD and all-cause mortality (Aune et 
al., 2017; Cullington et al., 2012; Hartaigh et al., 2014; McAlister, 2009; Zhang & 
Zhang, 2009). As such, the cardio-protective action of regular fish consumption is likely 
to be associated with its ability to slow resting heart rate when physiological strain is 
absent.  
In contrast to FO-induced slowing during rest, heart rate (initially depressed by 
ischaemia) rapidly recovered in FO supplemented animals. This suggests that during 
physiological strain (ischemia), the heart is protected against a loss of mechanical 
function and as a consequence sustained reduction in heart rate is attenuated. Support 
for this hypothesis can be found in previous studies which have demonstrated FO to 
slow resting heart rate but not impair peak heart rate during exercise in humans 
(Buckley et al., 2009; Macartney et al., 2014; Peoples et al., 2008). Interestingly, beta-
blockers, commonly used in the treatment of hypertension and heart failure (Lechat et 
al., 1998), inhibit peak heart rate responses by up to 30beats.min-1, and slow resting 




(Epstein et al., 1965). Heart rate reserve (the difference between resting and peak heart 
rate) is reduced by these changes, which can limit exercise tolerance in patients 
prescribed beta-blockers (Hradec et al., 2013; Piña et al., 2003). This highlights a 
potential clinical role for FO to modulate heart rate without compromising heart rate 
reserve and exercise tolerance. 
Resting heart rate was slowed without any well-defined changes to autonomic tone, 
suggestive of an intrinsic mechanism. Slowing of resting heart rate is commonly 
attributed to increased vagal tone, particularly in studies investigating exercise training 
induced bradycardia (Billman et al., 2015; Coote & White, 2015). It is likely that vagal 
tone contributes to slowing of resting heart rate but the exclusive action of increased 
vagal tone is to slow heart rate. In addition to heart rate slowing, supplementation of FO 
was shown to modulate heart rate and allow it to increase during ischaemia. Exercise 
training can also cause resting bradycardia without compromising peak heart rate 
(Blomqvist & Saltin, 1983; Scheuer & Tipton, 1977). Furthermore, both exercise 
training and dietary FO slow resting heart rate  of hearts studied ex vivo (Abdukeyum et 
al., 2008; D'Souza et al., 2014; Pepe & McLennan, 2002) and even in cardiac transplant 
patients (Harris et al., 2004), none of which would receive vagal stimulation. Given the 
findings from the current project and what is observed in exercise training induced 
slowing of resting heart rate, it is reasonable to suggest that both stimuli modify heart 
rate intrinsically, as was originally hypothesised for exercise training decades ago 
(Sutton et al., 1967). 
It is well established that the sino-atrial node is responsible for intrinsic pace-setting of 
the rhythmic electrical excitation patterns of the heart (Mangoni & Nargeot, 2008). 
Originally it was theorised that sarcolemma membrane ion channels were responsible 
for the ignition of action potentials in the sino-atrial node (Weidmann, 1955). However, 
it has now been postulated that the control of sino-atrial node firing is tightly regulated 
by two coupled processes (Yaniv et al., 2015). The first being, the hyperpolarisation 
activated sarcolemma cation current, commonly referred to as the ‘funny current’ and 
the second being, the spontaneous release of calcium from the sarcoplasmic reticulum, 
otherwise referred to as the ‘calcium clock’ (Maltsev & Lakatta, 2009; Yaniv et al., 
2015). It has been hypothesised that the funny current is responsible for stabilizing the 




variability, independent of autonomic tone (Zaniboni et al., 2014). Supplementation of 
FO has been demonstrated to slow the funny current in rabbit sino-atrial cells (Verkerk 
et al., 2009), in a similar fashion to exercise training induced electrical remodelling of 
the sino-atrial node (Boyett et al., 2017a; D'Souza et al., 2014; D’Souza et al., 2015a). 
It has also been demonstrated that LC n-3 PUFA can modulate other ion channel 
activities including voltage-gated Na+ (Xiao et al., 2005), K+ (Farag et al., 2016), Ca2+ 
channels (Pepe & McLennan, 2002) and the spontaneous release of Ca2+ from the 
sarcoplasmic reticulum which is closely linked to the calcium clock (Siddiqui et al., 
2008). Analysis of cellular mechanisms responsible for the heart rate slowing was 
beyond the scope of the experiments described in this thesis. However, the cellular 
evidence in conjunction with the physiological findings presented provides support for 
the hypothesis that LC n-3 PUFA mediated slowing of heart rate is closely linked to 
intrinsic beat rate modification at the sino-atrial node. 
7.1.1b Arrhythmias  
Ischaemic episodes as short as five minutes in the myocardium can lead to electrical 
instability and arrhythmias even in the absence of cell necrosis and reperfusion can 
exacerbate the instability (Bolli, 1988). This project demonstrated a potent anti-
arrhythmic action of dietary achievable FO doses during ischaemia and reperfusion, 
previously only described using therapeutic and supra-therapeutic doses (Abdukeyum et 
al., 2008; Abeywardena et al., 2016; Hartog et al., 1987; Hock et al., 1990; McLennan 
et al., 1988; McLennan et al., 1993; McLennan et al., 2007). This finding provides 
strong evidence, for the first time, to justify how increasing dietary FO intake in a 
typical Western-style diet containing high amounts of SFA and n-6 PUFA leads to the 
prevention of sudden (arrhythmic) cardiac death (Burr et al., 1989; Valagussa et al., 
1999) and addresses the confusion regarding the minimum dose required (Reiffel & 
McDonald, 2006) .  
The protection afforded by FO supplementation can be rationalised by comparing to 
ischaemic pre-conditioning of the myocardium, as both have been demonstrated to 
provide an effective anti-arrhythmic action (Abdukeyum et al., 2008). The cardio-
protective actions of ischaemic pre-conditioning are closely linked to alteration of 
intracellular signalling cascades, particularly Ca2+ regulation (Das & Das, 2008; Otani, 




opportunity for intracellular Ca2+ concentrations within myocardial cells to overload. 
Intracellular Ca2+ overload is associated with spontaneous depolarisation of non-
pacemaking cells and the generation of arrhythmias (Brooks et al., 1995; Rubart & 
Zipes, 2005), including the initiation of VT, VF and triggered activity (Antzelevitch & 
Burashnikov, 2011; Undrovinas et al., 1992). It was hypothesised that the slowing of 
heart rate was likely linked to modified Ca2+ regulation in pacemaker cells of the sino-
atrial node. Thus, it is plausible that the anti-arrhythmic action of myocardial DHA 
incorporation is also attributable to stabilisation of Ca2+ movement within non-
pacemaking myocytes.  
Paradoxically, increased incorporation of DHA into myocardial phospholipids would 
increase the peroxidation index, potentially leading to the production of arrhythmogenic 
oxidative products. However, when the peroxidation index is increased by phospholipid 
DHA incorporation persistent basal lipid oxidation occurs, as a consequence, anti-
oxidant enzymes such as mitochondrial superoxide dismutase (MnSOD) are continually 
upregulated (Abdukeyum et al., 2016). This observation is consistent with the up-
regulation of anti-oxidant systems that occurs with the regular oxidative stress of 
exercise training (Hoshida et al., 2002) or ischaemic pre-conditioning of the 
myocardium (Otani, 2008; Yellon & Downey, 2003). Furthermore, increased ADP 
sensitivity and reactive oxygen species generation are physiological consequences of 
DHA incorporation in skeletal muscle mitochondria, yet there is no evidence of 
oxidative damage (Herbst et al. 2014). It has also been demonstrated that 
cyclooxygenase and lipoxygenase enzymes are up-regulated in the myocardium during 
inflammatory events such as ischaemia and reperfusion (Jenkins et al., 2009). 
Enzymatic oxygenation of membrane bound EPA and DHA, via cyclooxygenases and 
lipoxygenases, leads to the formation of a range of unique PUFA-derived bioactive 
compounds involved in the resolution of inflammation, including: resolvins; 
neuroprostanes; maresins; protectins; and lipoxins (Serhan & Petasis, 2011). 
Furthermore, non-enzymatically generated endogenous lipid mediators have been 
shown to have the same anti-arrhythmic properties as DHA, suggesting they are also 
directly involved in the process (Roy et al., 2016; Roy et al., 2015). Although cellular 
mechanisms were not investigated in this research, the anti-arrhythmic action of dietary 




regulation, anti-oxidant systems and the resolution of inflammation and in many ways 
holds similarities to ischaemic preconditioning and exercise preconditioning.   
7.1.1c Contractile performance 
In addition to heart rate and rhythm, inotropy and lusitropy are critical for maintaining 
cardiac output and are therefore tightly controlled within the working physiological 
system. This project has provided evidence, for the first time, that dietary achievable FO 
doses attenuate post-ischaemic myocardial contractile dysfunction, previously described 
using therapeutic doses (Abdukeyum et al., 2008; Pepe & McLennan, 2002) and in a 
similar manner to ischaemic pre-conditioning (Efstathiou et al., 2001; Lasley et al., 
1993; Przyklenk & Kloner, 1998). Improved post-ischaemic myocardial contractile 
performance provides evidence that helps link the observation of reduced heart failure 
incidence amongst populations that regularly consume fish (Levitan et al., 2010).  
The modulation of myocardial post-ischaemic contractile dysfunction is remarkably 
similar to the contractile changes FO supplementation produces in skeletal muscle, 
particularly muscles susceptible to fatigue (Henry et al., 2015) and muscles acutely 
subjected to hypoxia (Peoples & McLennan, 2017). A common mechanism of action 
hypothesised to account for the physiological actions of FO on contractile performance 
is enhanced oxygen efficiency across organs, including the healthy or failing rat heart 
(McLennan et al., 2012; Pepe & McLennan, 2007), skeletal muscle (Peoples & 
McLennan, 2010, 2014, 2017) and confirmed as lower whole body oxygen consumption 
during exercise in healthy humans (Peoples et al., 2008). This hypothesis is 
strengthened by evidence that when rats are supplemented DHA they have increased 
chances of surviving asphyxia-induced cardiac arrest, suggestive of enhanced 
myocardial oxygen efficiency (Kim et al., 2016). Attributing enhanced contractile 
oxygen efficiency to increased phospholipid DHA concentration from FO is reinforced 
by environmental adaptations found in comparative physiology. Phospholipid DHA 
incorporation of excitable tissue increases in response to chronic hypoxia exposure in 
rats, presumably as a protective response (Jezkova et al., 2002). Equally, DHA is 
concentrated in the swimming muscles of the deep diving seal where contractile 
function is maintained in a low oxygen environment during breath hold periods of 
exceeding 12 minutes (Trumble & Kanatous, 2012). Likewise, phospholipid n-3 PUFA 




prolonged periods of time while maintaining wing contractile performance 
(McWilliams et al., 2004). Notably, DHA concentrations were shown to be highest in 
muscles with high proportions of fast oxidative glycolytic muscle fibres responsible for 
powerful yet sustained contraction in this thesis. Fast oxidative glycolytic muscles 
contain an extensive network of sarcoplasmic reticulum and mitochondria (Berchtold et 
al., 2000). Double packing of the mitochondrial membrane has been proposed as an 
explanation for such high LC n-3 PUFA concentrations (Infante et al., 2001). This 
suggests that phospholipid incorporation of DHA from FO is integral to maintaining 
contractile performance, particularly during conditions where oxygen availability is 
challenged. 
Regulation of Ca2+ recurs (already discussed in reference to heart rate and arrhythmia) 
as a unifying cellular mechanism to help justify the hypothesis that enhanced oxygen 
efficiency allows maintained contractile performance. Abnormalities in excitation-
contraction coupling as a result of Ca2+ regulation have been shown to cause inefficient 
oxygen use leading to contractile dysfunction (Brooks et al., 1995; Kristian & Siesjo, 
1998; Pepe & McLennan, 2002; Rubart & Zipes, 2005). In fact, it has been shown that 
the attenuation of post-ischaemic contractile dysfunction associated with ischaemic pre-
conditioning is partly due to optimised Ca2+ regulation (Das & Das, 2008). Research has 
identified that LC n-3 PUFA alters both sarcoplasmic reticulum Ca2+-ATPase (SERCA) 
mediated Ca2+ reuptake and ryanodine receptor (RyR) mediated Ca2+ release in isolated 
ventricular and atrial myocytes (Honen et al., 2003; Negretti et al., 2000; O'Neill et al., 
2002). Of physiological consequence, the maximal contractile rate of developed tension 
and relaxation in skeletal muscle has been shown to be partially protected during acute 
hypoxia in rats supplemented FO (Peoples & McLennan, 2017). Furthermore, from 
within a fatigued state, hind-limbs of animals fed FO demonstrated an augmented 
response to a caffeine bolus facilitates sarcoplasmic reticulum Ca2+ release (Fryer & 
Neering, 1989). For the reasons discussed, myocardial phospholipid DHA 
incorporation, caused by the provision of dietary achievable FO doses is essential for 
attenuating post-ischaemic contractile dysfunction demonstrated in this project. 
 7.1.1d Linking the effects of fish oil in the heart to phospholipid composition 
The dose-dependent and preferential incorporation of DHA into cardiac and skeletal 




n-3 PUFA have in the healthy physiological functioning of excitable tissue, particularly 
the heart. Historically, animal studies supplementing FO have used doses which are 
mostly unachievable in the equivalent human diet, making extrapolation of the 
physiological findings to human health ambiguous. Dose response studies (Slee et al., 
2010), covering the range used in the current research show that previous supra-
therapeutical doses of FO maximally increased myocardial DHA phospholipid fatty 
acid composition (Abdukeyum et al., 2008; Hock et al., 1990); the ModFO diet 
contributed 1/5 these doses or less, yet myocardial phospholipid DHA concentration 
was close to maximal. Remarkably, the LowFO diet, which supplemented FO at 
roughly 1/20th the dose of those previous studies, still resulted in about half maximal 
myocardial phospholipid DHA incorporation. Thus, the dietary equivalence of the doses 
used in this study (Human equivalence: LowFO ≈ EPA+DHA 570mg/d or ≈ 2 salmon 
[100g] serve/week; ModFO ≈ EPA+DHA 2.3g/d or ≈ 6 capsules per/day) allows 
translation of the cardiac physiological effects described to the reduced risk of 
cardiovascular disease consistently described in populations that regularly consume fish 
(Bang & Dyerberg, 1972; Burr et al., 1989; Hirai et al., 1980; Kagawa et al., 1982; 
Kromhout et al., 1985) ranging up to supplemental intake (Valagussa et al., 1999). 
Furthermore, phospholipid DHA incorporation and cardiac physiology was modified 
despite n-6 PUFA and SFA concentrations being held constant in the diet, in-line with 
relative concentrations consumed in a typical Western-style diet (Broadhurst et al., 
1998; Simopoulos, 1991; USDA, 2016). This supports and strengthens the notion that 
the addition of small amounts of FO to the diet exerts a protective effect directly on the 
heart (McLennan, 2014), similar to exercise training and ischaemic pre-conditioning. 
Therefore, nutritional interventions aiming to increase fish or FO intake could prove 
effective in improving heart function and reducing the risk of cardiovascular disease in 
high risk sedentary populations unable to exercise. The effectiveness of the LowFO diet 
suggests it is near threshold, thus supporting the suggestion that a dietary reference 
intake may be derived on the basis of healthy heart function (Flock et al., 2013). 
7.1.2 Future directions 
This series of experiments provided physiological evidence of FO modifying intrinsic 
heart rate and cardiac inotropic state. There was no well-defined indication that 




the heart provides a justification for the slowing of resting heart rate observed, however 
the contradicting evidence of stabilised sinus rhythm and faster recovery of heart rate 
during ischaemia alludes to the possibility that other processes were involved. As such, 
optimisation of cardiac function observed with FO feeding is likely related to an 
intrinsic action on the myocardium and pacemaker regions of the heart. Studies in heart 
transplant patients (Harris et al., 2004) and in ex vivo animal heart preparations provide 
further support to this hypothesis (Abdukeyum et al., 2008; Pepe & McLennan, 1996). 
However, the surgical and methodological process involved in setting up an ex vivo 
heart preparation, including the choice of perfusate or whole blood can significantly 
alter baseline cardiac function. It is even possible that the brief periods of ischaemia 
during setup may actually impart an ischaemic pre-conditioning like effect on the heart. 
Such investigations would benefit from less invasive surgical protocols such as 
echocardiography tracking of cardiac haemodynamic function. Therefore, further 
investigation of the influence of FO on intrinsic cardiac function is warranted using a 
pithed in vivo animal preparation to remove the influence of the autonomic nervous 
system while maintaining the heart in a working physiological system.  
Investigation of the mechanisms responsible for the physiological outcomes described 
was out of the scope of the current research. As such, cellular studies investigating sino-
atrial node spontaneous activity, sarcoplasmic reticulum Ca2+ regulation, anti-oxidant 
up-regulation and resolution processes are warranted. Studies aiming to investigate such 
outcomes would achieve more physiologically relevant outcomes through using cells 
obtained directly from animal’s fed dietary achievable FO doses, rather than using acute 
application of LC n-3 PUFA to the cell culture medium. This type of cellular 
experiment would allow a more direct translation of any observed changes to be 
specifically attributed to DHA phospholipid concentrations and the effects of diet as 
opposed to the effects of circulating DHA, solvents or non-specific detergent actions 
exposed in some studies when added acutely to the cell culture medium (refer to 
McLennan, P.L., 2014).      
Finally, the experiments completed in this research demonstrated physiological effects 
of dietary achievable FO doses on cardiac function while using an appropriate in vivo 
animal model and a background diet relevant to the typical Western-style diet. Skeletal 




auto-perfused rat hind-limb model using both dietary achievable (Henry et al., 2015) 
and supra-therapeutical FO doses (Peoples & McLennan, 2010, 2014, 2017); however 
never on the basis of muscle fibre content. The current research identified a strong 
association between increased DHA phospholipid concentrations in skeletal muscle 
with a high proportion of fast oxidative glycolytic fibres. Therefore, further 
investigation is warranted to determine if FO modifies contractile function uniformly 
across striated muscles (including heart), regardless of fibre type proportion, or is more 
effective in the presence of a high proportion of a particular fibre type.   
7.1.3 Application of the findings and final conclusions: The importance of nutritional 
pre-conditioning with increased fish or fish oil intake 
Cardiovascular disease persists as a principal contributing factor to worldwide 
morbidity and mortality. According to recent data released by the World Health 
Organisation almost one third of all deaths worldwide in 2008 were related to 
cardiovascular disease. Furthermore, the impact of cardiovascular disease is expected to 
increase substantially as the proportion of the aged population increases (Heidenreich et 
al., 2011). The physiological outcomes described in the current thesis are similar to the 
cardio-protective effects commonly observed with exercise training, remote and 
ischaemic pre-conditioning. The unpredictable onset of ischaemic/reperfusion injury 
and invasive methods required to implement remote or ischaemic pre-conditioning 
make it impractical in clinical practice (Iliodromitis et al., 2007). Additionally, the lack 
of specificity of potential therapeutic candidates drawn from ischaemic pre-conditioning 
further reduces the viability of such an approach (Otani, 2008). The shortfalls of 
implementing ischaemic pre-conditioning to prevent arrhythmias and cardiac contractile 
dysfunction induced by ischaemia and reperfusion injury could be overcome via 
‘nutritional pre-conditioning’ with increased dietary fish or FO intake (Abdukeyum et 
al., 2008). Increased physical activity (exercise training) is well-established to reduce 
the risk of cardiovascular disease (Mozaffarian et al., 2016; Thompson et al., 2003). 
The evidence from this research suggests that nutritional pre-conditioning with FO 
offers cardio-protection in a similar manner. Importantly, a habitual dietary approach to 
prevent cardiovascular disease, like increased physical activity levels, overcomes the 
need to predict the onset of ischaemia and reperfusion. Pharmacological therapies are 




form of cardiovascular disease, this makes dietary and exercise modifications a more 
effective preventative approach as they can be applied across vast populations with no 
prior indication of cardiovascular disease.   
It may be argued that the studies conducted in the current thesis were completed in rats, 
making the findings less applicable to human health. However, one of the main design 
issues of current trials in humans, which have often been unable to replicate the 
epidemiological findings, is the failure to measure or control for how much LC n-3 
PUFA an individual is consuming within and outside of the trial. A properly designed 
randomised controlled trial relies upon absolute seperation of the treated and control 
group. However, it has been highlighted that in investigations of FO supplements there 
is often considerable overlap of LC n-3 PUFA red blood cell phospholipid 
concentrations between study groups (James et al., 2014), yet trials often conclude that 
FO is ineffective, when in fact the design is flawed and sound conclusions can not be 
made. For example, the ORIGIN trial (Bosch et al., 2012) showed equal median 
EPA+DHA intake in control and treated groups at baseline but the interquartile dietary 
range (40-568mg/d) extended beyond the 250mg EPA+DHA which has been identified 
in epidemiology and randomized trials for maximal reduction in the risk of 
cardiovascular death (Kris-Etherton et al., 2009; Mozaffarian et al., 2005a). Using an 
animal model in the current studies allowed for precise FO dosing and definitive 
separation of dietary groups to identify physiologically plausible mechanisms of cardio-
protection. Thus, the current study was more akin to cohort and other observational 
studies that separate participants into quintiles or other percentiles according to 
estimated dietary intake or erythrocyte LC n-3 PUFA phospholipid concentrations 
(Siscovick et al., 1995).  Human observational studies commonly describe differences 
in relative risk between those who eat no fish and those who regularly eat some fish or 
much fish (Kromhout et al., 1985; Levitan et al., 2010; Mozaffarian et al., 2005a; 
Mozaffarian et al., 2005b) making them like the control group in comparison to dietary 
FO groups. 
Identification and correction of dietary deficiencies has led to considerable public health 
benefits in the prevention and treatment of a range of health problems (Blot et al., 1993; 
Holick, 2007). The applications of nutritional pre-conditioning with FO in the typical 




2014), as also could be implied from global erythrocyte EPA+DHA levels (Stark et al., 
2016), far outreach those of ischaemic pre-conditioning. In fact, extensive savings in 
European health budgets have been predicted if dietary FO intake can be increased 
(Shanahan, 2016). Despite this, there is evidence to suggest that there is insufficient 
nutritional education amongst current cardiovascular specialists, leading to 
misinformation and reluctance to provide patients with dietary advice (Devries et al., 
2017). Confusion surrounding the cardiovascular effects of dietary FO (Nestel et al., 
2015) likely exacerbates this problem. This research provides further evidence to 
demonstrate FO as a safe and effective tactic for improving intrinsic heart health and 
providing protection from cardiovascular disease and stress, with a clear translation path 
from animal to human health due to the nutritional relevance and physiologically 
appropriate in vivo model used. As such, observations made in this study could form 
part of the evidence used to inform and set dietary guidelines for fish intake (Flock et 
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